var title_f35_27_36272="Prolapsed internal hemorrhoids";
var content_f35_27_36272=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=GAST%2F75759&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=2\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=GAST%2F75759&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=2\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 470px\">",
"   <div class=\"ttl\">",
"    Prolapsed internal hemorrhoids",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 280px; height: 280px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    Internal hemorrhoids which have prolapsed outside of the anal canal and are visibly bleeding.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Reproduced with permission from the American Society of Colon and Rectal Surgeons.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f35_27_36272=[""].join("\n");
var outline_f35_27_36272=null;
var title_f35_27_36273="Moraxella sputum";
var content_f35_27_36273=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=ID%2F58978&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=2\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=ID%2F58978&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=2\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 470px\">",
"   <div class=\"ttl\">",
"    <em>",
"     Moraxella catarrhalis",
"    </em>",
"    in sputum",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 353px; height: 240px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    <em>",
"     Moraxella catarrhalis",
"    </em>",
"    under high power magnification (1000x) in sputum.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Courtesy of Harriet Provine.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f35_27_36273=[""].join("\n");
var outline_f35_27_36273=null;
var title_f35_27_36274="HDR cerv brachyther plan";
var content_f35_27_36274=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=OBGYN%2F51717&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=OBGYN%2F51717&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 470px\">",
"   <div class=\"ttl\">",
"    High dose rate (HDR) cervical brachytherapy planning",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 349px; height: 606px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    Orthogonal radiographs, (A) and (B), depicting placement of intrauterine tandem and vaginal ovoids. The images show the instruments in place in the uterus and vagina. In addition, there is barium contrast in the rectum, contrast in the Foley catheter balloon and radiopaque vaginal packing.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Courtesy of Kristin Bradley, MD and Derek McHaffie, MD.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f35_27_36274=[""].join("\n");
var outline_f35_27_36274=null;
var title_f35_27_36275="Removal large sessile polyp";
var content_f35_27_36275=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=GAST%2F53817&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=GAST%2F53817&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 562px\">",
"   <div class=\"ttl\">",
"    Postpolypectomy electrocoagulation syndrome after removal of a large sessile colon polyp",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 542px; height: 420px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    (A) Normally, the snare extends beyond the polyp, and the tip contacts mucosa behind the polyp (point a).",
"    <br/>",
"    (B) As the snare is closed, the tip may catch on the mucosa behind the polyp (point a) and draw it toward the polyp. The submucosa is bunched up into the snare, but the entrapped mucosa cannot be seen because it is hidden behind the polyp. Cutting through a broad based polyp may also transfer sufficient thermal energy to the deeper layers to result in a transmural burn.",
"    <br/>",
"    (C) After polypectomy, there is a large defect, and the wall beneath the area of denuded mucosa is thinner and more liable to conduct electrical energy (heat) to the serosal surface causing deep thermal damage, resulting in the postpolypectomy electrocoagulation syndrome.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f35_27_36275=[""].join("\n");
var outline_f35_27_36275=null;
var title_f35_27_36276="Collagen type III glomerulopathy";
var content_f35_27_36276=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=NEPH%2F86281&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=NEPH%2F86281&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 533px\">",
"   <div class=\"ttl\">",
"    Collagen type III glomerulopathy",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 513px; height: 193px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    (A) Light microscopy showing mesangial expansion and thickened capillary walls (hematoxylin and eosin stain).",
"    <br>",
"     (B) Electron microscopy showing subendothelial expansion with collagen fibrils.",
"     <div class=\"footnotes\">",
"     </div>",
"     <div class=\"reference\">",
"      Courtesy of Dr. Lynn Cornell, Department of Laboratory Medicine and Pathology, Mayo Clinic, Rochester, MN.",
"     </div>",
"    </br>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f35_27_36276=[""].join("\n");
var outline_f35_27_36276=null;
var title_f35_27_36277="Cutaneous lichen amyloid general view";
var content_f35_27_36277=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=ENDO%2F65753%7EENDO%2F69450&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=2\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=ENDO%2F65753%7EENDO%2F69450&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=2\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 488px\">",
"   <div class=\"ttl\">",
"    Cutaneous lichen amyloidosis in a patient with MEN2: General view",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 468px; height: 323px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    The skin lesion is usually described as pruritic, scaly, papular, pigmented, and located in the interscapular region or on the extensor surfaces of the extremities. Amyloid deposition has been documented histologically.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Courtesy of: Cornelis J Lips, MD.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 488px\">",
"   <div class=\"ttl\">",
"    Cutaneous lichen amyloidosis in a patient with MEN2: Close-up",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 468px; height: 311px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    The skin lesion is usually described as pruritic, scaly, papular, pigmented, and located in the interscapular region or on the extensor surfaces of the extremities. Amyloid deposition has been documented histologically.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Courtesy of: Cornelis J Lips, MD.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f35_27_36277=[""].join("\n");
var outline_f35_27_36277=null;
var title_f35_27_36278="Severe asthma: Evidence for heterogeneity of the disease";
var content_f35_27_36278=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"19\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"topicTitle\">",
"   Severe asthma: Evidence for heterogeneity of the disease",
"  </div>",
"  <div id=\"topicContributors\">",
"   <div>",
"    <a id=\"authors\">",
"    </a>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"mobipreview.htm?35/27/36278/contributors\">",
"     Author",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"mobipreview.htm?35/27/36278/contributors\">",
"     Sally Wenzel, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"mobipreview.htm?35/27/36278/contributors\">",
"     Section Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"mobipreview.htm?35/27/36278/contributors\">",
"     Peter J Barnes, DM, DSc, FRCP, FRS",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"mobipreview.htm?35/27/36278/contributors\">",
"     Deputy Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"mobipreview.htm?35/27/36278/contributors\">",
"     Helen Hollingsworth, MD",
"    </a>",
"    <br/>",
"   </div>",
"  </div>",
"  <div id=\"disclosures\">",
"   <a href=\"mobipreview.htm?35/27/36278/contributor-disclosure\" target=\"_blank\">",
"    Disclosures",
"   </a>",
"  </div>",
"  <div id=\"reviewProcess\">",
"   <span>",
"    All topics are updated as new evidence becomes available and our",
"   </span>",
"   <a href=\"/home/editorial-policy\" target=\"_blank\">",
"    peer review process",
"   </a>",
"   <span>",
"    is complete.",
"   </span>",
"  </div>",
"  <div id=\"literatureReviewDate\">",
"   <span class=\"emphasis\">",
"    Literature review current through:",
"   </span>",
"   Oct 2013.",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <span class=\"emphasis\">",
"    This topic last updated:",
"   </span>",
"   May 11, 2012.",
"  </div>",
"  <div id=\"topicText\">",
"   <p class=\"headingAnchor\" id=\"H1\">",
"    <span class=\"h1\">",
"     INTRODUCTION",
"    </span>",
"    &nbsp;&mdash;&nbsp;Asthma is defined and diagnosed through a combination of clinical symptoms and physiologic abnormalities, generally without reliance upon pathologic or biologic markers. However, the physiologic definition of asthma is relatively nonspecific, consisting of airway hyperreactivity and airflow limitation during expiration, which is variable",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    reversible with bronchodilators. In most asthma patients, the presence of bronchial hyperreactivity is never objectively confirmed.",
"   </p>",
"   <p>",
"    The definition of severe asthma relies on similar measures, but is restricted to patients with severe airflow limitation and airways hyperreactivity as well as prominent symptoms (",
"    <a class=\"graphic graphic_table graphicRef71425 graphicRef51579 graphicRef61691 \" href=\"mobipreview.htm?13/32/13839\">",
"     table 1A-C",
"    </a>",
"    ). These imprecise definitions leave considerable room for multiple pathologic processes to produce similar physiologic and clinical endpoints. Severe asthmatics present with widely varying clinical histories, physiologic changes (beyond changes in FEV1), and pathologic findings, suggesting either that severe asthma is not a single disease, or is a single process that produces widely varying host responses.",
"   </p>",
"   <p>",
"    The data suggesting multiple phenotypes within the classification of \"severe asthma\" are reviewed here. Interestingly, these phenotypes are now being identified both clinically and by statistical means, but the results appear quite similar [",
"    <a class=\"abstract\" href=\"mobipreview.htm?35/27/36278/abstract/1\">",
"     1",
"    </a>",
"    ]. Details regarding the classification, evaluation, and treatment of chronic severe persistent asthma are discussed separately. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?8/37/8794?source=see_link\">",
"     \"An overview of asthma management\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?13/49/14105?source=see_link\">",
"     \"Evaluation of severe asthma in adolescents and adults\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?3/17/3354?source=see_link\">",
"     \"Treatment of severe asthma in adolescents and adults\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?7/42/7849?source=see_link\">",
"     \"Glucocorticoid-resistant asthma\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H2\">",
"    <span class=\"h1\">",
"     EPIDEMIOLOGY",
"    </span>",
"    &nbsp;&mdash;&nbsp;Little is known about the epidemiology of severe asthma. It is estimated that 5 to 10 percent of patients with asthma have severe asthma [",
"    <a class=\"abstract\" href=\"mobipreview.htm?35/27/36278/abstract/2\">",
"     2",
"    </a>",
"    ]. Native Americans may have a particularly high risk of having severe asthma; one large prospective cohort study found that among the 6 percent of patients who had clinician-diagnosed asthma, 52 percent had severe asthma (with a mean FEV1 of 61 percent of predicted) [",
"    <a class=\"abstract\" href=\"mobipreview.htm?35/27/36278/abstract/3\">",
"     3",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H3\">",
"    <span class=\"h1\">",
"     CLINICAL COURSE",
"    </span>",
"    &nbsp;&mdash;&nbsp;Patients with severe asthma may have manifested severe disease all their life, developed progressively more severe disease over time, or may never have had the disease (to the best of their recollection) until some point in their adult life, after which the disease progressed at a rapid pace [",
"    <a class=\"abstract\" href=\"mobipreview.htm?35/27/36278/abstract/1\">",
"     1",
"    </a>",
"    ]. While some severe asthmatics have a clearly defined atopic history, others give little indication of an allergic component. This has led to the separation of asthmatics into \"extrinsic\" (allergic) and \"intrinsic\" (non-allergic) subgroups.",
"   </p>",
"   <p>",
"    Data from case series of patients with severe asthma suggest that childhood onset (before the age of 12) versus later onset (after age 12) also distinguishes two distinct subgroups [",
"    <a class=\"abstract\" href=\"mobipreview.htm?35/27/36278/abstract/1,4,5\">",
"     1,4,5",
"    </a>",
"    ]. Childhood onset asthma represents a relatively homogeneous group of patients, often with a strong allergic history and family history of asthma. In contrast, adult-onset asthmatics are a very mixed group of patients. Many adult-onset asthmatics relate the development of symptoms following a viral illness, occupational exposure, or the ingestion of",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?24/7/24698?source=see_link\">",
"     aspirin",
"    </a>",
"    , while such histories are less frequent among those with childhood onset asthma. In adult-onset asthma, an allergic component may be more difficult to confirm, as significantly fewer asthmatics with onset of disease after the age of 12 demonstrate positive allergy skin tests or specific allergic symptoms compared to early onset.",
"   </p>",
"   <p>",
"    Onset of asthma within a year of a woman&rsquo;s last menstrual period may define a separate asthma phenotype [",
"    <a class=\"abstract\" href=\"mobipreview.htm?35/27/36278/abstract/6,7\">",
"     6,7",
"    </a>",
"    ]. In a case series, induced sputum from 40 women with menopause onset asthma showed a higher percentage of neutrophils and slightly lower percentage of eosinophils compared with sputum from 35 women with premenopausal onset asthma [",
"    <a class=\"abstract\" href=\"mobipreview.htm?35/27/36278/abstract/7\">",
"     7",
"    </a>",
"    ]. None of the women with menopausal onset asthma were atopic, while 76 percent of the premenopausal asthma onset group were. Whether menopausal onset asthma is different from adult onset asthma in men requires additional study. Whether menopausal onset asthma is different from adult onset asthma in men requires additional study. How much overlap there is with the adult onset less atopic, generally obese women from the cluster analysis of the Severe Asthma Research Program population remains to be determined, but a large percentage of that population was also post menopausal [",
"    <a class=\"abstract\" href=\"mobipreview.htm?35/27/36278/abstract/1\">",
"     1",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Differences in symptoms lend further support to the concept that more than one disease may exist. Some of the most common symptom differences include the presence or absence of mucus production and the pattern of variability of severe airflow limitation [",
"    <a class=\"abstract\" href=\"mobipreview.htm?35/27/36278/abstract/8,9\">",
"     8,9",
"    </a>",
"    ]. African-American children appear to be at higher risk for a pattern of chronic, severe, minimally reversible airflow limitation. Although the use of glucocorticoids tends to be greater in these patients than among those with the more variable airflow pattern, glucocorticoids were generally instituted later in the course of illness.",
"   </p>",
"   <p>",
"    Some severe asthmatics have frequent episodes of extreme airflow limitation (brittle asthma), while others do not [",
"    <a class=\"abstract\" href=\"mobipreview.htm?35/27/36278/abstract/9\">",
"     9",
"    </a>",
"    ]. These patients have been classified further into those with consistently widely variable airflow and those who have sudden exacerbations on the background of relatively normal airflow.",
"   </p>",
"   <p>",
"    It is conceivable that a subgroup of patients diagnosed with severe asthma actually have constrictive bronchiolitis as the primary abnormality, but because they have at least partially reversible disease in response to bronchodilators and because pathologic specimens are not obtained, they are classified as asthmatic. One study suggests that only 50 percent of patients with biopsy proven constrictive bronchiolitis will demonstrate a classic \"mosaic\" (patchy hyperlucency) pattern on high resolution computerized tomography (CT) scans [",
"    <a class=\"abstract\" href=\"mobipreview.htm?35/27/36278/abstract/10\">",
"     10",
"    </a>",
"    ]. Unless tissue is obtained, these patients (especially those who would fall into the \"idiopathic\" bronchiolitis category) could easily be misdiagnosed with severe, refractory adult-onset asthma (",
"    <a class=\"graphic graphic_picture graphicRef75444 \" href=\"mobipreview.htm?16/7/16504\">",
"     picture 1",
"    </a>",
"    and",
"    <a class=\"graphic graphic_picture graphicRef62630 \" href=\"mobipreview.htm?34/5/34904\">",
"     picture 2",
"    </a>",
"    ). (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?23/43/24247?source=see_link\">",
"     \"Bronchiolitis in adults\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    As a group, patients with severe asthma are at significant risk for work disability. The prevalence of full work disability was 14 percent in a prospective cohort study of 865 American patients with severe asthma, and partial work disability was present in 38 percent [",
"    <a class=\"abstract\" href=\"mobipreview.htm?35/27/36278/abstract/11\">",
"     11",
"    </a>",
"    ]. However, the natural history of severe asthma, either adult or childhood onset over many years, remains poorly understood.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H4\">",
"    <span class=\"h1\">",
"     PHYSIOLOGY",
"    </span>",
"    &nbsp;&mdash;&nbsp;All severe asthmatics must meet the criteria for asthma as assessed by FEV1",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?10/32/10756?source=see_link\">",
"     methacholine",
"    </a>",
"    reactivity. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?21/61/22487?source=see_link\">",
"     \"Use of pulmonary function testing in the diagnosis of asthma\"",
"    </a>",
"    .) Further assessment of physiologic parameters suggests that other measures may vary among severe asthmatics [",
"    <a class=\"abstract\" href=\"mobipreview.htm?35/27/36278/abstract/12\">",
"     12",
"    </a>",
"    ]. Evidence for air trapping, as assessed by residual volume, is generally seen in severe, refractory asthma. However, some (but not all) severe asthmatics demonstrate loss of elastic recoil, either as seen on pressure-volume curves or through alterations in the forced vital capacity (FVC) to slow vital capacity (SVC) ratio [",
"    <a class=\"abstract\" href=\"mobipreview.htm?35/27/36278/abstract/13,14\">",
"     13,14",
"    </a>",
"    ]. Although a firm association with different clinical patterns awaits further study, a reduced",
"    <span class=\"nowrap\">",
"     FVC/SVC",
"    </span>",
"    was associated with a greater risk for near fatal events in one study [",
"    <a class=\"abstract\" href=\"mobipreview.htm?35/27/36278/abstract/14\">",
"     14",
"    </a>",
"    ]. Little is known about differences in the physiology or pathology of the small airways and alveoli in these two groups.",
"   </p>",
"   <p>",
"    It has also been suggested that severe asthmatics may demonstrate the \"loss of plateau\" to increasing concentrations of bronchoconstrictors, which could predispose to more complete airway closure. This effect has been proposed to be the consequence of airway wall thickening and loss of elastic recoil [",
"    <a class=\"abstract\" href=\"mobipreview.htm?35/27/36278/abstract/15,16\">",
"     15,16",
"    </a>",
"    ]. However, the majority of studies evaluating this parameter were done in mild to moderate rather than severe asthmatic patients [",
"    <a class=\"abstract\" href=\"mobipreview.htm?35/27/36278/abstract/17\">",
"     17",
"    </a>",
"    ]. Interestingly, some severe asthmatics manifest hypoxemia at night or during activity, whereas others do not, which could also suggest variation in the involvement of the small airways and lung parenchyma.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H5\">",
"    <span class=\"h1\">",
"     PATHOLOGY",
"    </span>",
"    &nbsp;&mdash;&nbsp;A survey of bronchoscopic studies of asthmatics of varying severity demonstrates a wide range in the types and quantities of infiltrating inflammatory cells, mediator and cytokine levels, epithelial and vascular changes, as well as sub-basement membrane thickness. Nevertheless, the vast majority of studies have elected to group all subjects together as having one disease, rather than attempting to discern the reasons for differences in the pathology or clinical severity. As endobronchial biopsy and lavage remain imperfect tools, it is likely that at least some of the observed pathologic variability is secondary to limitations of sampling. However, some differences also are likely due to differences in the underlying processes themselves.",
"   </p>",
"   <p>",
"    The effect of asthma on sub-basement membrane (SBM) thickness was examined in a study that compared endobronchial biopsies from normal subjects with those from patients with mild, moderate, or severe (glucocorticoid-dependent) asthma [",
"    <a class=\"abstract\" href=\"mobipreview.htm?35/27/36278/abstract/18\">",
"     18",
"    </a>",
"    ]. No difference was found in sub-basement membrane (SBM) thickness among the different asthma severities, but a slight thicker SBM was noted in patients with asthma compared to normal controls.",
"   </p>",
"   <p>",
"    In another study, endobronchial biopsies were obtained from 34 patients with severe, oral glucocorticoid-dependent asthma; 20 had tissue eosinophil numbers at least 2 standard deviations greater than the mean seen in normal controls, while 14 had eosinophils within the normal range [",
"    <a class=\"abstract\" href=\"mobipreview.htm?35/27/36278/abstract/14\">",
"     14",
"    </a>",
"    ]. When the patients were divided into those with and without large airway eosinophils, the high eosinophil group had increased sub-basement membrane (SBM) thickness, a marginally higher FEV1, and more frequent occurrence of near fatal events. Tissue lymphocytes and macrophages tracked closely with eosinophils in these severe asthmatics, while neutrophils appeared to be elevated in both groups.",
"   </p>",
"   <p>",
"    In the same study, transforming growth factor (TGF)-&szlig; positive submucosal cells were also increased in the group with eosinophils and a thicker SBM [",
"    <a class=\"abstract\" href=\"mobipreview.htm?35/27/36278/abstract/14\">",
"     14",
"    </a>",
"    ]. These differences appeared to have both physiologic and clinical implications, as the eosinophil-positive group demonstrated a reduced",
"    <span class=\"nowrap\">",
"     FVC/SVC",
"    </span>",
"    compared with the eosinophil-negative group. Those subjects with eosinophils, a thickened SBM, and a decreased",
"    <span class=\"nowrap\">",
"     FVC/SVC",
"    </span>",
"    also appeared to be at much greater risk for a near fatal event than those without eosinophils. However, there was no difference in the bronchodilator response in the two groups.",
"   </p>",
"   <p>",
"    Similar clinical differences related to the presence or absence of airway eosinophils have now been described by other centers, with some evidence to suggest that lung eosinophilia is more common in late onset, as compared to early onset disease [",
"    <a class=\"abstract\" href=\"mobipreview.htm?35/27/36278/abstract/4,5,19\">",
"     4,5,19",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    The importance of neutrophilia in asthma, which has now been described in several studies, remains poorly understood [",
"    <a class=\"abstract\" href=\"mobipreview.htm?35/27/36278/abstract/20-22\">",
"     20-22",
"    </a>",
"    ]. As glucocorticoids may prolong neutrophil survival, it is possible that the observed neutrophilia is a direct effect of glucocorticoid use in these patients. However, whether the neutrophilia plays any role in maintaining or worsening asthma is not yet known.",
"   </p>",
"   <p>",
"    The above findings suggest that a single pathology does not explain all cases of severe asthma. It appears that some patients with severe asthma fall into the category of \"classic asthmatic inflammation,\" with a poor response to glucocorticoid therapy. At least one other group may consist of patients with a different disease pathologically, or one in which glucocorticoids have completely suppressed the classic inflammatory response, but without effect on the clinical severity of disease. The importance of the presence of neutrophils in both subtypes requires further investigation.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H6\">",
"    <span class=\"h1\">",
"     RESPONSE TO THERAPY",
"    </span>",
"    &nbsp;&mdash;&nbsp;Clinicians have long been aware that asthmatics do not respond in a uniform fashion to various asthma medications, particularly glucocorticoids and other nonspecific",
"    <span class=\"nowrap\">",
"     anti-inflammatory/cytotoxic",
"    </span>",
"    medications [",
"    <a class=\"abstract\" href=\"mobipreview.htm?35/27/36278/abstract/23,24\">",
"     23,24",
"    </a>",
"    ]. Differential responses to leukotriene modulating drugs have also been noted [",
"    <a class=\"abstract\" href=\"mobipreview.htm?35/27/36278/abstract/25\">",
"     25",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?7/42/7849?source=see_link\">",
"     \"Glucocorticoid-resistant asthma\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?30/1/30746?source=see_link\">",
"     \"Agents affecting the 5-lipoxygenase pathway in the treatment of asthma\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    By definition, most severe asthmatics receive oral or high doses of inhaled glucocorticoids. However, even with these very potent anti-inflammatory drugs, the response to therapy is often variable [",
"    <a class=\"abstract\" href=\"mobipreview.htm?35/27/36278/abstract/26\">",
"     26",
"    </a>",
"    ]. In some severe asthmatics, the response appears to be shifted, so that although a response occurs, it requires extremely high doses. These patients would appear to be \"glucocorticoid-dependent.\" In others, even high doses of glucocorticoids may lead to little or no response, or even worsening. These patients may be truly glucocorticoid-resistant, but are likely in a minority. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?7/42/7849?source=see_link\">",
"     \"Glucocorticoid-resistant asthma\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    The airway histopathology in subgroups differentiated by response to treatment has not been adequately studied, but could very well be different. For example, eosinophilia has become a target of therapy for severe asthma, with studies suggesting that patients with airway or sputum eosinophilia are more likely to respond to glucocorticoid therapy. Thus, severe asthmatics with eosinophilia (either in tissue or sputum), despite treatment with inhaled and oral glucocorticoids, may benefit by modulation of their glucocorticoid dose on the basis of the amount of eosinophils present [",
"    <a class=\"abstract\" href=\"mobipreview.htm?35/27/36278/abstract/27\">",
"     27",
"    </a>",
"    ]. Studies of a monoclonal antibody to IL-5 in severe asthmatics with persistent sputum eosinophils have demonstrated efficacy in reducing asthma exacerbations [",
"    <a class=\"abstract\" href=\"mobipreview.htm?35/27/36278/abstract/28,29\">",
"     28,29",
"    </a>",
"    ]. However, this drug is not yet approved by the US Food and Drug Administration.",
"   </p>",
"   <p>",
"    Many, if not most studies of glucocorticoid resistance have been done in moderate rather than severe asthmatics, and extrapolation from those results is often difficult [",
"    <a class=\"abstract\" href=\"mobipreview.htm?35/27/36278/abstract/30,31\">",
"     30,31",
"    </a>",
"    ]. Some severe asthmatics may not demonstrate an improvement with glucocorticoids on a chronic basis, but may demonstrate improvement with glucocorticoids during a period of exacerbation. This difference in the acute versus chronic response has not been studied to date. In addition, patients with persistent sputum eosinophilia appear to respond better to high dose glucocorticoid therapy, than those with no evidence for eosinophilia [",
"    <a class=\"abstract\" href=\"mobipreview.htm?35/27/36278/abstract/27\">",
"     27",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    The monoclonal antibody to IgE (",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?37/46/38629?source=see_link\">",
"     omalizumab",
"    </a>",
"    ) has been used to treat the phenotype of allergic asthma with elevated IgE levels and positive allergy skin tests to perennial allergens. In clinical trials, the drug has been shown to have glucocorticoid sparing effects in patients on inhaled (but not oral) glucocorticoids [",
"    <a class=\"abstract\" href=\"mobipreview.htm?35/27/36278/abstract/32,33\">",
"     32,33",
"    </a>",
"    ]. As only about 30 percent of allergic asthmatics appear to respond to omalizumab, it remains to be determined whether there is a specific subphenotype of allergic asthma that responds better than others.",
"   </p>",
"   <p>",
"    Finally, most glucocorticoid-sparing trials that have been performed on unselected patients with severe, glucocorticoid-dependent asthma show only minimal efficacy, but with widely variable response patterns [",
"    <a class=\"abstract\" href=\"mobipreview.htm?35/27/36278/abstract/34-36\">",
"     34-36",
"    </a>",
"    ]. These have included studies with",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?23/38/24170?source=see_link\">",
"     methotrexate",
"    </a>",
"    , gold,",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?31/39/32368?source=see_link\">",
"     cyclosporine",
"    </a>",
"    , and intravenous gamma globulin. These differing responses to glucocorticoids and glucocorticoid-sparing agents also support the heterogeneity of the process. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?32/36/33354?source=see_link\">",
"     \"Alternative and experimental agents for the treatment of asthma\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H7\">",
"    <span class=\"h1\">",
"     SUMMARY",
"    </span>",
"    &nbsp;&mdash;&nbsp;Severe, refractory asthma is likely to represent a heterogeneous population. This heterogeneity is obvious to clinicians who treat asthma routinely. However, the specific subtypes have not yet been well defined. A better understanding of these subtypes has the potential to lead to improved treatment of this group of patients.",
"   </p>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div class=\"headingAnchor\" id=\"references\">",
"   <h1>",
"    REFERENCES",
"   </h1>",
"   <ol id=\"reference\">",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/27/36278/abstract/1\">",
"      Moore WC, Meyers DA, Wenzel SE, et al. Identification of asthma phenotypes using cluster analysis in the Severe Asthma Research Program. Am J Respir Crit Care Med 2010; 181:315.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/27/36278/abstract/2\">",
"      Moore WC, Bleecker ER, Curran-Everett D, et al. Characterization of the severe asthma phenotype by the National Heart, Lung, and Blood Institute's Severe Asthma Research Program. J Allergy Clin Immunol 2007; 119:405.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/27/36278/abstract/3\">",
"      Dixon AE, Yeh F, Welty TK, et al. Asthma in American Indian adults: the Strong Heart Study. Chest 2007; 131:1323.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/27/36278/abstract/4\">",
"      Miranda C, Busacker A, Balzar S, et al. Distinguishing severe asthma phenotypes: role of age at onset and eosinophilic inflammation. J Allergy Clin Immunol 2004; 113:101.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/27/36278/abstract/5\">",
"      Haldar P, Pavord ID, Shaw DE, et al. Cluster analysis and clinical asthma phenotypes. Am J Respir Crit Care Med 2008; 178:218.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/27/36278/abstract/6\">",
"      van den Berge M, Heijink HI, van Oosterhout AJ, Postma DS. The role of female sex hormones in the development and severity of allergic and non-allergic asthma. Clin Exp Allergy 2009; 39:1477.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/27/36278/abstract/7\">",
"      Foschino Barbaro MP, Costa VR, Resta O, et al. Menopausal asthma: a new biological phenotype? Allergy 2010; 65:1306.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/27/36278/abstract/8\">",
"      Chan MT, Leung DY, Szefler SJ, Spahn JD. Difficult-to-control asthma: clinical characteristics of steroid-insensitive asthma. J Allergy Clin Immunol 1998; 101:594.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/27/36278/abstract/9\">",
"      Ayres JG, Miles JF, Barnes PJ. Brittle asthma. Thorax 1998; 53:315.",
"     </a>",
"    </li>",
"    <li>",
"     Jensen SP, Lynch DA, Brown KK, et al. High resolution CT features of severe asthma and bronchiolitis obliterans (abstract). Radiologic Society of North America Meeting, 2000.",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/27/36278/abstract/11\">",
"      Eisner MD, Yelin EH, Katz PP, et al. Risk factors for work disability in severe adult asthma. Am J Med 2006; 119:884.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/27/36278/abstract/12\">",
"      Shaw DE, Berry MA, Hargadon B, et al. Association between neutrophilic airway inflammation and airflow limitation in adults with asthma. Chest 2007; 132:1871.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/27/36278/abstract/13\">",
"      Liu, A, Brugman, S, Schaeffer, E, et al. Reduced lung elasticity may characterize children with severe asthma (abstract). Am Rev Respir Dis 1990; 141:A906.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/27/36278/abstract/14\">",
"      Wenzel SE, Schwartz LB, Langmack EL, et al. Evidence that severe asthma can be divided pathologically into two inflammatory subtypes with distinct physiologic and clinical characteristics. Am J Respir Crit Care Med 1999; 160:1001.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/27/36278/abstract/15\">",
"      Woolcock AJ, Salome CM, Yan K. The shape of the dose-response curve to histamine in asthmatic and normal subjects. Am Rev Respir Dis 1984; 130:71.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/27/36278/abstract/16\">",
"      Wiggs BR, Bosken C, Par&eacute; PD, et al. A model of airway narrowing in asthma and in chronic obstructive pulmonary disease. Am Rev Respir Dis 1992; 145:1251.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/27/36278/abstract/17\">",
"      Booms P, Cheung D, Timmers MC, et al. Protective effect of inhaled budesonide against unlimited airway narrowing to methacholine in atopic patients with asthma. J Allergy Clin Immunol 1997; 99:330.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/27/36278/abstract/18\">",
"      Chu HW, Halliday JL, Martin RJ, et al. Collagen deposition in large airways may not differentiate severe asthma from milder forms of the disease. Am J Respir Crit Care Med 1998; 158:1936.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/27/36278/abstract/19\">",
"      Simpson JL, Scott R, Boyle MJ, Gibson PG. Inflammatory subtypes in asthma: assessment and identification using induced sputum. Respirology 2006; 11:54.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/27/36278/abstract/20\">",
"      Wenzel SE, Szefler SJ, Leung DY, et al. Bronchoscopic evaluation of severe asthma. Persistent inflammation associated with high dose glucocorticoids. Am J Respir Crit Care Med 1997; 156:737.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/27/36278/abstract/21\">",
"      Jatakanon A, Uasuf C, Maziak W, et al. Neutrophilic inflammation in severe persistent asthma. Am J Respir Crit Care Med 1999; 160:1532.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/27/36278/abstract/22\">",
"      Louis R, Lau LC, Bron AO, et al. The relationship between airways inflammation and asthma severity. Am J Respir Crit Care Med 2000; 161:9.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/27/36278/abstract/23\">",
"      Spector SL, Farr RS. The heterogeneity of asthmatic patients--an individualized approach to diagnosis and treatment. J Allergy Clin Immunol 1976; 57:499.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/27/36278/abstract/24\">",
"      Berry M, Morgan A, Shaw DE, et al. Pathological features and inhaled corticosteroid response of eosinophilic and non-eosinophilic asthma. Thorax 2007; 62:1043.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/27/36278/abstract/25\">",
"      Malmstrom K, Rodriguez-Gomez G, Guerra J, et al. Oral montelukast, inhaled beclomethasone, and placebo for chronic asthma. A randomized, controlled trial. Montelukast/Beclomethasone Study Group. Ann Intern Med 1999; 130:487.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/27/36278/abstract/26\">",
"      Chipps BE, Szefler SJ, Simons FE, et al. Demographic and clinical characteristics of children and adolescents with severe or difficult-to-treat asthma. J Allergy Clin Immunol 2007; 119:1156.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/27/36278/abstract/27\">",
"      Green RH, Brightling CE, McKenna S, et al. Asthma exacerbations and sputum eosinophil counts: a randomised controlled trial. Lancet 2002; 360:1715.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/27/36278/abstract/28\">",
"      Haldar P, Brightling CE, Hargadon B, et al. Mepolizumab and exacerbations of refractory eosinophilic asthma. N Engl J Med 2009; 360:973.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/27/36278/abstract/29\">",
"      Nair P, Pizzichini MM, Kjarsgaard M, et al. Mepolizumab for prednisone-dependent asthma with sputum eosinophilia. N Engl J Med 2009; 360:985.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/27/36278/abstract/30\">",
"      Sher ER, Leung DY, Surs W, et al. Steroid-resistant asthma. Cellular mechanisms contributing to inadequate response to glucocorticoid therapy. J Clin Invest 1994; 93:33.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/27/36278/abstract/31\">",
"      Adcock IM, Lane SJ, Brown CR, et al. Differences in binding of glucocorticoid receptor to DNA in steroid-resistant asthma. J Immunol 1995; 154:3500.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/27/36278/abstract/32\">",
"      Humbert M, Beasley R, Ayres J, et al. Benefits of omalizumab as add-on therapy in patients with severe persistent asthma who are inadequately controlled despite best available therapy (GINA 2002 step 4 treatment): INNOVATE. Allergy 2005; 60:309.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/27/36278/abstract/33\">",
"      Busse W, Corren J, Lanier BQ, et al. Omalizumab, anti-IgE recombinant humanized monoclonal antibody, for the treatment of severe allergic asthma. J Allergy Clin Immunol 2001; 108:184.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/27/36278/abstract/34\">",
"      Erzurum SC, Leff JA, Cochran JE, et al. Lack of benefit of methotrexate in severe, steroid-dependent asthma. A double-blind, placebo-controlled study. Ann Intern Med 1991; 114:353.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/27/36278/abstract/35\">",
"      Bernstein IL, Bernstein DI, Dubb JW, et al. A placebo-controlled multicenter study of auranofin in the treatment of patients with corticosteroid-dependent asthma. Auranofin Multicenter Drug Trial. J Allergy Clin Immunol 1996; 98:317.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/27/36278/abstract/36\">",
"      Lock SH, Kay AB, Barnes NC. Double-blind, placebo-controlled study of cyclosporin A as a corticosteroid-sparing agent in corticosteroid-dependent asthma. Am J Respir Crit Care Med 1996; 153:509.",
"     </a>",
"    </li>",
"   </ol>",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 544 Version 4.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.4 - C21.36",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     Southeast Alabama Med Ctr",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [1002-222.190.118.195-3C09538E6E-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f35_27_36278=[""].join("\n");
var outline_f35_27_36278=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li>",
"     <a class=\"sr_button\" href=\"#H7\" id=\"summRecButton\">",
"      <span>",
"       SUMMARY",
"      </span>",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H1\">",
"      INTRODUCTION",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H2\">",
"      EPIDEMIOLOGY",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H3\">",
"      CLINICAL COURSE",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H4\">",
"      PHYSIOLOGY",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H5\">",
"      PATHOLOGY",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H6\">",
"      RESPONSE TO THERAPY",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H7\">",
"      SUMMARY",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a href=\"#references\">",
"      REFERENCES",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   <div class=\"openRelatedGraphics\" id=\"PULM/544\" rel=\"outline_link\">",
"    GRAPHICS",
"    <a class=\"graphics_icon\" href=\"#\" title=\"View All Related Graphics\">",
"     View All",
"    </a>",
"   </div>",
"  </h1>",
"  <div id=\"relatedGraphics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"PULM/544|PIC\">",
"      <a href=\"#\" title=\"PICTURES\">",
"       PICTURES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_picture\" href=\"mobipreview.htm?16/7/16504\" title=\"picture 1\">",
"      Constrictive bronchiolitis Low",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_picture\" href=\"mobipreview.htm?34/5/34904\" title=\"picture 2\">",
"      Constrictive bronchiolitis High",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"PULM/544|TAB\">",
"      <a href=\"#\" title=\"TABLES\">",
"       TABLES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"mobipreview.htm?22/7/22653\" title=\"table 1A\">",
"      Asthma severity 12 and up",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"mobipreview.htm?14/35/14909\" title=\"table 1B\">",
"      Asthma severity 5 to 11 yrs",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"mobipreview.htm?40/41/41628\" title=\"table 1C\">",
"      Asthma severity 0 to 4 yrs",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?30/1/30746?source=related_link\">",
"      Agents affecting the 5-lipoxygenase pathway in the treatment of asthma",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?32/36/33354?source=related_link\">",
"      Alternative and experimental agents for the treatment of asthma",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?8/37/8794?source=related_link\">",
"      An overview of asthma management",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?23/43/24247?source=related_link\">",
"      Bronchiolitis in adults",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?13/49/14105?source=related_link\">",
"      Evaluation of severe asthma in adolescents and adults",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?7/42/7849?source=related_link\">",
"      Glucocorticoid-resistant asthma",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?3/17/3354?source=related_link\">",
"      Treatment of severe asthma in adolescents and adults",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?21/61/22487?source=related_link\">",
"      Use of pulmonary function testing in the diagnosis of asthma",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f35_27_36279="Pemetrexed: Drug information";
var content_f35_27_36279=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/wk_utd-rgb.myextg\" width=\"220px\">",
"   </img>",
"  </div>",
"  <div id=\"printHeaderText\">",
"   Official reprint from  UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"   <a href=\"file://www.uptodate.com\">",
"    www.uptodate.com",
"   </a>",
"   <br>",
"    &copy;2013 UpToDate",
"    <sup>",
"     &reg;",
"    </sup>",
"   </br>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"3\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"drugTitle\">",
"   Pemetrexed: Drug information",
"  </div>",
"  <div id=\"lexiTitleImg\">",
"   <img height=\"17\" src=\"./../images/lexiComp/Lexicomp_2012_71x17.myextg\" width=\"71\"/>",
"  </div>",
"  <div class=\"clear\">",
"  </div>",
"  <div id=\"drugCopy\">",
"   Copyright 1978-2013 Lexicomp, Inc. All rights reserved.",
"  </div>",
"  <div id=\"topicText\">",
"   (For additional information",
"   <a class=\"drug drug_patient\" href=\"mobipreview.htm?23/11/23732?source=see_link\">",
"    see \"Pemetrexed: Patient drug information\"",
"   </a>",
"   )",
"   <br/>",
"   For abbreviations and symbols that may be used in Lexicomp (",
"   <a class=\"graphic graphic_table\" href=\"mobipreview.htm?23/39/24183\">",
"    show table",
"   </a>",
"   )",
"   <div class=\"list ubnlist drugH1Div drugBrandNames\" id=\"F207166\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Brand Names: U.S.",
"    </span>",
"    <ul>",
"     <li>",
"      Alimta&reg;",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"list cbnlist drugH1Div drugBrandNames\" id=\"F854885\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Brand Names: Canada",
"    </span>",
"    <ul>",
"     <li>",
"      Alimta&reg;",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ex_sect_xr thclist drugH1Div drugBrandNames\" id=\"F207185\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pharmacologic Category",
"    </span>",
"    <ul>",
"     <li>",
"      Antineoplastic Agent, Antimetabolite;",
"     </li>",
"     <li>",
"      Antineoplastic Agent, Antimetabolite (Antifolate)",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"block doa drugH1Div\" id=\"F207168\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosing: Adult",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Details concerning dosing in combination regimens should also be consulted.",
"     <b>",
"      Note:",
"     </b>",
"     Start vitamin supplements 1 week before initial pemetrexed dose: Folic acid 400-1000 mcg daily orally (begin 7 days prior to treatment initiation; continue daily during treatment and for 21 days after last pemetrexed dose) and vitamin B",
"     <sub>",
"      12",
"     </sub>",
"     1000 mcg I.M. 7 days  prior to treatment initiation and then every 3 cycles. Give dexamethasone 4 mg orally twice daily for 3 days, beginning the day before treatment to minimize cutaneous reactions. New treatment cycles should not begin unless ANC &ge;1500/mm",
"     <sup>",
"      3",
"     </sup>",
"     , platelets &ge;100,000/mm",
"     <sup>",
"      3",
"     </sup>",
"     , and Cl",
"     <sub>",
"      cr",
"     </sub>",
"     &ge;45 mL/minute.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      Malignant pleural mesothelioma:",
"     </b>",
"     I.V.: 500 mg/m",
"     <sup>",
"      2",
"     </sup>",
"     on day 1 of each 21-day cycle (in combination with cisplatin)",
"     <b>",
"      or",
"     </b>",
"     (unlabeled) in combination with carboplatin (Castagneto, 2008; Ceresoli, 2006)",
"     <b>",
"      or",
"     </b>",
"     (unlabeled) as single-agent therapy (Jassem, 2008; Taylor, 2008)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;margin-top:2em;text-align:justify;\">",
"     <b>",
"      Nonsmall cell lung cancer:",
"     </b>",
"     I.V:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     <i>",
"      Initial treatment:",
"     </i>",
"     500 mg/m",
"     <sup>",
"      2",
"     </sup>",
"     on day 1 of each 21-day cycle (in combination with cisplatin)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     <i>",
"      Maintenance or second-line treatment:",
"     </i>",
"     500 mg/m",
"     <sup>",
"      2",
"     </sup>",
"     on day 1 of each 21-day cycle (as a single-agent)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      Bladder cancer (unlabeled use):",
"     </b>",
"     I.V.: 500 mg/m",
"     <sup>",
"      2",
"     </sup>",
"     on day 1 of each 21-day cycle (Sweeney, 2006)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      Cervical cancer, persistent or recurrent (unlabeled use):",
"     </b>",
"     I.V.: 500 mg/m",
"     <sup>",
"      2",
"     </sup>",
"     on day 1 of each 21-day cycle until disease progression or unacceptable toxicity occurs (Lorusso, 2010)",
"     <b>",
"      or",
"     </b>",
"     900 mg/m",
"     <sup>",
"      2",
"     </sup>",
"     on day 1 of each 21-day cycle (Miller, 2008)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      Ovarian cancer, platinum-resistant (unlabeled use):",
"     </b>",
"     I.V.: 500 mg/m",
"     <sup>",
"      2",
"     </sup>",
"     on day 1 of each 21-day cycle (Vergote, 2009)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      Thymic malignancies, metastatic (unlabeled use):",
"     </b>",
"     I.V.: 500 mg/m",
"     <sup>",
"      2",
"     </sup>",
"     on day 1 of each 21-day cycle for 6 cycles or until disease progression or unacceptable toxicity occurs (Loehrer, 2006)",
"    </p>",
"   </div>",
"   <div class=\"block doe drugH1Div\" id=\"F2997988\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosing: Geriatric",
"    </span>",
"    <p style=\"text-indent:0em;text-align:justify;display:inline\">",
"     Refer to adult dosing.",
"    </p>",
"   </div>",
"   <div class=\"block dor drugH1Div\" id=\"F207169\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosing: Renal Impairment",
"    </span>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Renal function may be estimated using the Cockcroft-Gault formula (using actual body weight) or glomerular filtration rate (GFR) measured by Tc99m-DPTA serum clearance.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Cl",
"     <sub>",
"      cr",
"     </sub>",
"     &ge;45 mL/minute: No dosage adjustment necessary.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Cl",
"     <sub>",
"      cr",
"     </sub>",
"     &lt;45 mL/minute: Use not recommended (an insufficient number of patients have been studied for dosage recommendations).",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <i>",
"      Concomitant NSAID use with renal dysfunction:",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Cl",
"     <sub>",
"      cr",
"     </sub>",
"     &ge;80 mL/minute: No dosage adjustment necessary.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Cl",
"     <sub>",
"      cr",
"     </sub>",
"     45 to 79 mL/minute and NSAIDs with short half-lives (eg, ibuprofen, indomethacin, ketoprofen, ketorolac): Avoid NSAID for 2 days before, the day of, and for 2 days following a dose of pemetrexed.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Any creatinine clearance and NSAIDs with long half-lives (eg, nabumetone, naproxen, oxaprozin, piroxicam): Avoid NSAID for 5 days before, the day of, and 2 days following a dose of pemetrexed.",
"    </p>",
"   </div>",
"   <div class=\"block doh drugH1Div\" id=\"F207170\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosing: Hepatic Impairment",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Grade 3 (5.1-20 times ULN)",
"     <b>",
"      or",
"     </b>",
"     4 (&gt;20 times ULN) transaminase elevation during treatment: Reduce pemetrexed dose to 75% of previous dose (and cisplatin).",
"    </p>",
"   </div>",
"   <div class=\"block dot drugH1Div\" id=\"F207186\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosing: Adjustment for Toxicity",
"    </span>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <i>",
"      Toxicity:",
"     </i>",
"     Discontinue if patient develops grade 3 or 4 toxicity after two dose reductions or immediately if grade 3 or 4 neurotoxicity develops",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <i>",
"      Hematologic toxicity:",
"     </i>",
"     Upon recovery, reinitiate therapy",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Nadir ANC &lt;500/mm",
"     <sup>",
"      3",
"     </sup>",
"     and nadir platelets &ge;50,000/mm",
"     <sup>",
"      3",
"     </sup>",
"     : Reduce dose to 75% of previous dose of pemetrexed (and cisplatin)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Nadir platelets &lt;50,000/mm",
"     <sup>",
"      3",
"     </sup>",
"     <b>",
"      without bleeding",
"     </b>",
"     (regardless of nadir ANC): Reduce dose to 75% of previous dose of pemetrexed (and cisplatin)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Nadir platelets &lt;50,000/mm",
"     <sup>",
"      3",
"     </sup>",
"     <b>",
"      with bleeding",
"     </b>",
"     (regardless of nadir ANC): Reduce dose to 50% of previous dose of pemetrexed (and cisplatin)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <i>",
"      Nonhematologic toxicity &ge;grade 3 (excluding neurotoxicity):",
"     </i>",
"     Withhold treatment until recovery to baseline; upon recovery, reinitiate therapy as follows:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Grade 3 or 4 toxicity (excluding mucositis): Reduce dose to 75% of previous dose of pemetrexed (and cisplatin)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Grade 3 or 4 diarrhea or any diarrhea requiring hospitalization: Reduce dose to 75% of previous dose of pemetrexed (and cisplatin)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Grade 3 or 4 mucositis: Reduce pemetrexed dose to 50% of previous dose (continue cisplatin at 100% of previous dose)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <i>",
"      Neurotoxicity:",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Grade 0-1: Continue pemetrexed at 100% of previous dose (and cisplatin)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Grade 2: Continue pemetrexed at 100% of previous dose; reduce cisplatin dose to 50% of previous dose",
"    </p>",
"   </div>",
"   <div class=\"block foc drugH1Div\" id=\"F207144\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosage Forms: U.S.",
"    </span>",
"    <p style=\"text-indent:0em;text-align:justify;display:inline\">",
"     Excipient information presented when available (limited, particularly for generics); consult specific product labeling.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Injection, powder for reconstitution:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Alimta&reg;: 100 mg, 500 mg",
"    </p>",
"   </div>",
"   <div class=\"block geq drugH1Div\" id=\"F2998602\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Generic Equivalent Available: U.S.",
"    </span>",
"    <p style=\"text-indent:0em;text-align:justify;display:inline\">",
"     No",
"    </p>",
"   </div>",
"   <div class=\"block adm drugH1Div\" id=\"F207146\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Administration",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     I.V.: Infuse over 10 minutes.",
"    </p>",
"    <p style=\"text-indent:0em;margin-top:2em;\">",
"     Hazardous agent; use appropriate precautions for handling and disposal",
"     <a href=\"file://www.cdc.gov/niosh/docs/2012-150/pdfs/2012-150.pdf\" target=\"_blank\">",
"      (NIOSH, 2012)",
"     </a>",
"     .",
"    </p>",
"   </div>",
"   <div class=\"block scp drugH1Div\" id=\"F207191\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Compatibility",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Stable in D",
"     <sub>",
"      5",
"     </sub>",
"     W (Zhang, 2006), NS; physically",
"     <b>",
"      incompatible",
"     </b>",
"     with calcium-containing products, including Ringer&rsquo;s and lactated Ringer&rsquo;s injection.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      Y-site administration: Compatible:",
"     </b>",
"     Acyclovir, amifostine, amikacin, aminophylline, ampicillin, ampicillin/sulbactam, aztreonam, bumetanide, buprenorphine, butorphanol, carboplatin, cefuroxime, cimetidine, cisplatin, clindamycin, cyclophosphamide, cytarabine, dexamethasone sodium phosphate, dexrazoxane, diphenhydramine, docetaxel, dopamine, enalaprilat, famotidine, fluconazole, fluorouracil, ganciclovir, granisetron, haloperidol, heparin, hydromorphone, hydroxyzine, ifosfamide, leucovorin calcium, lorazepam, mannitol, meperidine, mesna, methylprednisolone sodium succinate, metoclopramide, morphine, paclitaxel, potassium chloride, promethazine, ranitidine, sodium bicarbonate, ticarcillin/clavulanate potassium, trimethoprim/sulfamethoxazole, vancomycin, vinblastine, vincristine, zidovudine.",
"     <b>",
"      Incompatible:",
"     </b>",
"     Amphotericin B, calcium gluconate, cefazolin, cefotaxime, cefotetan, cefoxitin, ceftazidime, chlorpromazine, ciprofloxacin, dobutamine, doxorubicin, doxycycline, droperidol, gemcitabine, gentamicin, irinotecan, metronidazole, minocycline, mitoxantrone, nalbuphine, ondansetron, prochlorperazine edisylate, tobramycin, topotecan.",
"     <b>",
"      Variable (consult detailed reference):",
"     </b>",
"     Ceftriaxone.",
"    </p>",
"   </div>",
"   <div class=\"block use drugH1Div\" id=\"F207145\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Use",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Treatment of unresectable malignant pleural mesothelioma (in combination with cisplatin); treatment of locally advanced or metastatic",
"     <b>",
"      non",
"     </b>",
"     squamous nonsmall cell lung cancer (NSCLC; as initial treatment in combination with cisplatin, as single-agent maintenance treatment after 4 cycles of initial platinum-based double therapy, and single-agent treatment after prior chemotherapy)",
"    </p>",
"    <p style=\"text-indent:0em;margin-top:2em;\">",
"     <b>",
"      Note:",
"     </b>",
"     Not indicated for the treatment of",
"     <b>",
"      squamous",
"     </b>",
"     cell NSCLC",
"    </p>",
"   </div>",
"   <div class=\"block usu drugH1Div\" id=\"F207182\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Use - Unlabeled",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Treatment of bladder cancer (metastatic), cervical cancer (recurrent or metastatic), ovarian cancer (recurrent or persistent), thymic malignancies; treatment of malignant pleural mesothelioma (either as a single agent or in combination with carboplatin)",
"    </p>",
"   </div>",
"   <div class=\"block mst drugH1Div\" id=\"F3401929\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Medication Safety Issues",
"    </span>",
"    <div class=\"collapsible\">",
"     <span class=\"collapsible-title\">",
"      Sound-alike/look-alike issues:",
"     </span>",
"     <div class=\"collapsible-wrap\">",
"      <p style=\"text-indent:-2em;margin-left:4em;\">",
"       PEMEtrexed may be confused with methotrexate, PRALAtrexate",
"      </p>",
"     </div>",
"    </div>",
"    <div class=\"collapsible\">",
"     <span class=\"collapsible-title\">",
"      High alert medication:",
"     </span>",
"     <div class=\"collapsible-wrap\">",
"      <p style=\"text-indent:-2em;margin-left:4em;\">",
"       This medication is in a class the Institute for Safe Medication Practices (ISMP) includes among its list of drug classes which have a heightened risk of causing significant patient harm when used in error.",
"      </p>",
"     </div>",
"    </div>",
"   </div>",
"   <div class=\"block ars drugH1Div\" id=\"F207183\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Adverse Reactions Significant",
"    </span>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     &gt;10%:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Central nervous system: Fatigue (18% to 34%; dose-limiting)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Dermatologic: Rash/desquamation (10% to 14%)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Gastrointestinal: Nausea (12% to 31%), anorexia (19% to 22%), vomiting (6% to 16%), stomatitis (5% to 15%), diarrhea (5% to 13%)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Hematologic: Anemia (15% to 19%; grades 3/4: 3% to 5%), leukopenia (6% to 12%; grades 3/4: 2% to 4%), neutropenia (6% to 11%; grades 3/4: 3% to 5%; dose-limiting; nadir: 8-10 days; recovery: 4-8 days after nadir)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Respiratory: Pharyngitis (15%)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     1% to 10%:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Cardiovascular: Edema (1% to 5%)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Central nervous system: Fever (1% to 8%)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Dermatologic: Pruritus (1% to 7%), alopecia (1% to 6%), erythema multiforme (&le;5%)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Gastrointestinal: Constipation (1% to 6%), weight loss (1%), abdominal pain (&le;5%)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Hematologic: Thrombocytopenia (1% to 8%; grades 3/4: 2%; dose-limiting), febrile neutropenia (grades 3/4: 2%)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Hepatic: ALT increased (8% to 10%; grades 3/4: &le;2%), AST increased (7% to 8%; grades 3/4: &le;1%)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Neuromuscular &amp; skeletal: Sensory neuropathy (&le;9%), motor neuropathy (&le;5%)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Ocular: Conjunctivitis (&le;5%), lacrimation increased (&le;5%)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Renal: Creatinine increased/creatinine clearance decreased (1% to 5%)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Miscellaneous: Allergic reaction/hypersensitivity (&le;5%), infection (&le;5%), sepsis (1%)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     &lt;1% (Limited to important or life-threatening): Arrhythmia, colitis, dehydration, esophagitis, gastrointestinal obstruction, hemolytic anemia, hepatobiliary failure, hypertension, interstitial pneumonitis, pancreatitis, pancytopenia, peripheral ischemia, pulmonary embolism, radiation recall (median onset: 6 days; range: 1-35 days), renal failure, Stevens-Johnson syndrome, supraventricular arrhythmia, syncope, thrombosis/embolism, toxic epidermal necrolysis, ventricular tachycardia",
"    </p>",
"   </div>",
"   <div class=\"block coi drugH1Div\" id=\"F207149\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Contraindications",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Severe hypersensitivity to pemetrexed or any component of the formulation",
"    </p>",
"    <p style=\"text-indent:0em;margin-left:0em;margin-top:2em;\">",
"     Canadian labeling (additional contraindications; not in U.S. labeling): Concomitant yellow fever vaccine",
"    </p>",
"   </div>",
"   <div class=\"block war drugH1Div\" id=\"F207134\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Warnings/Precautions",
"    </span>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      <i>",
"       Concerns related to adverse effects:",
"      </i>",
"     </b>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Bone marrow suppression: May cause anemia, neutropenia, thrombocytopenia and/or pancytopenia; frequent laboratory monitoring is necessary (myelosuppression is often dose-limiting). Dose reductions in subsequent cycles may be required. Prophylactic folic acid and vitamin B",
"     <sub>",
"      12",
"     </sub>",
"     supplements are necessary to reduce hematologic toxicity, febrile neutropenia and infection; initiate supplementation 1 week before the first dose of pemetrexed.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Cutaneous reactions: May occur; pretreatment with dexamethasone is necessary to reduce the incidence and severity of cutaneous reactions. Rarely, Stevens-Johnson syndrome and toxic epidermal necrolysis have been reported.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Gastrointestinal toxicity: May occur; prophylactic folic acid and vitamin B",
"     <sub>",
"      12",
"     </sub>",
"     supplements are necessary to reduce gastrointestinal toxicity; initiate supplementation 1 week before the first dose of pemetrexed.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Hepatotoxicity: Serious hepatotoxicity (including rare fatalities) has been observed with monotherapy and in association with other chemotherapy, although underlying risk factors were present in some cases. Use caution with hepatic impairment not due to metastases; may require dose adjustment.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Hypersensitivity: Hypersensitivity (including anaphylaxis) has been reported with use.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Respiratory: Interstitial pneumonitis with respiratory insufficiency has been observed with use; interrupt therapy and evaluate promptly with progressive dyspnea and cough.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      <i>",
"       Disease-related concerns:",
"      </i>",
"     </b>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Renal impairment: Decreased renal function results in increased toxicity. The manufacturer does not recommend use if Cl",
"     <sub>",
"      cr",
"     </sub>",
"     &lt;45 mL/minute. Use caution in patients receiving concurrent nephrotoxins; may result in delayed pemetrexed clearance.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Third space fluid: Although the effect of third space fluid is not fully defined, studies have determined pemetrexed concentrations in patients with mild-to-moderate ascites/pleural effusions were similar to concentrations in trials of patients without third space fluid accumulation. Drainage of fluid from ascites/effusions may be considered, but is not likely necessary.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      <i>",
"       Concurrent drug therapy issues:",
"      </i>",
"     </b>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; NSAIDs: NSAIDs may reduce the clearance of pemetrexed. In patients with Cl",
"     <sub>",
"      cr",
"     </sub>",
"     45-79 mL/minute, interruption of NSAID therapy may be necessary prior to, during, and immediately after pemetrexed therapy.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      <i>",
"       Special handling:",
"      </i>",
"     </b>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Hazardous agent: Use appropriate precautions for handling and disposal",
"     <a href=\"file://www.cdc.gov/niosh/docs/2012-150/pdfs/2012-150.pdf\" target=\"_blank\">",
"      (NIOSH, 2012)",
"     </a>",
"     .",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      <i>",
"       Other warnings/precautions:",
"      </i>",
"     </b>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; NSCLC appropriate use: Not indicated for use in patients with squamous cell NSCLC.",
"    </p>",
"   </div>",
"   <div class=\"block cyt drugH1Div\" id=\"F13299833\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Metabolism/Transport Effects",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     None known.",
"    </p>",
"   </div>",
"   <div class=\"block dri drugH1Div\" id=\"F207138\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Drug Interactions",
"    </span>",
"    <br/>",
"    <br/>",
"    <div class=\"lexi\" id=\"lexiInteractAddInfo\">",
"     (For additional information:",
"     <a class=\"dip\" href=\"./drug-interaction\" target=\"_blank\">",
"      Launch Lexi-Interact&trade; Drug Interactions Program",
"     </a>",
"     )",
"    </div>",
"    <div class=\"lexi\" id=\"lexiInteractImgB\">",
"     <img border=\"0\" height=\"17\" src=\"./../images/lexiComp/Lexicomp_2012_71x17.myextg\" width=\"71\"/>",
"    </div>",
"    <div class=\"clear\">",
"    </div>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     BCG: Immunosuppressants may diminish the therapeutic effect of BCG.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     CloZAPine: Myelosuppressive Agents may enhance the adverse/toxic effect of CloZAPine. Specifically, the risk for agranulocytosis may be increased.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Coccidioidin Skin Test: Immunosuppressants may diminish the diagnostic effect of Coccidioidin Skin Test.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Denosumab: May enhance the adverse/toxic effect of Immunosuppressants. Specifically, the risk for serious infections may be increased.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Echinacea: May diminish the therapeutic effect of Immunosuppressants.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Leflunomide: Immunosuppressants may enhance the adverse/toxic effect of Leflunomide. Specifically, the risk for hematologic toxicity such as pancytopenia, agranulocytosis, and/or thrombocytopenia may be increased.  Management: Consider not using a leflunomide loading dose in patients receiving other immunosuppressants.  Patients receiving both leflunomide and another immunosuppressant should be monitored for bone marrow suppression at least monthly.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Natalizumab: Immunosuppressants may enhance the adverse/toxic effect of Natalizumab. Specifically, the risk of concurrent infection may be increased.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     NSAID (Nonselective): May increase the serum concentration of PEMEtrexed. Management: Patients with mild-to-moderate renal insufficiency (estimated creatinine clearance 45-79 mL/min) should avoid NSAIDs for 2-5 days prior to, the day of, and 2 days after pemetrexed.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Pimecrolimus: May enhance the adverse/toxic effect of Immunosuppressants.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Roflumilast: May enhance the immunosuppressive effect of Immunosuppressants.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Sipuleucel-T: Immunosuppressants may diminish the therapeutic effect of Sipuleucel-T.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Tacrolimus (Topical): May enhance the adverse/toxic effect of Immunosuppressants.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Tofacitinib: Immunosuppressants may enhance the immunosuppressive effect of Tofacitinib.  Management: Concurrent use with antirheumatic doses of methotrexate or other non-disease modifying antirheumatic drugs (non-DMARDs) is permitted, and this warning seems to particularly focused on more potent immunosuppressants.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Trastuzumab: May enhance the neutropenic effect of Immunosuppressants.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Vaccines (Inactivated): Immunosuppressants may diminish the therapeutic effect of Vaccines (Inactivated).",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Vaccines (Live): Immunosuppressants may enhance the adverse/toxic effect of Vaccines (Live). Vaccinial infections may develop. Immunosuppressants may diminish the therapeutic effect of Vaccines (Live).  Management: Avoid use of live organism vaccines with immunosuppressants; live-attenuated vaccines should not be given for at least 3 months after immunosuppressants.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"   </div>",
"   <div class=\"block foi drugH1Div\" id=\"F207162\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Ethanol/Nutrition/Herb Interactions",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Lower ANC nadirs occur in patients with elevated baseline cystathionine or homocysteine concentrations. Levels of these substances can be reduced by folic acid and vitamin B",
"     <sub>",
"      12",
"     </sub>",
"     supplementation.",
"    </p>",
"   </div>",
"   <div class=\"block prf drugH1Div\" id=\"F207140\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pregnancy Risk Factor",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     D (",
"     <a class=\"graphic graphic_table\" href=\"mobipreview.htm?16/42/17068\">",
"      show table",
"     </a>",
"     )",
"    </p>",
"   </div>",
"   <div class=\"block pri drugH1Div\" id=\"F207151\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pregnancy Implications",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Adverse effects (embryotoxicity, fetotoxicity and teratogenicity) were observed in animal reproduction studies. Based on the mechanism of action, may cause fetal harm if administered to a pregnant woman. Women of childbearing potential should have a negative serum pregnancy test prior to treatment and should use effective contraceptive measures to avoid becoming pregnant during treatment. Irreversible infertility has been reported in males; prior to receiving treatment, males should be counseled on sperm storage. The Canadian labeling recommends that males receiving therapy use effective contraceptive measures and not father a child during, and for up to 6 months after therapy.",
"    </p>",
"   </div>",
"   <div class=\"block lac drugH1Div\" id=\"F207176\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Lactation",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Excretion in breast milk unknown/not recommended",
"    </p>",
"   </div>",
"   <div class=\"block brc drugH1Div\" id=\"F2997980\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Breast-Feeding Considerations",
"    </span>",
"    <p style=\"text-indent:0em;text-align:justify;display:inline\">",
"     According to the manufacturer, the decision to continue or discontinue breast-feeding during therapy should take into account the risk of exposure to the infant and the benefits of treatment to the mother.",
"    </p>",
"   </div>",
"   <div class=\"block dic drugH1Div\" id=\"F207152\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dietary Considerations",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Initiate folic acid supplementation 1 week before first dose of pemetrexed, continue for full course of therapy, and for 21 days after last dose. Institute vitamin B",
"     <sub>",
"      12",
"     </sub>",
"     1 week before the first dose; administer every 9 weeks thereafter.",
"    </p>",
"   </div>",
"   <div class=\"block fee drugH1Div\" id=\"F4589208\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pricing: U.S. (Medi-Span&reg;)",
"    </span>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      Solution (reconstituted)",
"     </b>",
"     (Alimta Intravenous)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     100 mg (1): $695.40",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     500 mg (1): $3477.00",
"    </p>",
"   </div>",
"   <div class=\"block mop drugH1Div\" id=\"F207142\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Monitoring Parameters",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     CBC with differential and platelets (before each dose; monitor for nadir and recovery); serum creatinine, creatinine clearance, BUN, total bilirubin, ALT, AST (periodic); signs/symptoms of mucositis and diarrhea",
"    </p>",
"   </div>",
"   <div class=\"list fbnlist drugH1Div drugBrandNames\" id=\"F207153\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     International Brand Names",
"    </span>",
"    <ul>",
"     <li>",
"      Alimta (AR, AT, AU, BE, BG, BR, CH, CL, CN, CO, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HK, HN, ID, IE, IL, IT, KP, MT, MX, MY, NL, NO, NZ, PE, PH, PL, PT, RU, SE, SG, SK, TH, TR, TW);",
"     </li>",
"     <li>",
"      Jepale (CL);",
"     </li>",
"     <li>",
"      Jie Baili (CL)",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"block pha drugH1Div\" id=\"F207133\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Mechanism of Action",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Antifolate; disrupts folate-dependent metabolic processes essential for cell replication. Inhibits thymidylate synthase (TS), dihydrofolate reductase (DHFR), glycinamide ribonucleotide formyltransferase (GARFT), and aminoimidazole carboxamide ribonucleotide formyltransferase (AICARFT), the enzymes involved in folate metabolism and DNA synthesis, resulting in inhibition of purine and thymidine nucleotide and protein synthesis.",
"    </p>",
"   </div>",
"   <div class=\"block phk drugH1Div\" id=\"F207148\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pharmacodynamics/Kinetics",
"    </span>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Distribution: V",
"     <sub>",
"      dss",
"     </sub>",
"     : 16.1 L",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Protein binding: ~73% to 81%",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Metabolism: Minimal",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Half-life elimination: Normal renal function: 3.5 hours; Cl",
"     <sub>",
"      cr",
"     </sub>",
"     40-59 mL/minute: 5.3-5.8 hours",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Excretion: Urine (70% to 90% as unchanged drug)",
"    </p>",
"   </div>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div class=\"headingAnchor\" id=\"references\">",
"   <h1>",
"    REFERENCES",
"   </h1>",
"   <ol id=\"reference\">",
"    <li>",
"     <div class=\"reference\">",
"      Castagneto B, Botta M, Aitini E, et al, &ldquo;Phase II Study of Pemetrexed in Combination With Carboplatin in Patients With Malignant Pleural Mesothelioma (MPM),&rdquo;",
"      <i>",
"       Ann Oncol",
"      </i>",
"      , 2008, 19(2):370-3.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"mobipreview.htm?35/27/36279/abstract-text/18156144/pubmed\" id=\"18156144\" target=\"_blank\">",
"        18156144",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Ceresoli GL, Zucali PA, Favaretto AG, et al, &ldquo;Phase II Study of Pemetrexed Plus Carboplatin in Malignant Pleural Mesothelioma,&rdquo;",
"      <i>",
"       J Clin Oncol",
"      </i>",
"      , 2006, 24(9):1443-8.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"mobipreview.htm?35/27/36279/abstract-text/16549838/pubmed\" id=\"16549838\" target=\"_blank\">",
"        16549838",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Ciuleanu T, Brodowicz T, Zielinski C, et al, &ldquo;Maintenance Pemetrexed Plus Best Supportive Care versus Placebo Plus Best Supportive Care for Non-Small-Cell Lung Cancer: A Randomised, Double-Blind, Phase 3 Study,&rdquo;",
"      <i>",
"       Lancet",
"      </i>",
"      , 2009, 374(9699):1432-40.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"mobipreview.htm?35/27/36279/abstract-text/19767093/pubmed\" id=\"19767093\" target=\"_blank\">",
"        19767093",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Gr&oslash;nberg BH, Bremnes RM, Fl&oslash;tten O, et al, &ldquo;Phase III Study by the Norwegian Lung Cancer Study Group: Pemetrexed Plus Carboplatin Compared With Gemcitabine Plus Carboplatin as First-Line Chemotherapy in Advanced Non-Small-Cell Lung Cancer,&rdquo;",
"      <i>",
"       J Clin Oncol",
"      </i>",
"      , 2009, 27(19):3217-24.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"mobipreview.htm?35/27/36279/abstract-text/19433683/pubmed\" id=\"19433683\" target=\"_blank\">",
"        19433683",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Hanna N, Shepherd FA, Fossella FV, et al, &ldquo;Randomized Phase III Trial of Pemetrexed versus Docetaxel in Patients With Non-Small-Cell Lung Cancer Previously Treated With Chemotherapy,&rdquo;",
"      <i>",
"       J Clin Oncol",
"      </i>",
"      , 2004, 22(9):1589-97.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"mobipreview.htm?35/27/36279/abstract-text/15117980/pubmed\" id=\"15117980\" target=\"_blank\">",
"        15117980",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Jassem J, Ramlau R, Santoro A, et al, &ldquo;Phase III Trial of Pemetrexed Plus Best Supportive Care Compared With Best Supportive Care in Previously Treated Patients With Advanced Malignant Pleural Mesothelioma,&rdquo;",
"      <i>",
"       J Clin Oncol",
"      </i>",
"      , 2008, 26(10):1698-704.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"mobipreview.htm?35/27/36279/abstract-text/18375898/pubmed\" id=\"18375898\" target=\"_blank\">",
"        18375898",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Loehrer PJ, Yiannoutsos CT, Dropcho S, et al, &ldquo;A Phase II Trial of Pemetrexed in Patients With Recurrent Thymoma or Thymic Carcinoma,&rdquo;",
"      <i>",
"       J Clin Oncol",
"      </i>",
"      , 2006, 24(suppl):7079 [abstract 7079 from 2006 ASCO Annual Meeting].",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Lorusso D, Ferrandina G, Pignata S, et al, &ldquo;Evaluation of Pemetrexed (Alimta, LY231514) as Second-Line Chemotherapy in Persistent or Recurrent Carcinoma of the Cervix: The CERVIX 1 Study of the MITO (Multicentre Italian Trials in Ovarian Cancer and Gynecologic Malignancies) Group,&rdquo;",
"      <i>",
"       Ann Oncol",
"      </i>",
"      , 2010, 21(1):61-6.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"mobipreview.htm?35/27/36279/abstract-text/19605508/pubmed\" id=\"19605508\" target=\"_blank\">",
"        19605508",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Miller DS, Blessing JA, Bodurka DC, et al, &ldquo;Evaluation of Pemetrexed (Alimta, LY231514) as Second Line Chemotherapy in Persistent or Recurrent Carcinoma of the Cervix: A Phase II Study of the Gynecologic Oncology Group,&rdquo;",
"      <i>",
"       Gynecol Oncol",
"      </i>",
"      , 2008, 110(1):65-70.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"mobipreview.htm?35/27/36279/abstract-text/18455781/pubmed\" id=\"18455781\" target=\"_blank\">",
"        18455781",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Miller DS, Blessing JA, Krasner CN, et al, &ldquo;Phase II Evaluation of Pemetrexed in the Treatment of Recurrent or Persistent Platinum-Resistant Ovarian or Primary Peritoneal Carcinoma: A Study of the Gynecologic Oncology Group,&rdquo;",
"      <i>",
"       J Clin Oncol",
"      </i>",
"      , 2009, 27(16):2686-91.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"mobipreview.htm?35/27/36279/abstract-text/19332726/pubmed\" id=\"19332726\" target=\"_blank\">",
"        19332726",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Mita AC, Sweeney CJ, Baker SD, et al, &ldquo;Phase I and Pharmacokinetic Study of Pemetrexed Administered Every 3 Weeks to Advanced Cancer Patients With Normal and Impaired Renal Function,&rdquo;",
"      <i>",
"       J Clin Oncol",
"      </i>",
"      , 2006, 24(4):552-62.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"mobipreview.htm?35/27/36279/abstract-text/16391300/pubmed\" id=\"16391300\" target=\"_blank\">",
"        16391300",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      National Institute for Occupational Safety and Health (NIOSH), \"NIOSH List of Antineoplastic and Other Hazardous Drugs in Healthcare Settings 2012.\" Available at",
"      <a href=\"file://www.cdc.gov/niosh/docs/2012-150/pdfs/2012-150.pdf\" target=\"_blank\">",
"       file://www.cdc.gov/niosh/docs/2012-150/pdfs/2012-150.pdf",
"      </a>",
"      . Accessed January 21, 2013.",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Ouellet D, Periclou AP, Johnson RD, et al, &ldquo;Population Pharmacokinetics of Pemetrexed Disodium (ALIMTA) in Patients With Cancer,&rdquo;",
"      <i>",
"       Cancer Chemother Pharmacol",
"      </i>",
"      , 2000, 46(3):227-34.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"mobipreview.htm?35/27/36279/abstract-text/11021740/pubmed\" id=\"11021740\" target=\"_blank\">",
"        11021740",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Paz-Ares L, Bezares S, Tabernero JM, et al, &ldquo;Review of a Promising New Agent - Pemetrexed Disodium,&rdquo;",
"      <i>",
"       Cancer",
"      </i>",
"      , 2003, 97(8 Suppl):2056-63.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"mobipreview.htm?35/27/36279/abstract-text/12673697/pubmed\" id=\"12673697\" target=\"_blank\">",
"        12673697",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Rusch VW, &ldquo;Pemetrexed and Cisplatin for Malignant Pleural Mesothelioma: A New Standard of Care?&rdquo;",
"      <i>",
"       J Clin Oncol",
"      </i>",
"      , 2003, 21(14):2629-30.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"mobipreview.htm?35/27/36279/abstract-text/12860935/pubmed\" id=\"12860935\" target=\"_blank\">",
"        12860935",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Scagliotti GV, Parikh P, von Pawel J, et al, &ldquo;Phase III Study Comparing Cisplatin Plus Gemcitabine With Cisplatin Plus Pemetrexed in Chemotherapy-Naive Patients With Advanced-Stage Non-Small-Cell Lun Cancer,&rdquo;",
"      <i>",
"       J Clin Oncol",
"      </i>",
"      , 2008, 26(21):3543-51.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"mobipreview.htm?35/27/36279/abstract-text/18506025/pubmed\" id=\"18506025\" target=\"_blank\">",
"        18506025",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Schmitt J and Loehrer PJ Sr, &ldquo;The Role of Chemotherapy in Advanced Thymoma,&rdquo;",
"      <i>",
"       J Thorac Oncol",
"      </i>",
"      , 2010, 5(10 Suppl 4):357-60.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"mobipreview.htm?35/27/36279/abstract-text/20859133/pubmed\" id=\"20859133\" target=\"_blank\">",
"        20859133",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Socinski MA, Smit EF, Lorigan P, et al, &ldquo;Phase III study of Pemetrexed Plus Carboplatin Compared With Etoposide Plus Carboplatin in Chemotherapy-Naive Patients With Extensive-Stage Small-Cell Lung Cancer,&rdquo;",
"      <i>",
"       J Clin Oncol",
"      </i>",
"      , 2009, 27(28):4787-92.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"mobipreview.htm?35/27/36279/abstract-text/19720897/pubmed\" id=\"19720897\" target=\"_blank\">",
"        19720897",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Sweeney CJ, Roth BJ, Kabbinavar FF, et al, &ldquo;Phase II Study of Pemetrexed for Second-Line Treatment of Transitional Cell Cancer of the Urothelium,&rdquo;",
"      <i>",
"       J Clin Oncol",
"      </i>",
"      , 2006, 24(21):3451-7.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"mobipreview.htm?35/27/36279/abstract-text/16849761/pubmed\" id=\"16849761\" target=\"_blank\">",
"        16849761",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Sweeney CJ, Takimoto CH, Latz JE, et al, &ldquo;Two Drug Interaction Studies Evaluating the Pharmacokinetics and Toxicity of Pemetrexed When Coadministered With Aspirin or Ibuprofen in Patients With Advanced Cancer,&rdquo;",
"      <i>",
"       Clin Cancer Res",
"      </i>",
"      , 2006, 12(2):536-42.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"mobipreview.htm?35/27/36279/abstract-text/16428497/pubmed\" id=\"16428497\" target=\"_blank\">",
"        16428497",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Taylor P, Castagneto B, Dark G, et al, &ldquo;Single-Agent Pemetrexed for Chemona&iuml;ve and Pretreated Patients With Malignant Pleural Mesothelioma: Results of an International Expanded Access Program,&rdquo;",
"      <i>",
"       J Thorac Oncol",
"      </i>",
"      , 2008, 3(7):764-71",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"mobipreview.htm?35/27/36279/abstract-text/18594323/pubmed\" id=\"18594323\" target=\"_blank\">",
"        18594323",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Trissel LA, Saenz CA, Ogundele AB, et al, &ldquo;Physical Compatibility of Pemetrexed Disodium With Other Drugs During Simulated Y-Site Administration,&rdquo;",
"      <i>",
"       Am J Health Syst Pharm",
"      </i>",
"      , 2004, 61(21):2289-93.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"mobipreview.htm?35/27/36279/abstract-text/15552637/pubmed\" id=\"15552637\" target=\"_blank\">",
"        15552637",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Urba S, van Herpen CM, Sahoo TP, et al, &ldquo;Pemetrexed in Combination With Cisplatin versus Cisplatin Monotherapy in Patients With Recurrent or Metastatic Head and Neck Cancer: Final Results of a Randomized, Double-Blind, Placebo-Controlled, Phase 3 Study,&rdquo;",
"      <i>",
"       Cancer",
"      </i>",
"      , 2012, 118(19):4694-705.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"mobipreview.htm?35/27/36279/abstract-text/22434360/pubmed\" id=\"22434360\" target=\"_blank\">",
"        22434360",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Vergote I, Calvert H, Kania M, et al, &ldquo;A Randomised, Double-Blind, Phase II Study of Two Doses of Pemetrexed in the Treatment of Platinum-Resistant, Epithelial Ovarian or Primary Peritoneal Cancer,&rdquo;",
"      <i>",
"       Eur J Cancer",
"      </i>",
"      , 2009, 45(8):1415-23.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"mobipreview.htm?35/27/36279/abstract-text/19168349/pubmed\" id=\"19168349\" target=\"_blank\">",
"        19168349",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Zhang Y and Trissel LA, &ldquo;Physical and Chemical Stability of Pemetrexed in Infusion Solutions,&rdquo;",
"      <i>",
"       Ann Pharmacother",
"      </i>",
"      , 2006, 40(6):1082-5.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"mobipreview.htm?35/27/36279/abstract-text/16720706/pubmed\" id=\"16720706\" target=\"_blank\">",
"        16720706",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Zhang Y and Trissel LA, &ldquo;Physical and Chemical Stability of Pemetrexed Solutions in Plastic Syringes,&rdquo;",
"      <i>",
"       Ann Pharmacother",
"      </i>",
"      , 2005, 39(12):2026-8.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"mobipreview.htm?35/27/36279/abstract-text/16227449/pubmed\" id=\"16227449\" target=\"_blank\">",
"        16227449",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"   </ol>",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 10098 Version 41.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.3 - C21.34",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     Morehouse School of Medicine",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [0603-210.101.131.232-DB21B48F7E-S473950.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f35_27_36279=[""].join("\n");
var outline_f35_27_36279=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F207166\">",
"      Brand Names: U.S.",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F854885\">",
"      Brand Names: Canada",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F207185\">",
"      Pharmacologic Category",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F207168\">",
"      Dosing: Adult",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F2997988\">",
"      Dosing: Geriatric",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F207169\">",
"      Dosing: Renal Impairment",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F207170\">",
"      Dosing: Hepatic Impairment",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F207186\">",
"      Dosing: Adjustment for Toxicity",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F207144\">",
"      Dosage Forms: U.S.",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F2998602\">",
"      Generic Equivalent Available: U.S.",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F207146\">",
"      Administration",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F207191\">",
"      Compatibility",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F207145\">",
"      Use",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F207182\">",
"      Use - Unlabeled",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F3401929\">",
"      Medication Safety Issues",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F207183\">",
"      Adverse Reactions Significant",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F207149\">",
"      Contraindications",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F207134\">",
"      Warnings/Precautions",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F13299833\">",
"      Metabolism/Transport Effects",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F207138\">",
"      Drug Interactions",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F207162\">",
"      Ethanol/Nutrition/Herb Interactions",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F207140\">",
"      Pregnancy Risk Factor",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F207151\">",
"      Pregnancy Implications",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F207176\">",
"      Lactation",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F2997980\">",
"      Breast-Feeding Considerations",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F207152\">",
"      Dietary Considerations",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F4589208\">",
"      Pricing: U.S. (Medi-Span&reg;)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F207142\">",
"      Monitoring Parameters",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F207153\">",
"      International Brand Names",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F207133\">",
"      Mechanism of Action",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F207148\">",
"      Pharmacodynamics/Kinetics",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a href=\"#references\">",
"      REFERENCES",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   <div class=\"openRelatedGraphics\" id=\"DRUG_GEN/10098\" rel=\"outline_link\">",
"    GRAPHICS",
"    <a class=\"graphics_icon\" href=\"#\" title=\"View All Related Graphics\">",
"     View All",
"    </a>",
"   </div>",
"  </h1>",
"  <div id=\"relatedGraphics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"DRUG_GEN/10098|TAB\">",
"      <a href=\"#\" title=\"TABLES\">",
"       TABLES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"mobipreview.htm?23/39/24183\" title=\"Lexicomp clinical abbreviations\">",
"      Lexicomp clinical abbreviations",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"drug drug_patient\" href=\"mobipreview.htm?23/11/23732?source=related_link\">",
"      Pemetrexed: Patient drug information",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f35_27_36280="Cytotoxicity assays I";
var content_f35_27_36280=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=ALLRG%2F55165&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=2\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=ALLRG%2F55165&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=2\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 534px\">",
"   <div class=\"ttl\">",
"    Flow cytometry based cytotoxicity assay",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 514px; height: 544px; background-image: url(data:image/gif;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    Target cells (K562 cell line) are fluorescently labeled and incubated with increasing ratios of individual's PBMCs. Cytotoxicity is measured by staining of the labeled target cells with 7-AAD, an indicator of cell death, and cell size which decreases upon apoptosis.",
"    <div class=\"footnotes\">",
"     %: percent.",
"    </div>",
"    <div class=\"reference\">",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f35_27_36280=[""].join("\n");
var outline_f35_27_36280=null;
var title_f35_27_36281="Pregnancy risks in women with type 1 and type 2 diabetes mellitus";
var content_f35_27_36281=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"4\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"topicTitle\">",
"   Pregnancy risks in women with type 1 and type 2 diabetes mellitus",
"  </div>",
"  <div id=\"topicContributors\">",
"   <div>",
"    <a id=\"authors\">",
"    </a>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"mobipreview.htm?35/27/36281/contributors\">",
"     Authors",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"mobipreview.htm?35/27/36281/contributors\">",
"     Thomas R Moore, MD",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"mobipreview.htm?35/27/36281/contributors\">",
"     Lois Jovanovic, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"mobipreview.htm?35/27/36281/contributors\">",
"     Section Editors",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"mobipreview.htm?35/27/36281/contributors\">",
"     David M Nathan, MD",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"mobipreview.htm?35/27/36281/contributors\">",
"     Michael F Greene, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"mobipreview.htm?35/27/36281/contributors\">",
"     Deputy Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"mobipreview.htm?35/27/36281/contributors\">",
"     Vanessa A Barss, MD",
"    </a>",
"    <br/>",
"   </div>",
"  </div>",
"  <div id=\"disclosures\">",
"   <a href=\"mobipreview.htm?35/27/36281/contributor-disclosure\" target=\"_blank\">",
"    Disclosures",
"   </a>",
"  </div>",
"  <div id=\"reviewProcess\">",
"   <span>",
"    All topics are updated as new evidence becomes available and our",
"   </span>",
"   <a href=\"/home/editorial-policy\" target=\"_blank\">",
"    peer review process",
"   </a>",
"   <span>",
"    is complete.",
"   </span>",
"  </div>",
"  <div id=\"literatureReviewDate\">",
"   <span class=\"emphasis\">",
"    Literature review current through:",
"   </span>",
"   Oct 2013.",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <span class=\"emphasis\">",
"    This topic last updated:",
"   </span>",
"   Jan 23, 2012.",
"  </div>",
"  <div id=\"topicText\">",
"   <p class=\"headingAnchor\" id=\"H1\">",
"    <span class=\"h1\">",
"     INTRODUCTION",
"    </span>",
"    &nbsp;&mdash;&nbsp;Diabetes in pregnant women may be pregestational, where the diabetes (type 1 or type 2) was diagnosed before pregnancy, or gestational, which refers to diabetes diagnosed during pregnancy. The prevalence of pregestational diabetes among women in their reproductive years is increasing. In a retrospective study of 175,249 pregnancies, the prevalence of pregestational diabetes rose from 0.81 percent in 1999 to 1.82 percent in 2005 [",
"    <a class=\"abstract\" href=\"mobipreview.htm?35/27/36281/abstract/1\">",
"     1",
"    </a>",
"    ]. &nbsp;",
"   </p>",
"   <p>",
"    The importance of preconceptional evaluation and counseling of women with pregestational diabetes mellitus (type 1 or type 2) cannot be overstated [",
"    <a class=\"abstract\" href=\"mobipreview.htm?35/27/36281/abstract/2\">",
"     2",
"    </a>",
"    ]. Women who are in poor glycemic control during the period of fetal organogenesis, which is nearly complete by seven weeks postconception, have a high incidence of spontaneous abortion and fetuses with congenital anomalies [",
"    <a class=\"abstract\" href=\"mobipreview.htm?35/27/36281/abstract/3\">",
"     3",
"    </a>",
"    ]. Later in pregnancy, poor glycemic control increases the risk of macrosomia and its sequelae. For women with type 1 diabetes, the presence of vascular complications is associated with an increased risk of preterm delivery and perinatal mortality [",
"    <a class=\"abstract\" href=\"mobipreview.htm?35/27/36281/abstract/4\">",
"     4",
"    </a>",
"    ]. In addition to fetal complications, the physiological changes associated with pregnancy can adversely impact maternal health. Retinopathy, nephropathy, hypertension, neuropathy, cardiovascular disease, and thyroid disease can all affect and be affected by pregnancy.",
"   </p>",
"   <p>",
"    This topic will review the potential fetal, maternal, and neonatal complications associated with pregnancy in women whose diabetes antedates the pregnancy. The evaluation of these women is discussed separately. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?41/31/42487?source=see_link\">",
"     \"Prepregnancy evaluation and management of women with type 1 or type 2 diabetes mellitus\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Medical treatment of diabetes during pregnancy and obstetrical management of pregnancy in diabetic women are also discussed separately. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?20/19/20794?source=see_link\">",
"     \"Medical management of type 1 and type 2 diabetes mellitus in pregnant women\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?34/62/35818?source=see_link\">",
"     \"Obstetrical management of pregnancy complicated by pregestational diabetes mellitus\"",
"    </a>",
"    .) Diagnosis and treatment of gestational diabetes is also reviewed separately. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?8/63/9210?source=see_link\">",
"     \"Screening and diagnosis of diabetes mellitus during pregnancy\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?36/62/37866?source=see_link\">",
"     \"Medical management and follow-up of gestational diabetes mellitus\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H2\">",
"    <span class=\"h1\">",
"     OVERVIEW OF PREGNANCY OUTCOME",
"    </span>",
"    &nbsp;&mdash;&nbsp;The increased risk of pregnancy complications in women with pregestational diabetes was illustrated in a prospective series from Sweden, which included 5089 singleton pregnancies in women with type 1 diabetes and 1.2 million singleton pregnancies in the general obstetrical population from 1991 and 2003 [",
"    <a class=\"abstract\" href=\"mobipreview.htm?35/27/36281/abstract/5\">",
"     5",
"    </a>",
"    ]. A small number of women with type 2 diabetes were included with the diabetes group because, from 1991 to 1997, women with pregestational diabetes were not categorized as type 1 or 2 in the database.",
"   </p>",
"   <p>",
"    Adverse pregnancy outcomes were consistently and significantly higher for women with type 1 diabetes [",
"    <a class=\"abstract\" href=\"mobipreview.htm?35/27/36281/abstract/5\">",
"     5",
"    </a>",
"    ]:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Cesarean delivery: 46 versus 12 percent",
"     </li>",
"     <li>",
"      Large for gestational age infant (&ge;97.5 percentile): 31 versus 3.6 percent",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    <ul class=\"hyphen-block\">",
"     <li>",
"      Birth weight &ge;4500 grams: 12.6 versus 3.9 percent",
"     </li>",
"     <li>",
"      Birth weight &ge;5000 grams: 2.7 versus 0.5 percent",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Shoulder dystocia: 13.7 versus 0.2 percent",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    <ul class=\"hyphen-block\">",
"     <li>",
"      Erb's palsy: 2.1 versus 0.2 percent",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Preeclampsia",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    <ul class=\"hyphen-block\">",
"     <li>",
"      Mild: 9.7 versus 2.0 percent",
"     </li>",
"     <li>",
"      Severe: 4.3 versus 0.8 percent",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Major malformations: 4.7 versus 1.8 percent",
"     </li>",
"     <li>",
"      Preterm birth",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    <ul class=\"hyphen-block\">",
"     <li>",
"      &lt;37 weeks of gestation: 21 versus 5.1 percent",
"     </li>",
"     <li>",
"      &lt;32 weeks: 2.3 versus 0.7 percent",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Respiratory distress syndrome: 1 versus 0.2 percent",
"     </li>",
"     <li>",
"      Stillbirth: 1.5 versus 0.3 percent",
"     </li>",
"     <li>",
"      Perinatal mortality:",
"      <span class=\"nowrap\">",
"       20/1000",
"      </span>",
"      versus",
"      <span class=\"nowrap\">",
"       4.8/1000",
"      </span>",
"     </li>",
"     <li>",
"      Neonatal death (day 0 to 28 of life):",
"      <span class=\"nowrap\">",
"       7/1000",
"      </span>",
"      versus",
"      <span class=\"nowrap\">",
"       2.2/1000",
"      </span>",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    One exception was \"small for gestational age,\" which occurred less frequently in pregnancies of women with diabetes: 2.3 versus 2.5 percent.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H3\">",
"    <span class=\"h1\">",
"     FETAL AND NEONATAL COMPLICATIONS",
"    </span>",
"    &nbsp;&mdash;&nbsp;The three major potential fetal complications among women with pregestational diabetes are: congenital malformations, spontaneous abortion, and macrosomia (birthweight above the 90",
"    <sup>",
"     th",
"    </sup>",
"    percentile or &gt;4000 g). Hyperglycemia is the most important determinant of these risks. This conclusion is supported by repeated observations that normalizing blood glucose concentrations before and early in pregnancy can reduce the risk of spontaneous abortion and congenital malformations to nearly that of non-diabetic women [",
"    <a class=\"abstract\" href=\"mobipreview.htm?35/27/36281/abstract/6-11\">",
"     6-11",
"    </a>",
"    ]. The frequency of macrosomia, which evolves later in pregnancy, can be lowered, as well [",
"    <a class=\"abstract\" href=\"mobipreview.htm?35/27/36281/abstract/12\">",
"     12",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H4\">",
"    <span class=\"h2\">",
"     Congenital malformations",
"    </span>",
"    &nbsp;&mdash;&nbsp;Studies have consistently shown that major congenital malformations (ie, those that require surgical correction or affect the health of the infant) occur more often in infants of women with diabetes than in infants of women without diabetes and this excess risk is related to the level of maternal hyperglycemia during the embryonic period. The overall risk of one or more major anomalies is 6 to 7 percent, which is more than double the risk in the general obstetric population [",
"    <a class=\"abstract\" href=\"mobipreview.htm?35/27/36281/abstract/13\">",
"     13",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    The fetal anomalies associated with exposure to hyperglycemia in early pregnancy generally span the range of the anomalies found in offspring of non-diabetic women, except that infants of women with diabetes appear to be at significantly higher risk of renal",
"    <span class=\"nowrap\">",
"     agenesis/caudal",
"    </span>",
"    dysgenesis syndrome, congenital heart defects, and neural tube defects [",
"    <a class=\"abstract\" href=\"mobipreview.htm?35/27/36281/abstract/12,14-16\">",
"     12,14-16",
"    </a>",
"    ]. For example, sacral",
"    <span class=\"nowrap\">",
"     agenesis/caudal",
"    </span>",
"    dysplasia is rare in the general population, but highly associated with maternal diabetes, and accounts for 15 to 20 percent of all cases [",
"    <a class=\"abstract\" href=\"mobipreview.htm?35/27/36281/abstract/15,17\">",
"     15,17",
"    </a>",
"    ]. The congenital heart defects increased in diabetic pregnancy include heterotaxia, tetralogy of Fallot, transposition of the great arteries, septal defects, anomalous pulmonary venous return, and various defects causing left or right outflow obstruction. Central nervous system defects include anencephaly, spina bifida, encephalocele, hydrocephaly, and",
"    <span class=\"nowrap\">",
"     anotia/microtia.",
"    </span>",
"    The risks of limb deficiencies, hypospadias, and orofacial clefts are also increased.",
"   </p>",
"   <p>",
"    In vitro studies of rodent embryo cultures have demonstrated that increasing glucose concentration causes embryopathy in a dose-dependent fashion [",
"    <a class=\"abstract\" href=\"mobipreview.htm?35/27/36281/abstract/18,19\">",
"     18,19",
"    </a>",
"    ]. There are probably several mechanisms by which hyperglycemia leads to dysmorphogenesis. It is known that excess glucose metabolism by embryos in a hyperglycemic environment disturbs a complex network of biochemical pathways [",
"    <a class=\"abstract\" href=\"mobipreview.htm?35/27/36281/abstract/20\">",
"     20",
"    </a>",
"    ]. One consequence of this disturbance is oxidative stress, which inhibits expression of regulatory genes, such as Pax3, which control essential developmental processes in the early embryo, resulting in apoptosis as well as abnormal cellular proliferation and differentiation [",
"    <a class=\"abstract\" href=\"mobipreview.htm?35/27/36281/abstract/21-28\">",
"     21-28",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Hypoglycemia related to insulin therapy or insulin secreting tumors does not appear to be teratogenic in human embryos. However, there are many reports demonstrating dysmorphogenesis resulting from hypoglycemia in rodents, who may be more dependent upon high maternal blood glucose levels to achieve adequate transplacental passage of glucose [",
"    <a class=\"abstract\" href=\"mobipreview.htm?35/27/36281/abstract/29\">",
"     29",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?8/61/9174?source=see_link\">",
"     Folic acid",
"    </a>",
"    supplementation preconceptionally and during organogenesis can decrease the risk of some neural tube defects, and possibly other congenital anomalies. Some clinicians recommended enhanced folic acid supplementation (4 mg daily) in women with pregestational diabetes, while others do not because they believe that glucose-mediated neural tube defects probably are not prevented by folic acid supplementation. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?4/61/5081?source=see_link\">",
"     \"Folic acid for prevention of neural tube defects\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?16/25/16794?source=see_link&amp;anchor=H25#H25\">",
"     \"Preconception evaluation and counseling\", section on 'Nutrition and supplements'",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?41/31/42487?source=see_link&amp;anchor=H13#H13\">",
"     \"Prepregnancy evaluation and management of women with type 1 or type 2 diabetes mellitus\", section on 'Folic acid supplements'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H5\">",
"    <span class=\"h2\">",
"     Spontaneous abortion",
"    </span>",
"    &nbsp;&mdash;&nbsp;The increased frequency of spontaneous abortion in poorly controlled diabetic women is thought to be secondary to hyperglycemia, maternal vascular disease, including uteroplacental insufficiency, and possibly immunologic factors [",
"    <a class=\"abstract\" href=\"mobipreview.htm?35/27/36281/abstract/30-32\">",
"     30-32",
"    </a>",
"    ]. The excess risk of spontaneous abortion in diabetic women is probably related, in part, to the increased frequency of dysmorphogenesis (see above). By comparison, at least one-half of spontaneous abortions in the general population are related to chromosomal abnormalities [",
"    <a class=\"abstract\" href=\"mobipreview.htm?35/27/36281/abstract/11,33\">",
"     11,33",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?19/23/19834?source=see_link\">",
"     \"Spontaneous abortion: Risk factors, etiology, clinical manifestations, and diagnostic evaluation\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H6\">",
"    <span class=\"h2\">",
"     Macrosomia",
"    </span>",
"    &nbsp;&mdash;&nbsp;Macrosomia is typically defined as birth weight greater than 4.0 to 4.5 kg or above the 90th percentile for gestational age. The most serious potential complication of macrosomia is shoulder dystocia, which may result in brachial plexus injury to the infant. Macrosomia also increases the likelihood that a cesarean delivery will be performed [",
"    <a class=\"abstract\" href=\"mobipreview.htm?35/27/36281/abstract/34\">",
"     34",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?16/1/16408?source=see_link\">",
"     \"Timing and route of delivery in pregnancies at risk of shoulder dystocia\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?34/62/35818?source=see_link&amp;anchor=H24#H24\">",
"     \"Obstetrical management of pregnancy complicated by pregestational diabetes mellitus\", section on 'Route of delivery'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Maternal diabetes mellitus significantly increases the chance of having a macrosomic infant; it also alters the anthropomorphic measurements of infants of diabetic mothers compared to offspring of nondiabetic women [",
"    <a class=\"abstract\" href=\"mobipreview.htm?35/27/36281/abstract/35,36\">",
"     35,36",
"    </a>",
"    ]. Macrosomic infants of diabetic mothers have larger shoulder and extremity circumferences, a decreased head-to-shoulder ratio, higher body fat, and thicker upper extremity skinfolds compared to nondiabetic control infants of similar weight and length [",
"    <a class=\"abstract\" href=\"mobipreview.htm?35/27/36281/abstract/36\">",
"     36",
"    </a>",
"    ]. These changes are caused, at least in part, by increased maternal-fetal transfer of substrates (glucose, amino acids) leading to fetal hyperinsulinemia and storage of excess nutrients as fat [",
"    <a class=\"abstract\" href=\"mobipreview.htm?35/27/36281/abstract/37\">",
"     37",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Although macrosomia is typically considered a late",
"    <span class=\"nowrap\">",
"     pregnancy/neonatal",
"    </span>",
"    problem, the pathogenetic factors leading to macrosomia appear to be present in early pregnancy. Support for this conclusion derives from the observation that tight control of maternal blood glucose concentration at conception and the first trimester has a greater impact on reducing the risk of delivering a macrosomic neonate than late pregnancy glycemic control [",
"    <a class=\"abstract\" href=\"mobipreview.htm?35/27/36281/abstract/12,38,39\">",
"     12,38,39",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    By comparison, the effect of hypoglycemia on fetal growth has not been studied extensively. One series suggested that mean blood glucose less than or equal to 86",
"    <span class=\"nowrap\">",
"     mg/dL",
"    </span>",
"    during pregnancy was associated with an increased frequency of small for gestational age infants [",
"    <a class=\"abstract\" href=\"mobipreview.htm?35/27/36281/abstract/40\">",
"     40",
"    </a>",
"    ]. However, episodic hypoglycemia during pregnancy has also been associated with an increased frequency of macrosomia, presumably due to rebound hyperglycemia.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H7\">",
"    <span class=\"h2\">",
"     Polyhydramnios",
"    </span>",
"    &nbsp;&mdash;&nbsp;Polyhydramnios (ie, excessive amniotic fluid) occurs more frequently in pregnancies complicated by diabetes, especially those with poor glycemic control and large for gestational age fetuses [",
"    <a class=\"abstract\" href=\"mobipreview.htm?35/27/36281/abstract/41\">",
"     41",
"    </a>",
"    ], although the pathophysiology is poorly understood. Polyhydramnios can be uncomfortable for the mother and increases the risk of fetal death and preterm birth. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?4/44/4808?source=see_link\">",
"     \"Polyhydramnios\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H8\">",
"    <span class=\"h2\">",
"     Preterm birth",
"    </span>",
"    &nbsp;&mdash;&nbsp;Women with pregestational diabetes mellitus have higher rates of both indicated preterm delivery (22 versus 3 percent; odds ratio 8.1; 95% CI 6.0-10.9) and spontaneous preterm delivery (16 versus 11 percent; odds ratio 1.6; 95% CI 1.2-2.2) compared to healthy controls [",
"    <a class=\"abstract\" href=\"mobipreview.htm?35/27/36281/abstract/42\">",
"     42",
"    </a>",
"    ]. The reasons for the increase in spontaneous preterm delivery are not well-defined, but the increase in indicated preterm delivery is related to such factors as preeclampsia, worsening nephropathy, macrosomia, and poor glycemic control, all of which are associated with a higher risk of late fetal death. Preterm infants are at increased risk of hyaline membrane disease, especially in the setting of poor maternal glycemic control. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?34/62/35818?source=see_link\">",
"     \"Obstetrical management of pregnancy complicated by pregestational diabetes mellitus\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H9\">",
"    <span class=\"h2\">",
"     Perinatal mortality",
"    </span>",
"    &nbsp;&mdash;&nbsp;The incidence of late fetal death in pregnancies complicated by diabetes mellitus, which was 50 percent in the pre-insulin era, has been steadily falling, presumably due to stricter glycemic control and improvements in obstetrical and neonatal care [",
"    <a class=\"abstract\" href=\"mobipreview.htm?35/27/36281/abstract/42,43\">",
"     42,43",
"    </a>",
"    ]. The stillbirth rate in women with optimal glycemic control now approaches that of nondiabetic women [",
"    <a class=\"abstract\" href=\"mobipreview.htm?35/27/36281/abstract/43-45\">",
"     43-45",
"    </a>",
"    ], especially in the absence of macrosomia and polyhydramnios. Congenital malformations now account for approximately 50 percent of the perinatal deaths in infants of diabetic mothers [",
"    <a class=\"abstract\" href=\"mobipreview.htm?35/27/36281/abstract/46\">",
"     46",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?34/62/35818?source=see_link&amp;anchor=H23#H23\">",
"     \"Obstetrical management of pregnancy complicated by pregestational diabetes mellitus\", section on 'Timing of delivery'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H10\">",
"    <span class=\"h2\">",
"     Neurodevelopmental outcome",
"    </span>",
"    &nbsp;&mdash;&nbsp;Maternal hypoglycemia has not been shown to adversely affect the fetus's long-term neurodevelopment, but data are sparse [",
"    <a class=\"abstract\" href=\"mobipreview.htm?35/27/36281/abstract/47\">",
"     47",
"    </a>",
"    ]. Whether hyperglycemia has long-term effects on neurodevelopment and behavior is also unclear [",
"    <a class=\"abstract\" href=\"mobipreview.htm?35/27/36281/abstract/48\">",
"     48",
"    </a>",
"    ]. Few studies have been performed and they have not adequately controlled for confounders.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H11\">",
"    <span class=\"h1\">",
"     OFFSPRING RISKS",
"    </span>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H12\">",
"    <span class=\"h2\">",
"     Neonatal complications",
"    </span>",
"    &nbsp;&mdash;&nbsp;Potential neonatal issues occurring in offspring of diabetic mothers, include:",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      Morbidity associated with preterm birth",
"     </li>",
"     <li>",
"      Macrosomia, which increases the risk of birth injury (eg, brachial plexus injury)",
"     </li>",
"     <li>",
"      Morbidity associated with growth restriction (in women with vascular or renal disease)",
"     </li>",
"     <li>",
"      Erythrocytosis",
"     </li>",
"     <li>",
"      Hyperbilirubinemia",
"     </li>",
"     <li>",
"      Cardiomyopathy",
"     </li>",
"     <li>",
"      Hypoglycemia and other metabolic abnormalities",
"     </li>",
"     <li>",
"      Respiratory problems",
"     </li>",
"     <li>",
"      Congenital anomalies and their management",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    These problems are discussed in depth separately. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?43/48/44809?source=see_link\">",
"     \"Infant of a diabetic mother\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H13\">",
"    <span class=\"h2\">",
"     Risk of developing diabetes",
"    </span>",
"    &nbsp;&mdash;&nbsp;The risk of diabetes developing in offspring of diabetic parents depends on a number of factors, including whether the mother or father is the affected parent, the type of diabetes (type 1, type 2, type 2 polyglandular autoimmune syndrome, maturity onset diabetes of the young),",
"    <span class=\"nowrap\">",
"     race/ethnicity,",
"    </span>",
"    and lifestyle issues [",
"    <a class=\"abstract\" href=\"mobipreview.htm?35/27/36281/abstract/49\">",
"     49",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    According to the American Diabetes Association [",
"    <a class=\"abstract\" href=\"mobipreview.htm?35/27/36281/abstract/50\">",
"     50",
"    </a>",
"    ]:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Offspring of a father with type 1 diabetes have a 1 in 17 risk of developing type 1 diabetes. Offspring of a mother with type 1 diabetes have a 1 in 25 risk if, at the time of pregnancy, the mother is less than 25 years of age but a 1 in 100 risk if the mother is 25 years of age or older. These risks are doubled if the affected parent developed diabetes before age 11. If both parents have type 1 diabetes, the risk to offspring is between 1 in 10 and 1 in 4.",
"     </li>",
"     <li>",
"      Fifty percent of offspring of a parent with type 2 polyglandular autoimmune syndrome will develop the same disorder.",
"     </li>",
"     <li>",
"      The risk of diabetes in offspring of a parent with type 2 diabetes is 1 in 7 if the parent was diagnosed before age 50 and 1 in 13 if the parent was diagnosed after age 50. There is some evidence that the offspring's risk is greater when the parent with type 2 diabetes is the mother. If both parents have type 2 diabetes, the risk to offspring is about 1 in 2.",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?43/48/44809?source=see_link&amp;anchor=H27#H27\">",
"     \"Infant of a diabetic mother\", section on 'Diabetes'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H7424803\">",
"    <span class=\"h2\">",
"     Risk of adult obesity and diabetes",
"    </span>",
"    &nbsp;&mdash;&nbsp;It is possible that maternal hyperglycemia, which accelerates fetal fat accretion and pancreatic hypertrophy during pregnancy, could have lasting effects on metabolism. These metabolic effects could increase the likelihood that the increased fat mass evident at birth would be retained into childhood and beyond. The effects of fetal exposure to diabetes were assessed in a study of a cohort of siblings where one sibling was exposed in utero to maternal diabetes while the other, older sibling was not the product of a pregnancy complicated by diabetes [",
"    <a class=\"abstract\" href=\"mobipreview.htm?35/27/36281/abstract/51\">",
"     51",
"    </a>",
"    ]. The siblings exposed to diabetes in utero and those not exposed came from similar gene pools and ate at the same table during their childhood years. However, at age 21 years the body mass index in the siblings exposed to diabetes in utero was twice that observed among the unexposed siblings. In another study by the same investigators [",
"    <a class=\"abstract\" href=\"mobipreview.htm?35/27/36281/abstract/52\">",
"     52",
"    </a>",
"    ], women who were obese at birth, as indicated by a birthweight &gt;4500 g, were at a four-fold increased risk of developing GDM in their own pregnancies. It is well known that 50 percent of women who develop GDM in pregnancy develop overt diabetes within five years subsequent to the pregnancy.",
"   </p>",
"   <p>",
"    The relationship of fetal obesity to subsequent adult health was assessed in a 24-year follow-up study of 597 children of four different groups of mothers: (1) with GDM, (2) with risk factors for GDM but normoglycemic, (3) with preexisting type 1 diabetes mellitus, and (4) normoglycemic but with risk factors for GDM [",
"    <a class=\"abstract\" href=\"mobipreview.htm?35/27/36281/abstract/52\">",
"     52",
"    </a>",
"    ]. The risk of developing adult overweight was doubled in the offspring of women with GDM and type 1 diabetes compared to offspring of normoglycemic mothers (adjusted OR 1.79; 95% CI 1.0&ndash;3.24). The risk of the metabolic syndrome (hypertension, obesity, and dyslipidemia) in the offspring of women with GDM and type 1 diabetes was increased 4-fold and 2.5-fold, respectively.",
"   </p>",
"   <p>",
"    This evidence strongly suggests that hyperglycemia during pregnancy, whether arising from type 1 diabetes mellitus or GDM, can impose metabolic changes upon the fetus that may promote obesity and the metabolic syndrome later in adult life.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H14\">",
"    <span class=\"h1\">",
"     MATERNAL ISSUES",
"    </span>",
"    &nbsp;&mdash;&nbsp;The preceding discussion has emphasized the risk to the fetus and neonate; prepregnancy counseling should also address the potential risks of pregnancy to the mother. Two large prospective studies of women with type 1 diabetes, the Diabetes Control and Complications Trial (DCCT) and the EURODIAB Prospective Complications Study (PCS), concluded that pregnancy was not a risk factor for development of early nephropathy, retinopathy, or neuropathy after adjusting for confounders such as age, duration of diabetes, and A1C [",
"    <a class=\"abstract\" href=\"mobipreview.htm?35/27/36281/abstract/53,54\">",
"     53,54",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H15\">",
"    <span class=\"h2\">",
"     Diabetic retinopathy",
"    </span>",
"    &nbsp;&mdash;&nbsp;Diabetic retinopathy worsens in some women during pregnancy, although it is not likely to develop de novo in women with no retinopathy before pregnancy [",
"    <a class=\"abstract\" href=\"mobipreview.htm?35/27/36281/abstract/55\">",
"     55",
"    </a>",
"    ]. The likelihood of retinopathy being present is related to the duration of diabetes and to the degree of glycemic control. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?35/11/36023?source=see_link&amp;anchor=H10#H10\">",
"     \"Classification and clinical features of diabetic retinopathy\", section on 'Natural history'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Strict glycemic control, which is clearly beneficial to the developing fetus, has been associated with worsening retinopathy, with a particular increase in the formation of soft exudates (",
"    <a class=\"graphic graphic_figure graphicRef61305 \" href=\"mobipreview.htm?28/32/29197\">",
"     figure 1",
"    </a>",
"    ) [",
"    <a class=\"abstract\" href=\"mobipreview.htm?35/27/36281/abstract/53,56-60\">",
"     53,56-60",
"    </a>",
"    ]. The degree to which this occurs during pregnancy is related to the baseline level of retinal disease and, in part, to the acute reduction of chronic hyperglycemia [",
"    <a class=\"abstract\" href=\"mobipreview.htm?35/27/36281/abstract/61\">",
"     61",
"    </a>",
"    ]. The Diabetes in Early Pregnancy study found that, among 140 women who did not have proliferative retinopathy at conception, progression of retinopathy occurred in 20 percent of those with microaneurysms or mild nonproliferative retinopathy and 55 percent of those with moderate-to-severe nonproliferative retinopathy [",
"    <a class=\"abstract\" href=\"mobipreview.htm?35/27/36281/abstract/56\">",
"     56",
"    </a>",
"    ]. In addition, 10 percent of those who had no baseline retinopathy developed retinopathy. Proliferative retinopathy developed in 6 percent of women with mild and 29 percent of women with moderate-to-severe baseline retinopathy.",
"   </p>",
"   <p>",
"    Worsening of retinopathy is thought to be mediated by closure of small retinal blood vessels which had been narrowed but patent. One theory is that correction of hyperglycemia lowers the plasma volume which can put these marginal vessels at risk. Hypertension, smoking, hyperlipidemia, and hypoglycemia have also been associated with acceleration of the retinopathy [",
"    <a class=\"abstract\" href=\"mobipreview.htm?35/27/36281/abstract/62-64\">",
"     62-64",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?35/11/36023?source=see_link&amp;anchor=H12#H12\">",
"     \"Classification and clinical features of diabetic retinopathy\", section on 'Worsening during pregnancy'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Laser therapy is an effective treatment of retinopathy and the benefits of maternal normoglycemia for the fetus far outweigh the modest, transient deterioration in retinopathy accruing from better glycemic control.",
"   </p>",
"   <p>",
"    After pregnancy, milder forms of diabetic retinopathy typically regress [",
"    <a class=\"abstract\" href=\"mobipreview.htm?35/27/36281/abstract/65,66\">",
"     65,66",
"    </a>",
"    ]; however, some women with severe forms of diabetic retinopathy may show persistence or progression [",
"    <a class=\"abstract\" href=\"mobipreview.htm?35/27/36281/abstract/67\">",
"     67",
"    </a>",
"    ]. Therefore, treatment during pregnancy should be considered and close follow-up postpartum is warranted.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H16\">",
"    <span class=\"h2\">",
"     Diabetic nephropathy",
"    </span>",
"    &nbsp;&mdash;&nbsp;The presence of diabetic nephropathy and its acceleration are a concern for both fetus and mother. Both microalbuminuria and overt nephropathy are associated with an increased rate of preterm birth, primarily due to preeclampsia [",
"    <a class=\"abstract\" href=\"mobipreview.htm?35/27/36281/abstract/68,69\">",
"     68,69",
"    </a>",
"    ]. Hypertension and preeclampsia can also lead to fetal growth restriction and, rarely, fetal or maternal death.",
"   </p>",
"   <p>",
"    Pregnancy does not appear to increase the risk of dialysis and diabetic nephropathy if neither was present before conception [",
"    <a class=\"abstract\" href=\"mobipreview.htm?35/27/36281/abstract/70\">",
"     70",
"    </a>",
"    ]. On the other hand, the effect of pregnancy on the course of established nephropathy in the mother is less clear. The glomerular filtration rate, as estimated from the creatinine clearance, declines during pregnancy in about one-third of women with diabetic nephropathy, while another one-third do not have the normal pregnancy-induced rise. This appears to occur even if strict glycemic control is maintained [",
"    <a class=\"abstract\" href=\"mobipreview.htm?35/27/36281/abstract/71\">",
"     71",
"    </a>",
"    ]. Among women with overt proteinuria at baseline, urinary protein excretion can rise dramatically as pregnancy progresses, similar to the effect of pregnancy in other proteinuric states; after delivery, protein excretion decreases in most women [",
"    <a class=\"abstract\" href=\"mobipreview.htm?35/27/36281/abstract/72,73\">",
"     72,73",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?21/19/21816?source=see_link\">",
"     \"Pregnancy in women with diabetic nephropathy\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    As in other forms of renal disease, pregnancy is not associated with permanent worsening of renal function in the majority of diabetic women in the absence of uncontrolled hypertension or a baseline serum creatinine concentration above 1.5",
"    <span class=\"nowrap\">",
"     mg/dL",
"    </span>",
"    (132",
"    <span class=\"nowrap\">",
"     mumol/L)",
"    </span>",
"    [",
"    <a class=\"abstract\" href=\"mobipreview.htm?35/27/36281/abstract/70,72\">",
"     70,72",
"    </a>",
"    ]. The risk of permanent loss of renal function correlates with the prepregnancy creatinine concentration. The danger of pregnancy in women with significant prepregnancy renal insufficiency was illustrated by a study of 11 women in whom serum creatinine concentrations were &ge;1.4",
"    <span class=\"nowrap\">",
"     mg/dL",
"    </span>",
"    (124",
"    <span class=\"nowrap\">",
"     mumol/L)",
"    </span>",
"    at the onset of pregnancy [",
"    <a class=\"abstract\" href=\"mobipreview.htm?35/27/36281/abstract/74\">",
"     74",
"    </a>",
"    ]. Renal function remained stable in 27 percent, transiently worsened in 27 percent, and permanently declined in 45 percent. Similar findings have been reported by others [",
"    <a class=\"abstract\" href=\"mobipreview.htm?35/27/36281/abstract/75\">",
"     75",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H17\">",
"    <span class=\"h2\">",
"     Hypertension/preeclampsia",
"    </span>",
"    &nbsp;&mdash;&nbsp;The prevalence of hypertension and preeclampsia is increased in pregnant women with diabetes and is related to both pregestational hypertension and vascular disease. In one review, as an example, the prevalence of preeclampsia in women with diabetes with and without vascular disease was 17 and 8 percent, respectively, compared to a rate of 5 to 8 percent in nondiabetic pregnancies [",
"    <a class=\"abstract\" href=\"mobipreview.htm?35/27/36281/abstract/76\">",
"     76",
"    </a>",
"    ]. In another series of 462 women with pregestational diabetes, the rate of preeclampsia in women with White classification B, C, D, and",
"    <span class=\"nowrap\">",
"     F/R",
"    </span>",
"    (",
"    <a class=\"graphic graphic_table graphicRef79735 \" href=\"mobipreview.htm?41/12/42187\">",
"     table 1",
"    </a>",
"    ) was 11, 22, 21, and 36 percent, respectively [",
"    <a class=\"abstract\" href=\"mobipreview.htm?35/27/36281/abstract/77\">",
"     77",
"    </a>",
"    ]. Insulin resistance appears to increase the risk of preeclampsia, even in the absence of overt diabetes [",
"    <a class=\"abstract\" href=\"mobipreview.htm?35/27/36281/abstract/78,79\">",
"     78,79",
"    </a>",
"    ]. Impaired endothelium-dependent vasodilation appears to be related to the duration of diabetes [",
"    <a class=\"abstract\" href=\"mobipreview.htm?35/27/36281/abstract/80\">",
"     80",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    There is also some evidence that poor glycemic control increases the risk of developing preeclampsia [",
"    <a class=\"abstract\" href=\"mobipreview.htm?35/27/36281/abstract/81-84\">",
"     81-84",
"    </a>",
"    ]. If confirmed as an independent risk factor, this would be one of the few modifiable risk factors for preeclampsia and yet another reason for women to achieve and maintain good glycemic control.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H18\">",
"    <span class=\"h2\">",
"     Cardiovascular disease",
"    </span>",
"    &nbsp;&mdash;&nbsp;Women with diabetes have an increased risk for atherosclerosis due both to diabetes and to the frequent presence of other risk factors and diabetic women with coronary heart disease are more likely to be asymptomatic than nondiabetic patients with coronary heart disease [",
"    <a class=\"abstract\" href=\"mobipreview.htm?35/27/36281/abstract/85,86\">",
"     85,86",
"    </a>",
"    ]. Pregnancy confers increased demands on the heart and atherosclerotic heart disease carries a high risk of maternal mortality; therefore, assessment of cardiovascular status is important, even in young women. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?35/38/36458?source=see_link&amp;anchor=H8#H8\">",
"     \"Overview of medical care in adults with diabetes mellitus\", section on 'Screening for coronary heart disease'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H19\">",
"    <span class=\"h2\">",
"     Thyroid disease",
"    </span>",
"    &nbsp;&mdash;&nbsp;There is a well described association between diabetes and immune-mediated thyroid dysfunction [",
"    <a class=\"abstract\" href=\"mobipreview.htm?35/27/36281/abstract/87,88\">",
"     87,88",
"    </a>",
"    ]. The risk of developing thyroid dysfunction is 5 to 10 percent annually in women with type 1 diabetes. The effects of thyroid disease on pregnancy and vice versa are discussed separately. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?15/51/16186?source=see_link\">",
"     \"Overview of thyroid disease in pregnancy\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H20\">",
"    <span class=\"h2\">",
"     Peripheral and autonomic neuropathy",
"    </span>",
"    &nbsp;&mdash;&nbsp;Pregnancy probably does not affect the course of somatic or autonomic neuropathy [",
"    <a class=\"abstract\" href=\"mobipreview.htm?35/27/36281/abstract/89\">",
"     89",
"    </a>",
"    ]. However, women with neuropathy (autonomic or peripheral) are at increased risk of pregnancy complications, such as hyperemesis gravidarum (related to gastroparesis), hypoglycemia unawareness, orthostatic hypotension, urinary retention, and carpal tunnel syndrome. In addition, the cardiovascular adjustments to pregnancy may be impaired in women with diabetic neuropathy; as an example, normal increases in cardiac output and blood volume may not occur [",
"    <a class=\"abstract\" href=\"mobipreview.htm?35/27/36281/abstract/90\">",
"     90",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H21\">",
"    <span class=\"h2\">",
"     Infection",
"    </span>",
"    &nbsp;&mdash;&nbsp;There is a three- to five-fold greater propensity for urinary tract infection in nonpregnant diabetic women, especially those with poor glycemic control or end-organ damage [",
"    <a class=\"abstract\" href=\"mobipreview.htm?35/27/36281/abstract/91\">",
"     91",
"    </a>",
"    ], and urinary tract infections are likely to be more severe in diabetic than nondiabetic women. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?41/19/42295?source=see_link\">",
"     \"Approach to the adult with asymptomatic bacteriuria\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Infection increases the risk of developing preterm labor or diabetic ketoacidosis, the latter can cause fetal death in addition to maternal morbidity. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?34/62/35818?source=see_link&amp;anchor=H27#H27\">",
"     \"Obstetrical management of pregnancy complicated by pregestational diabetes mellitus\", section on 'Diabetic ketoacidosis'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H22\">",
"    <span class=\"h1\">",
"     EVALUATION AND MANAGEMENT",
"    </span>",
"    &nbsp;&mdash;&nbsp;(see",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?41/31/42487?source=see_link\">",
"     \"Prepregnancy evaluation and management of women with type 1 or type 2 diabetes mellitus\"",
"    </a>",
"    ).",
"   </p>",
"   <p class=\"headingAnchor\" id=\"PATIENT_INFORMATION\">",
"    <span class=\"h1\">",
"     INFORMATION FOR PATIENTS",
"    </span>",
"    &nbsp;&mdash;&nbsp;UpToDate offers two types of patient education materials, &ldquo;The Basics&rdquo; and &ldquo;Beyond the Basics.&rdquo; The Basics patient education pieces are written in plain language, at the 5",
"    <sup>",
"     th",
"    </sup>",
"    to 6",
"    <sup>",
"     th",
"    </sup>",
"    grade reading level, and they answer the four or five key questions a patient might have about a given condition. These articles are best for patients who want a general overview and who prefer short, easy-to-read materials. Beyond the Basics patient education pieces are longer, more sophisticated, and more detailed. These articles are written at the 10",
"    <sup>",
"     th",
"    </sup>",
"    to 12",
"    <sup>",
"     th",
"    </sup>",
"    grade reading level and are best for patients who want in-depth information and are comfortable with some medical jargon.",
"   </p>",
"   <p>",
"    Here are the patient education articles that are relevant to this topic. We encourage you to print or e-mail these topics to your patients. (You can also locate patient education articles on a variety of subjects by searching on &ldquo;patient info&rdquo; and the keyword(s) of interest.)",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Basics topics (see",
"      <a class=\"medical medical_basics\" href=\"mobipreview.htm?30/62/31714?source=see_link\">",
"       \"Patient information: Care during pregnancy for women with type 1 or type 2 diabetes (The Basics)\"",
"      </a>",
"      and",
"      <a class=\"medical medical_basics\" href=\"mobipreview.htm?14/47/15091?source=see_link\">",
"       \"Patient information: Preparing for pregnancy when you have diabetes (The Basics)\"",
"      </a>",
"      )",
"     </li>",
"     <li>",
"      Beyond the Basics topics (see",
"      <a class=\"medical medical_patient\" href=\"mobipreview.htm?10/45/10966?source=see_link\">",
"       \"Patient information: Care during pregnancy for women with type 1 or 2 diabetes mellitus (Beyond the Basics)\"",
"      </a>",
"      )",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H23\">",
"    <span class=\"h1\">",
"     SUMMARY AND RECOMMENDATIONS",
"    </span>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      All women of childbearing age with diabetes should be educated about the potential effects of diabetes on the fetus and course of pregnancy, and the effects of pregnancy on diabetes.",
"     </li>",
"     <li>",
"      The three major potential",
"      <span class=\"nowrap\">",
"       fetal/pregnancy",
"      </span>",
"      complications among women with pregestational diabetes are: congenital malformations, spontaneous abortion, and macrosomia. Hyperglycemia is probably the most important determinant of these risks. Thus, the importance of achieving good glycemic control before conception and maintaining good glycemic control across gestation cannot be overstated.",
"     </li>",
"     <li>",
"      Offspring of women with pregestational diabetes are at increased risk of a variety of problems in the neonatal period and developing obesity, hypertension and diabetes later in life.",
"     </li>",
"     <li>",
"      Diabetic retinopathy worsens in some women during pregnancy, although it is not likely to develop de novo in women with no retinopathy before pregnancy.",
"     </li>",
"     <li>",
"      Pregnancy is not associated with permanent worsening of renal function in the majority of diabetic women in the absence of uncontrolled hypertension or baseline serum creatinine concentration above 1.5",
"      <span class=\"nowrap\">",
"       mg/dL",
"      </span>",
"      (132",
"      <span class=\"nowrap\">",
"       mumol/L).",
"      </span>",
"     </li>",
"    </ul>",
"   </p>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div class=\"headingAnchor\" id=\"references\">",
"   <h1>",
"    REFERENCES",
"   </h1>",
"   <ol id=\"reference\">",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/27/36281/abstract/1\">",
"      Lawrence JM, Contreras R, Chen W, Sacks DA. Trends in the prevalence of preexisting diabetes and gestational diabetes mellitus among a racially/ethnically diverse population of pregnant women, 1999-2005. Diabetes Care 2008; 31:899.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/27/36281/abstract/2\">",
"      American Diabetes Association. Preconception care of women with diabetes. Diabetes Care 2004; 27 Suppl 1:S76.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/27/36281/abstract/3\">",
"      Temple R, Aldridge V, Greenwood R, et al. Association between outcome of pregnancy and glycaemic control in early pregnancy in type 1 diabetes: population based study. BMJ 2002; 325:1275.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/27/36281/abstract/4\">",
"      Gonzalez-Gonzalez NL, Ramirez O, Mozas J, et al. Factors influencing pregnancy outcome in women with type 2 versus type 1 diabetes mellitus. Acta Obstet Gynecol Scand 2008; 87:43.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/27/36281/abstract/5\">",
"      Persson M, Norman M, Hanson U. Obstetric and perinatal outcomes in type 1 diabetic pregnancies: A large, population-based study. Diabetes Care 2009; 32:2005.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/27/36281/abstract/6\">",
"      Greene MF, Hare JW, Cloherty JP, et al. First-trimester hemoglobin A1 and risk for major malformation and spontaneous abortion in diabetic pregnancy. Teratology 1989; 39:225.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/27/36281/abstract/7\">",
"      Damm P, M&oslash;lsted-Pedersen L. Significant decrease in congenital malformations in newborn infants of an unselected population of diabetic women. Am J Obstet Gynecol 1989; 161:1163.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/27/36281/abstract/8\">",
"      Kitzmiller JL, Gavin LA, Gin GD, et al. Preconception care of diabetes. Glycemic control prevents congenital anomalies. JAMA 1991; 265:731.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/27/36281/abstract/9\">",
"      Fuhrmann K, Reiher H, Semmler K, Gl&ouml;ckner E. The effect of intensified conventional insulin therapy before and during pregnancy on the malformation rate in offspring of diabetic mothers. Exp Clin Endocrinol 1984; 83:173.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/27/36281/abstract/10\">",
"      Steel JM, Johnstone FD, Hepburn DA, Smith AF. Can prepregnancy care of diabetic women reduce the risk of abnormal babies? BMJ 1990; 301:1070.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/27/36281/abstract/11\">",
"      Pregnancy outcomes in the Diabetes Control and Complications Trial. Am J Obstet Gynecol 1996; 174:1343.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/27/36281/abstract/12\">",
"      Page RC, Kirk BA, Fay T, et al. Is macrosomia associated with poor glycaemic control in diabetic pregnancy? Diabet Med 1996; 13:170.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/27/36281/abstract/13\">",
"      Greene MF. Spontaneous abortions and major malformations in women with diabetes mellitus. Semin Reprod Endocrinol 1999; 17:127.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/27/36281/abstract/14\">",
"      Macintosh MC, Fleming KM, Bailey JA, et al. Perinatal mortality and congenital anomalies in babies of women with type 1 or type 2 diabetes in England, Wales, and Northern Ireland: population based study. BMJ 2006; 333:177.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/27/36281/abstract/15\">",
"      Correa A, Gilboa SM, Besser LM, et al. Diabetes mellitus and birth defects. Am J Obstet Gynecol 2008; 199:237.e1.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/27/36281/abstract/16\">",
"      Kucera J. Rate and type of congenital anomalies among offspring of diabetic women. J Reprod Med 1971; 7:73.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/27/36281/abstract/17\">",
"      Becerra JE, Khoury MJ, Cordero JF, Erickson JD. Diabetes mellitus during pregnancy and the risks for specific birth defects: a population-based case-control study. Pediatrics 1990; 85:1.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/27/36281/abstract/18\">",
"      Reece EA, Wiznitzer A, Homko CJ, et al. Synchronization of the factors critical for diabetic teratogenesis: an in vitro model. Am J Obstet Gynecol 1996; 174:1284.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/27/36281/abstract/19\">",
"      Fraser RB, Waite SL, Wood KA, Martin KL. Impact of hyperglycemia on early embryo development and embryopathy: in vitro experiments using a mouse model. Hum Reprod 2007; 22:3059.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/27/36281/abstract/20\">",
"      Loeken MR. Advances in understanding the molecular causes of diabetes-induced birth defects. J Soc Gynecol Investig 2006; 13:2.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/27/36281/abstract/21\">",
"      Moley KH, Chi MM, Knudson CM, et al. Hyperglycemia induces apoptosis in pre-implantation embryos through cell death effector pathways. Nat Med 1998; 4:1421.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/27/36281/abstract/22\">",
"      Keim AL, Chi MM, Moley KH. Hyperglycemia-induced apoptotic cell death in the mouse blastocyst is dependent on expression of p53. Mol Reprod Dev 2001; 60:214.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/27/36281/abstract/23\">",
"      Pani L, Horal M, Loeken MR. Rescue of neural tube defects in Pax-3-deficient embryos by p53 loss of function: implications for Pax-3- dependent development and tumorigenesis. Genes Dev 2002; 16:676.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/27/36281/abstract/24\">",
"      Loeken MR. Current perspectives on the causes of neural tube defects resulting from diabetic pregnancy. Am J Med Genet C Semin Med Genet 2005; 135C:77.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/27/36281/abstract/25\">",
"      Wentzel P, Welsh N, Eriksson UJ. Developmental damage, increased lipid peroxidation, diminished cyclooxygenase-2 gene expression, and lowered prostaglandin E2 levels in rat embryos exposed to a diabetic environment. Diabetes 1999; 48:813.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/27/36281/abstract/26\">",
"      Wentzel P, Eriksson UJ. Antioxidants diminish developmental damage induced by high glucose and cyclooxygenase inhibitors in rat embryos in vitro. Diabetes 1998; 47:677.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/27/36281/abstract/27\">",
"      Li R, Chase M, Jung SK, et al. Hypoxic stress in diabetic pregnancy contributes to impaired embryo gene expression and defective development by inducing oxidative stress. Am J Physiol Endocrinol Metab 2005; 289:E591.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/27/36281/abstract/28\">",
"      Fu J, Tay SS, Ling EA, Dheen ST. High glucose alters the expression of genes involved in proliferation and cell-fate specification of embryonic neural stem cells. Diabetologia 2006; 49:1027.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/27/36281/abstract/29\">",
"      Cousins L. Etiology and prevention of congenital anomalies among infants of overt diabetic women. Clin Obstet Gynecol 1991; 34:481.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/27/36281/abstract/30\">",
"      Miller E, Hare JW, Cloherty JP, et al. Elevated maternal hemoglobin A1c in early pregnancy and major congenital anomalies in infants of diabetic mothers. N Engl J Med 1981; 304:1331.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/27/36281/abstract/31\">",
"      Kitzmiller JL, Watt N, Driscoll SG. Decidual arteriopathy in hypertension and diabetes in pregnancy: immunofluorescent studies. Am J Obstet Gynecol 1981; 141:773.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/27/36281/abstract/32\">",
"      Jovanovic L, Knopp RH, Kim H, et al. Elevated pregnancy losses at high and low extremes of maternal glucose in early normal and diabetic pregnancy: evidence for a protective adaptation in diabetes. Diabetes Care 2005; 28:1113.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/27/36281/abstract/33\">",
"      Bou&eacute; J, Lazar P. Retrospective and prospective epidemiological studies of 1500 karyotyped spontaneous human abortions. Teratology 1975; 12:11.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/27/36281/abstract/34\">",
"      Boulet SL, Alexander GR, Salihu HM. Secular trends in cesarean delivery rates among macrosomic deliveries in the United States, 1989 to 2002. J Perinatol 2005; 25:569.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/27/36281/abstract/35\">",
"      Modanlou HD, Komatsu G, Dorchester W, et al. Large-for-gestational-age neonates: anthropometric reasons for shoulder dystocia. Obstet Gynecol 1982; 60:417.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/27/36281/abstract/36\">",
"      McFarland MB, Trylovich CG, Langer O. Anthropometric differences in macrosomic infants of diabetic and nondiabetic mothers. J Matern Fetal Med 1998; 7:292.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/27/36281/abstract/37\">",
"      Seidman DS, Laor A, Stevenson DK, et al. Macrosomia does not predict overweight in late adolescence in infants of diabetic mothers. Acta Obstet Gynecol Scand 1998; 77:58.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/27/36281/abstract/38\">",
"      Rey E, Atti&eacute; C, Bonin A. The effects of first-trimester diabetes control on the incidence of macrosomia. Am J Obstet Gynecol 1999; 181:202.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/27/36281/abstract/39\">",
"      Gold AE, Reilly R, Little J, Walker JD. The effect of glycemic control in the pre-conception period and early pregnancy on birth weight in women with IDDM. Diabetes Care 1998; 21:535.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/27/36281/abstract/40\">",
"      Langer O, Levy J, Brustman L, et al. Glycemic control in gestational diabetes mellitus--how tight is tight enough: small for gestational age versus large for gestational age? Am J Obstet Gynecol 1989; 161:646.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/27/36281/abstract/41\">",
"      Idris N, Wong SF, Thomae M, et al. Influence of polyhydramnios on perinatal outcome in pregestational diabetic pregnancies. Ultrasound Obstet Gynecol 2010; 36:338.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/27/36281/abstract/42\">",
"      Sibai BM, Caritis SN, Hauth JC, et al. Preterm delivery in women with pregestational diabetes mellitus or chronic hypertension relative to women with uncomplicated pregnancies. The National institute of Child health and Human Development Maternal- Fetal Medicine Units Network. Am J Obstet Gynecol 2000; 183:1520.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/27/36281/abstract/43\">",
"      McElvy SS, Miodovnik M, Rosenn B, et al. A focused preconceptional and early pregnancy program in women with type 1 diabetes reduces perinatal mortality and malformation rates to general population levels. J Matern Fetal Med 2000; 9:14.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/27/36281/abstract/44\">",
"      Roberts AB, Pattison NS. Pregnancy in women with diabetes mellitus, twenty years experience: 1968-1987. N Z Med J 1990; 103:211.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/27/36281/abstract/45\">",
"      Johnstone FD, Lindsay RS, Steel J. Type 1 diabetes and pregnancy: trends in birth weight over 40 years at a single clinic. Obstet Gynecol 2006; 107:1297.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/27/36281/abstract/46\">",
"      Weintrob N, Karp M, Hod M. Short- and long-range complications in offspring of diabetic mothers. J Diabetes Complications 1996; 10:294.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/27/36281/abstract/47\">",
"      ter Braak EW, Evers IM, Willem Erkelens D, Visser GH. Maternal hypoglycemia during pregnancy in type 1 diabetes: maternal and fetal consequences. Diabetes Metab Res Rev 2002; 18:96.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/27/36281/abstract/48\">",
"      Ornoy A. Growth and neurodevelopmental outcome of children born to mothers with pregestational and gestational diabetes. Pediatr Endocrinol Rev 2005; 3:104.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/27/36281/abstract/49\">",
"      Poston L. Developmental programming and diabetes - The human experience and insight from animal models. Best Pract Res Clin Endocrinol Metab 2010; 24:541.",
"     </a>",
"    </li>",
"    <li>",
"     www.diabetes.org/genetics.jsp (accessed June 28, 2006).",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/27/36281/abstract/51\">",
"      Dabelea D, Hanson RL, Lindsay RS, et al. Intrauterine exposure to diabetes conveys risks for type 2 diabetes and obesity: a study of discordant sibships. Diabetes 2000; 49:2208.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/27/36281/abstract/52\">",
"      Clausen TD, Mathiesen ER, Hansen T, et al. Overweight and the metabolic syndrome in adult offspring of women with diet-treated gestational diabetes mellitus or type 1 diabetes. J Clin Endocrinol Metab 2009; 94:2464.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/27/36281/abstract/53\">",
"      Diabetes Control and Complications Trial Research Group. Effect of pregnancy on microvascular complications in the diabetes control and complications trial. The Diabetes Control and Complications Trial Research Group. Diabetes Care 2000; 23:1084.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/27/36281/abstract/54\">",
"      V&eacute;rier-Mine O, Chaturvedi N, Webb D, Fuller JH. Is pregnancy a risk factor for microvascular complications? The EURODIAB Prospective Complications Study. Diabet Med 2005; 22:1503.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/27/36281/abstract/55\">",
"      Star J, Carpenter MW. The effect of pregnancy on the natural history of diabetic retinopathy and nephropathy. Clin Perinatol 1998; 25:887.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/27/36281/abstract/56\">",
"      Chew EY, Mills JL, Metzger BE, et al. Metabolic control and progression of retinopathy. The Diabetes in Early Pregnancy Study. National Institute of Child Health and Human Development Diabetes in Early Pregnancy Study. Diabetes Care 1995; 18:631.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/27/36281/abstract/57\">",
"      Wang PH, Lau J, Chalmers TC. Meta-analysis of effects of intensive blood-glucose control on late complications of type I diabetes. Lancet 1993; 341:1306.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/27/36281/abstract/58\">",
"      Lauritzen T, Frost-Larsen K, Larsen HW, Deckert T. Effect of 1 year of near-normal blood glucose levels on retinopathy in insulin-dependent diabetics. Lancet 1983; 1:200.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/27/36281/abstract/59\">",
"      Blood glucose control and the evolution of diabetic retinopathy and albuminuria. A preliminary multicenter trial. The Kroc Collaborative Study Group. N Engl J Med 1984; 311:365.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/27/36281/abstract/60\">",
"      Jampol, LM, Phelps, R, Sakol, P, et al. Diabetic retinopathy during pregnancy: Role of regulation of hyperglycemia invest. Ophthalmol Vis Sci 1986; 27:4.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/27/36281/abstract/61\">",
"      Early worsening of diabetic retinopathy in the Diabetes Control and Complications Trial. Arch Ophthalmol 1998; 116:874.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/27/36281/abstract/62\">",
"      Tasman W. Diabetic vitreous hemorrhage and its relationship to hypoglycemia. Mod Probl Ophthalmol 1979; 20:413.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/27/36281/abstract/63\">",
"      Klein R, Klein BE, Moss SE, et al. Retinopathy in young-onset diabetic patients. Diabetes Care 1985; 8:311.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/27/36281/abstract/64\">",
"      Rand LI, Krolewski AS, Aiello LM, et al. Multiple factors in the prediction of risk of proliferative diabetic retinopathy. N Engl J Med 1985; 313:1433.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/27/36281/abstract/65\">",
"      Sunness JS. The pregnant woman's eye. Surv Ophthalmol 1988; 32:219.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/27/36281/abstract/66\">",
"      Serup, L. Influence of pregnancy on diabetic retinopathy. Acta Endocrinol (Copenh) 1986; 22:122.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/27/36281/abstract/67\">",
"      Chan WC, Lim LT, Quinn MJ, et al. Management and outcome of sight-threatening diabetic retinopathy in pregnancy. Eye (Lond) 2004; 18:826.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/27/36281/abstract/68\">",
"      Ekbom P, Damm P, Feldt-Rasmussen B, et al. Pregnancy outcome in type 1 diabetic women with microalbuminuria. Diabetes Care 2001; 24:1739.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/27/36281/abstract/69\">",
"      Khoury JC, Miodovnik M, LeMasters G, Sibai B. Pregnancy outcome and progression of diabetic nephropathy. What's next? J Matern Fetal Neonatal Med 2002; 11:238.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/27/36281/abstract/70\">",
"      Miodovnik M, Rosenn BM, Khoury JC, et al. Does pregnancy increase the risk for development and progression of diabetic nephropathy? Am J Obstet Gynecol 1996; 174:1180.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/27/36281/abstract/71\">",
"      Jovanovic R, Jovanovic L. Obstetric management when normoglycemia is maintained in diabetic pregnant women with vascular compromise. Am J Obstet Gynecol 1984; 149:617.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/27/36281/abstract/72\">",
"      Kitzmiller JL, Brown ER, Phillippe M, et al. Diabetic nephropathy and perinatal outcome. Am J Obstet Gynecol 1981; 141:741.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/27/36281/abstract/73\">",
"      Reece EA, Coustan DR, Hayslett JP, et al. Diabetic nephropathy: pregnancy performance and fetomaternal outcome. Am J Obstet Gynecol 1988; 159:56.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/27/36281/abstract/74\">",
"      Purdy LP, Hantsch CE, Molitch ME, et al. Effect of pregnancy on renal function in patients with moderate-to-severe diabetic renal insufficiency. Diabetes Care 1996; 19:1067.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/27/36281/abstract/75\">",
"      Irfan S, Arain TM, Shaukat A, Shahid A. Effect of pregnancy on diabetic nephropathy and retinopathy. J Coll Physicians Surg Pak 2004; 14:75.",
"     </a>",
"    </li>",
"    <li>",
"     Acker DB, Barss VA. Obstetrical complications. In: Diabetes Complication Pregnancy, 2nd ed, Brown FM, Hare JW (Eds) (Eds), Wiley-Liss, New York 1995. p.153.",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/27/36281/abstract/77\">",
"      Sibai BM, Caritis S, Hauth J, et al. Risks of preeclampsia and adverse neonatal outcomes among women with pregestational diabetes mellitus. National Institute of Child Health and Human Development Network of Maternal-Fetal Medicine Units. Am J Obstet Gynecol 2000; 182:364.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/27/36281/abstract/78\">",
"      Innes KE, Wimsatt JH, McDuffie R. Relative glucose tolerance and subsequent development of hypertension in pregnancy. Obstet Gynecol 2001; 97:905.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/27/36281/abstract/79\">",
"      Joffe GM, Esterlitz JR, Levine RJ, et al. The relationship between abnormal glucose tolerance and hypertensive disorders of pregnancy in healthy nulliparous women. Calcium for Preeclampsia Prevention (CPEP) Study Group. Am J Obstet Gynecol 1998; 179:1032.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/27/36281/abstract/80\">",
"      Savvidou MD, Geerts L, Nicolaides KH. Impaired vascular reactivity in pregnant women with insulin-dependent diabetes mellitus. Am J Obstet Gynecol 2002; 186:84.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/27/36281/abstract/81\">",
"      Leguizam&oacute;n GF, Zeff NP, Fern&aacute;ndez A. Hypertension and the pregnancy complicated by diabetes. Curr Diab Rep 2006; 6:297.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/27/36281/abstract/82\">",
"      Temple RC, Aldridge V, Stanley K, Murphy HR. Glycaemic control throughout pregnancy and risk of pre-eclampsia in women with type I diabetes. BJOG 2006; 113:1329.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/27/36281/abstract/83\">",
"      Hiilesmaa V, Suhonen L, Teramo K. Glycaemic control is associated with pre-eclampsia but not with pregnancy-induced hypertension in women with type I diabetes mellitus. Diabetologia 2000; 43:1534.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/27/36281/abstract/84\">",
"      Holmes VA, Young IS, Patterson CC, et al. Optimal glycemic control, pre-eclampsia, and gestational hypertension in women with type 1 diabetes in the diabetes and pre-eclampsia intervention trial. Diabetes Care 2011; 34:1683.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/27/36281/abstract/85\">",
"      Nathan DM, Cleary PA, Backlund JY, et al. Intensive diabetes treatment and cardiovascular disease in patients with type 1 diabetes. N Engl J Med 2005; 353:2643.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/27/36281/abstract/86\">",
"      Laing SP, Swerdlow AJ, Slater SD, et al. Mortality from heart disease in a cohort of 23,000 patients with insulin-treated diabetes. Diabetologia 2003; 46:760.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/27/36281/abstract/87\">",
"      Perros P, McCrimmon RJ, Shaw G, Frier BM. Frequency of thyroid dysfunction in diabetic patients: value of annual screening. Diabet Med 1995; 12:622.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/27/36281/abstract/88\">",
"      Hillier TA, Vesco KK, Pedula KL, et al. Screening for gestational diabetes mellitus: a systematic review for the U.S. Preventive Services Task Force. Ann Intern Med 2008; 148:766.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/27/36281/abstract/89\">",
"      Lapolla A, Cardone C, Negrin P, et al. Pregnancy does not induce or worsen retinal and peripheral nerve dysfunction in insulin-dependent diabetic women. J Diabetes Complications 1998; 12:74.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/27/36281/abstract/90\">",
"      Mabie WC. Peripheral neuropathies during pregnancy. Clin Obstet Gynecol 2005; 48:57.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/27/36281/abstract/91\">",
"      Zhanel GG, Nicolle LE, Harding GK. Prevalence of asymptomatic bacteriuria and associated host factors in women with diabetes mellitus. The Manitoba Diabetic Urinary Infection Study Group. Clin Infect Dis 1995; 21:316.",
"     </a>",
"    </li>",
"   </ol>",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 4796 Version 10.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.4 - C21.36",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     Southeast Alabama Med Ctr",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [1003-200.167.4.114-B6D75EF485-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f35_27_36281=[""].join("\n");
var outline_f35_27_36281=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li>",
"     <a class=\"sr_button\" href=\"#H23\" id=\"summRecButton\">",
"      <span>",
"       SUMMARY &amp; RECOMMENDATIONS",
"      </span>",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H1\">",
"      INTRODUCTION",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H2\">",
"      OVERVIEW OF PREGNANCY OUTCOME",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H3\">",
"      FETAL AND NEONATAL COMPLICATIONS",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H4\">",
"      Congenital malformations",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H5\">",
"      Spontaneous abortion",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H6\">",
"      Macrosomia",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H7\">",
"      Polyhydramnios",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H8\">",
"      Preterm birth",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H9\">",
"      Perinatal mortality",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H10\">",
"      Neurodevelopmental outcome",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H11\">",
"      OFFSPRING RISKS",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H12\">",
"      Neonatal complications",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H13\">",
"      Risk of developing diabetes",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H7424803\">",
"      Risk of adult obesity and diabetes",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H14\">",
"      MATERNAL ISSUES",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H15\">",
"      Diabetic retinopathy",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H16\">",
"      Diabetic nephropathy",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H17\">",
"      Hypertension/preeclampsia",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H18\">",
"      Cardiovascular disease",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H19\">",
"      Thyroid disease",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H20\">",
"      Peripheral and autonomic neuropathy",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H21\">",
"      Infection",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H22\">",
"      EVALUATION AND MANAGEMENT",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#PATIENT_INFORMATION\">",
"      INFORMATION FOR PATIENTS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H23\">",
"      SUMMARY AND RECOMMENDATIONS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a href=\"#references\">",
"      REFERENCES",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   <div class=\"openRelatedGraphics\" id=\"OBGYN/4796\" rel=\"outline_link\">",
"    GRAPHICS",
"    <a class=\"graphics_icon\" href=\"#\" title=\"View All Related Graphics\">",
"     View All",
"    </a>",
"   </div>",
"  </h1>",
"  <div id=\"relatedGraphics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"OBGYN/4796|FIG\">",
"      <a href=\"#\" title=\"FIGURES\">",
"       FIGURES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_figure\" href=\"mobipreview.htm?28/32/29197\" title=\"figure 1\">",
"      Strict glycemic control slows progression of retinopathy",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"OBGYN/4796|TAB\">",
"      <a href=\"#\" title=\"TABLES\">",
"       TABLES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"mobipreview.htm?41/12/42187\" title=\"table 1\">",
"      White classification",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?41/19/42295?source=related_link\">",
"      Approach to the adult with asymptomatic bacteriuria",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?35/11/36023?source=related_link\">",
"      Classification and clinical features of diabetic retinopathy",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?4/61/5081?source=related_link\">",
"      Folic acid for prevention of neural tube defects",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?43/48/44809?source=related_link\">",
"      Infant of a diabetic mother",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?36/62/37866?source=related_link\">",
"      Medical management and follow-up of gestational diabetes mellitus",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?20/19/20794?source=related_link\">",
"      Medical management of type 1 and type 2 diabetes mellitus in pregnant women",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?34/62/35818?source=related_link\">",
"      Obstetrical management of pregnancy complicated by pregestational diabetes mellitus",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?35/38/36458?source=related_link\">",
"      Overview of medical care in adults with diabetes mellitus",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?15/51/16186?source=related_link\">",
"      Overview of thyroid disease in pregnancy",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_patient\" href=\"mobipreview.htm?10/45/10966?source=related_link\">",
"      Patient information: Care during pregnancy for women with type 1 or 2 diabetes mellitus (Beyond the Basics)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_basics\" href=\"mobipreview.htm?30/62/31714?source=related_link\">",
"      Patient information: Care during pregnancy for women with type 1 or type 2 diabetes (The Basics)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_basics\" href=\"mobipreview.htm?14/47/15091?source=related_link\">",
"      Patient information: Preparing for pregnancy when you have diabetes (The Basics)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?4/44/4808?source=related_link\">",
"      Polyhydramnios",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?16/25/16794?source=related_link\">",
"      Preconception evaluation and counseling",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?21/19/21816?source=related_link\">",
"      Pregnancy in women with diabetic nephropathy",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?41/31/42487?source=related_link\">",
"      Prepregnancy evaluation and management of women with type 1 or type 2 diabetes mellitus",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?8/63/9210?source=related_link\">",
"      Screening and diagnosis of diabetes mellitus during pregnancy",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?19/23/19834?source=related_link\">",
"      Spontaneous abortion: Risk factors, etiology, clinical manifestations, and diagnostic evaluation",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?16/1/16408?source=related_link\">",
"      Timing and route of delivery in pregnancies at risk of shoulder dystocia",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f35_27_36282="Rationale for and clinical trials of beta blockers in heart failure due to systolic dysfunction";
var content_f35_27_36282=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"4\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"topicTitle\">",
"   Rationale for and clinical trials of beta blockers in heart failure due to systolic dysfunction",
"  </div>",
"  <div id=\"topicContributors\">",
"   <div>",
"    <a id=\"authors\">",
"    </a>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"mobipreview.htm?35/27/36282/contributors\">",
"     Author",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"mobipreview.htm?35/27/36282/contributors\">",
"     Wilson S Colucci, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"mobipreview.htm?35/27/36282/contributors\">",
"     Section Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"mobipreview.htm?35/27/36282/contributors\">",
"     Stephen S Gottlieb, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"mobipreview.htm?35/27/36282/contributors\">",
"     Deputy Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"mobipreview.htm?35/27/36282/contributors\">",
"     Susan B Yeon, MD, JD, FACC",
"    </a>",
"    <br/>",
"   </div>",
"  </div>",
"  <div id=\"disclosures\">",
"   <a href=\"mobipreview.htm?35/27/36282/contributor-disclosure\" target=\"_blank\">",
"    Disclosures",
"   </a>",
"  </div>",
"  <div id=\"reviewProcess\">",
"   <span>",
"    All topics are updated as new evidence becomes available and our",
"   </span>",
"   <a href=\"/home/editorial-policy\" target=\"_blank\">",
"    peer review process",
"   </a>",
"   <span>",
"    is complete.",
"   </span>",
"  </div>",
"  <div id=\"literatureReviewDate\">",
"   <span class=\"emphasis\">",
"    Literature review current through:",
"   </span>",
"   Oct 2013.",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <span class=\"emphasis\">",
"    This topic last updated:",
"   </span>",
"   Oct 16, 2012.",
"  </div>",
"  <div id=\"topicText\">",
"   <p class=\"headingAnchor\" id=\"H1\">",
"    <span class=\"h1\">",
"     INTRODUCTION",
"    </span>",
"    &nbsp;&mdash;&nbsp;In patients with heart failure (HF) due to systolic dysfunction, clinical trials have demonstrated that beta blocker use slows HF progression and improves survival. The data supporting the efficacy of beta blockers in patients with HF due to systolic dysfunction are presented here. Beta blockers are started at low doses, and titrated up to effective doses.",
"   </p>",
"   <p>",
"    The clinical use of beta blockers, an overview of medical therapy in patients with heart failure due to systolic dysfunction, and the possible role of beta blockers in asymptomatic left ventricular (LV) dysfunction and in patients with diastolic dysfunction are discussed separately. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?12/38/12905?source=see_link\">",
"     \"Use of beta blockers in heart failure due to systolic dysfunction\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?37/63/38906?source=see_link\">",
"     \"Overview of the therapy of heart failure due to systolic dysfunction\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?27/59/28601?source=see_link\">",
"     \"Evaluation and management of asymptomatic left ventricular systolic dysfunction\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?6/54/7018?source=see_link\">",
"     \"Treatment and prognosis of diastolic heart failure\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H2\">",
"    <span class=\"h1\">",
"     RATIONALE FOR BETA BLOCKER THERAPY",
"    </span>",
"    &nbsp;&mdash;&nbsp;Symptomatic HF results in activation of neurohumoral mechanisms, including the sympathetic nervous system [",
"    <a class=\"abstract\" href=\"mobipreview.htm?35/27/36282/abstract/1\">",
"     1",
"    </a>",
"    ]. An elevated plasma norepinephrine concentration is a marker for poor survival in these patients [",
"    <a class=\"abstract\" href=\"mobipreview.htm?35/27/36282/abstract/2\">",
"     2",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?31/44/32455?source=see_link\">",
"     \"Pathophysiology of heart failure: Neurohumoral adaptations\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?32/48/33546?source=see_link&amp;anchor=H15#H15\">",
"     \"Predictors of survival in heart failure due to systolic dysfunction\", section on 'Neurohumoral activation and heart rate'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    The increase in sympathetic activity may have deleterious effects and a number of trials have shown that blockade of beta adrenergic receptors leads to symptomatic improvement and enhanced survival in many patients with HF [",
"    <a class=\"abstract\" href=\"mobipreview.htm?35/27/36282/abstract/3,4\">",
"     3,4",
"    </a>",
"    ]. As a result of this compelling evidence, beta blockers are now an important component of standard therapy in HF. This is an important shift, since beta blockers were previously considered contraindicated in patients with HF because of their negative inotropic activity.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H3\">",
"    <span class=\"h2\">",
"     Possible mechanisms of benefit",
"    </span>",
"    &nbsp;&mdash;&nbsp;It seems likely that a number of factors contribute to the beneficial effect of beta blockers in HF [",
"    <a class=\"abstract\" href=\"mobipreview.htm?35/27/36282/abstract/5,6\">",
"     5,6",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Long-term exposure to catecholamines is directly detrimental to the myocardium in both animals and humans [",
"      <a class=\"abstract\" href=\"mobipreview.htm?35/27/36282/abstract/7-9\">",
"       7-9",
"      </a>",
"      ]. The effect of catecholamines on the heart and the likelihood of developing HF may be amplified by gene polymorphisms in adrenergic receptors that enhance cardiac sympathetic activity. In a report in which 159 patients with HF were compared to 189 controls, blacks who were homozygous for a particular alpha-2C receptor polymorphism had a marked increase in the risk of HF (adjusted odds ratio 5.7); the risk was further increased in blacks who were also homozygous for a beta-1 receptor polymorphism (odds ratio 10.1) [",
"      <a class=\"abstract\" href=\"mobipreview.htm?35/27/36282/abstract/10\">",
"       10",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      Chronic stimulation of beta receptors reduces the responsiveness to beta adrenergic agonists due to downregulation and desensitization of the beta receptor and its coupled signaling pathways [",
"      <a class=\"abstract\" href=\"mobipreview.htm?35/27/36282/abstract/1,11-13\">",
"       1,11-13",
"      </a>",
"      ]. Beta blockade upregulates myocardial beta-1-receptor density in patients with HF [",
"      <a class=\"abstract\" href=\"mobipreview.htm?35/27/36282/abstract/11\">",
"       11",
"      </a>",
"      ], helping to restore the inotropic and chronotropic responsiveness of the myocardium, thereby improving contractile function.",
"     </li>",
"     <li>",
"      Beta blockers reduce the circulating level of vasoconstrictors, including norepinephrine [",
"      <a class=\"abstract\" href=\"mobipreview.htm?35/27/36282/abstract/14,15\">",
"       14,15",
"      </a>",
"      ], renin [",
"      <a class=\"abstract\" href=\"mobipreview.htm?35/27/36282/abstract/16,17\">",
"       16,17",
"      </a>",
"      ], and endothelin [",
"      <a class=\"abstract\" href=\"mobipreview.htm?35/27/36282/abstract/18\">",
"       18",
"      </a>",
"      ]. Vasoconstriction induced by these hormones increases afterload, thereby promoting the rate of progression of cardiac dysfunction.",
"     </li>",
"     <li>",
"      Beta blockade may reduce myocardial gene production of some of the inflammatory cytokines that occurs during the development of HF [",
"      <a class=\"abstract\" href=\"mobipreview.htm?35/27/36282/abstract/19-21\">",
"       19-21",
"      </a>",
"      ]. (See",
"      <a class=\"medical medical_review\" href=\"mobipreview.htm?12/36/12872?source=see_link\">",
"       \"Nitric oxide, other hormones, cytokines, and chemokines in heart failure\"",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      Beta blockers have a beneficial effect on LV remodeling and can decrease LV end-systolic and end-diastolic volume [",
"      <a class=\"abstract\" href=\"mobipreview.htm?35/27/36282/abstract/22-24\">",
"       22-24",
"      </a>",
"      ]. The improvement in LV geometry can diminish functional mitral regurgitation [",
"      <a class=\"abstract\" href=\"mobipreview.htm?35/27/36282/abstract/25,26\">",
"       25,26",
"      </a>",
"      ]. (See",
"      <a class=\"medical medical_review\" href=\"mobipreview.htm?19/25/19865?source=see_link\">",
"       \"Cardiac remodeling: Basic aspects\"",
"      </a>",
"      and",
"      <a class=\"medical medical_review\" href=\"mobipreview.htm?9/36/9799?source=see_link\">",
"       \"Functional mitral regurgitation\"",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      In ischemic cardiomyopathy, beta blockers may improve function in regions of hibernating myocardium by reducing myocardial oxygen consumption and increasing diastolic perfusion [",
"      <a class=\"abstract\" href=\"mobipreview.htm?35/27/36282/abstract/27\">",
"       27",
"      </a>",
"      ]. (See",
"      <a class=\"medical medical_review\" href=\"mobipreview.htm?8/35/8759?source=see_link\">",
"       \"Clinical syndromes of stunned or hibernating myocardium\"",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      Functional improvement with beta blockers is associated with normalization in the expression of a number of myocardial genes [",
"      <a class=\"abstract\" href=\"mobipreview.htm?35/27/36282/abstract/28\">",
"       28",
"      </a>",
"      ]. The changes that occur would be expected to enhance contractility and reduce pathologic hypertrophy, but it is not clear if they were responsible for or a result of the clinical improvement.",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    In addition to possible hemodynamic benefits, beta blockers also decrease the frequency of ventricular premature beats and the incidence of sudden cardiac death (SCD), especially after a myocardial infarction. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?10/53/11098?source=see_link\">",
"     \"Beta blockers in the management of acute coronary syndrome\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H4\">",
"    <span class=\"h1\">",
"     EFFECTS OF BETA BLOCKADE IN HF",
"    </span>",
"    &nbsp;&mdash;&nbsp;Early physiology studies demonstrated that beta blockade results in volume expansion [",
"    <a class=\"abstract\" href=\"mobipreview.htm?35/27/36282/abstract/29-31\">",
"     29-31",
"    </a>",
"    ]. For these and other reasons, beta blockers were long considered at least relatively contraindicated in patients with HF. However, evidence has now established that cautious use of beta blockers, initiated in stable patients, results in important benefits, including reduced mortality.",
"   </p>",
"   <p>",
"    What follows is a brief review of the studies that evaluated the effects of beta blockade on hemodynamics, LVEF, and exercise capacity in patients with HF. This will be followed by a discussion of the major trials that have evaluated the efficacy of beta blockers on patient survival [",
"    <a class=\"abstract\" href=\"mobipreview.htm?35/27/36282/abstract/6\">",
"     6",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H5\">",
"    <span class=\"h2\">",
"     Ventricular performance",
"    </span>",
"    &nbsp;&mdash;&nbsp;The first observation suggesting that beta blockade might be beneficial in HF was made in 1975 [",
"    <a class=\"abstract\" href=\"mobipreview.htm?35/27/36282/abstract/32\">",
"     32",
"    </a>",
"    ]. The administration of beta blocker to seven patients with congestive cardiomyopathy resulted in improvements in LVEF and overall clinical status.",
"   </p>",
"   <p>",
"    Subsequent reports consistently confirmed these findings, demonstrating that over a three to six month period of follow-up, beta blockers led to improvements in LVEF and resting hemodynamics [",
"    <a class=\"abstract\" href=\"mobipreview.htm?35/27/36282/abstract/14,17,23,33-37\">",
"     14,17,23,33-37",
"    </a>",
"    ]. One study, for example, performed a double-blind, placebo-controlled comparison of bucindolol plus standard therapy versus placebo plus standard therapy in 24 patients with HF due to idiopathic dilated cardiomyopathy [",
"    <a class=\"abstract\" href=\"mobipreview.htm?35/27/36282/abstract/14\">",
"     14",
"    </a>",
"    ]. Bucindolol (12.5 mg twice daily), a nonselective beta blocker with direct vasodilatory activity, was given acutely and was tolerated in 23 of the 24 patients. Long-term therapy resulted in improvements in LVEF, cardiac index, and LV stroke work, while mean pulmonary capillary wedge pressure (PCWP) and heart rate decreased. NYHA functional class also improved in the bucindolol group (p&lt;0.01).",
"   </p>",
"   <p>",
"    Similar improvements have been demonstrated with",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?38/31/39417?source=see_link\">",
"     metoprolol",
"    </a>",
"    and",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?2/29/2520?source=see_link\">",
"     bisoprolol",
"    </a>",
"    , which are beta-1 selective agents [",
"    <a class=\"abstract\" href=\"mobipreview.htm?35/27/36282/abstract/23,34\">",
"     23,34",
"    </a>",
"    ], and",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?9/22/9577?source=see_link\">",
"     carvedilol",
"    </a>",
"    , a nonselective beta blocker that also blocks the alpha-1 receptor [",
"    <a class=\"abstract\" href=\"mobipreview.htm?35/27/36282/abstract/35-37\">",
"     35-37",
"    </a>",
"    ]. The improvement in LVEF (",
"    <a class=\"graphic graphic_figure graphicRef65184 \" href=\"mobipreview.htm?25/13/25821\">",
"     figure 1",
"    </a>",
"    ) and the reduction in symptoms observed with carvedilol occurred in patients with mild (class II) and more severe disease (class III and IV); dose-dependence was more prominent in patients with idiopathic dilated cardiomyopathy (",
"    <a class=\"graphic graphic_figure graphicRef57443 \" href=\"mobipreview.htm?40/3/41021\">",
"     figure 2",
"    </a>",
"    )&nbsp;[",
"    <a class=\"abstract\" href=\"mobipreview.htm?35/27/36282/abstract/38\">",
"     38",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Improvement in contractile function with beta blocker therapy occurs in regions of dysfunctional but viable myocardium, but not in regions of extensive scarring. This is illustrated by the following observations:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      In one report, 45 patients with cardiomyopathy (28 ischemic and 17 nonischemic) underwent cardiovascular magnetic resonance imaging (CMR) with gadolinium enhancement, followed by six months of beta blocker therapy [",
"      <a class=\"abstract\" href=\"mobipreview.htm?35/27/36282/abstract/39\">",
"       39",
"      </a>",
"      ]. Contractility improved in 56 percent of regions with no scarring but in only 3 percent of regions with more than 75 percent scarring. (See",
"      <a class=\"medical medical_review\" href=\"mobipreview.htm?34/3/34874?source=see_link&amp;anchor=H36992805#H36992805\">",
"       \"Clinical utility of cardiovascular magnetic resonance imaging\", section on 'Infarct detection and sizing'",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      In another study, 41 patients in the BEST trial with NYHA class III to IV HF underwent",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?24/57/25494?source=see_link\">",
"       dobutamine",
"      </a>",
"      stress echocardiography before treatment with bucindolol [",
"      <a class=\"abstract\" href=\"mobipreview.htm?35/27/36282/abstract/40\">",
"       40",
"      </a>",
"      ]. There was a significant correlation between contractile reserve assessed by dobutamine echo and the improvement in LVEF after three months of therapy.",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H6\">",
"    <span class=\"h2\">",
"     Exercise capacity",
"    </span>",
"    &nbsp;&mdash;&nbsp;Several small studies have demonstrated an increase in maximum exercise duration following the administration of a beta blocker in HF due to either idiopathic dilated cardiomyopathy or ischemic heart disease [",
"    <a class=\"abstract\" href=\"mobipreview.htm?35/27/36282/abstract/14,41,42\">",
"     14,41,42",
"    </a>",
"    ]. This improvement in exercise duration may be associated with a reduction in maximal VO2 (oxygen utilization), an effect that is probably due in part to an attenuation in the heart rate response to exercise. In addition, the nonselective beta blockers",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?8/49/8986?source=see_link\">",
"     propranolol",
"    </a>",
"    and",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?9/22/9577?source=see_link\">",
"     carvedilol",
"    </a>",
"    do not prevent patients from deriving benefit from exercise training [",
"    <a class=\"abstract\" href=\"mobipreview.htm?35/27/36282/abstract/43\">",
"     43",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H7\">",
"    <span class=\"h2\">",
"     Cardiac remodeling",
"    </span>",
"    &nbsp;&mdash;&nbsp;Chronic beta blocker therapy can have a favorable impact on cardiac remodeling. This issue is discussed in detail separately. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?0/52/842?source=see_link&amp;anchor=H17#H17\">",
"     \"Cardiac remodeling: Clinical assessment and therapy\", section on 'Beta blockers'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H8\">",
"    <span class=\"h2\">",
"     Reduced risk of atrial fibrillation",
"    </span>",
"    &nbsp;&mdash;&nbsp;There is evidence that beta blockers may also reduce the likelihood of the development of AF in patients with HF due to systolic dysfunction. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?12/24/12682?source=see_link&amp;anchor=H20#H20\">",
"     \"Antiarrhythmic drugs to maintain sinus rhythm in patients with atrial fibrillation: Clinical trials\", section on 'Beta blockers'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H9\">",
"    <span class=\"h1\">",
"     CLINICAL TRIALS",
"    </span>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H21350370\">",
"    <span class=\"h2\">",
"     Summary of benefits",
"    </span>",
"    &nbsp;&mdash;&nbsp;Beta blocker trials in patients with HF due to systolic dysfunction have demonstrated reductions in mortality, hospitalization rates and symptoms. A number of major trials have demonstrated a survival benefit with several beta blockers (sustained release",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?38/31/39417?source=see_link\">",
"     metoprolol",
"    </a>",
"    succinate,",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?9/22/9577?source=see_link\">",
"     carvedilol",
"    </a>",
"    , and",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?2/29/2520?source=see_link\">",
"     bisoprolol",
"    </a>",
"    ) in selected patients with HF. Before reviewing the data from the specific trials, the range of benefit can be illustrated by findings from a meta-analysis that included 22 trials involving more than 10,000 patients, almost all of whom had NYHA class II or III HF and were also treated with ACE inhibitors [",
"    <a class=\"abstract\" href=\"mobipreview.htm?35/27/36282/abstract/3\">",
"     3",
"    </a>",
"    ]. The following findings were noted:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Beta blockers significantly reduced mortality at one year (odds ratio 0.65, 95% CI 0.53-0.80) and two years (odds ratio 0.72, 95% CI 0.61-0.84). Assuming a mortality rate of 12 percent in the placebo group at one year (derived from the three largest and most recent trials), beta blocker therapy saved 3.8 lives in the first year per 100 patients treated.",
"     </li>",
"     <li>",
"      Beta blockers also reduced hospitalization for HF (odds ratio 0.64, 95% CI 0.53-0.79) with an absolute benefit of four fewer hospitalizations in the first year per 100 patients treated [",
"      <a class=\"abstract\" href=\"mobipreview.htm?35/27/36282/abstract/3\">",
"       3",
"      </a>",
"      ].",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Similar findings were noted in a meta-analysis limited to the large randomized trials described below [",
"    <a class=\"abstract\" href=\"mobipreview.htm?35/27/36282/abstract/4\">",
"     4",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Symptomatic benefit, such as improvement in symptoms scores, NYHA functional class, and exercise tolerance, has been observed in randomized trials comparing",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?38/31/39417?source=see_link\">",
"     metoprolol",
"    </a>",
"    <span class=\"nowrap\">",
"     CR/XL",
"    </span>",
"    or",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?9/22/9577?source=see_link\">",
"     carvedilol",
"    </a>",
"    to placebo [",
"    <a class=\"abstract\" href=\"mobipreview.htm?35/27/36282/abstract/44-46\">",
"     44-46",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Concerns about potential risks of beta blocker therapy in such patients with HF are discussed separately. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?12/38/12905?source=see_link&amp;anchor=H19#H19\">",
"     \"Use of beta blockers in heart failure due to systolic dysfunction\", section on 'Adverse effects'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H10\">",
"    <span class=\"h2\">",
"     Metoprolol trials",
"    </span>",
"    &nbsp;&mdash;&nbsp;The efficacy of",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?38/31/39417?source=see_link\">",
"     metoprolol",
"    </a>",
"    has been evaluated in several randomized trials, including MDC, MERIT-HF, and RESOLVD.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H11\">",
"    <span class=\"h3\">",
"     MDC trial",
"    </span>",
"    &nbsp;&mdash;&nbsp;The",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?38/31/39417?source=see_link\">",
"     Metoprolol",
"    </a>",
"    in Dilated Cardiomyopathy (MDC) trial randomly assigned 383 patients to placebo or metoprolol tartrate (beginning at a dose of 10 mg and increasing slowly to a maximum of 150",
"    <span class=\"nowrap\">",
"     mg/day)",
"    </span>",
"    [",
"    <a class=\"abstract\" href=\"mobipreview.htm?35/27/36282/abstract/47\">",
"     47",
"    </a>",
"    ]. Eligible patients were required to have dilated cardiomyopathy, symptomatic HF, an LVEF &lt;40 percent, and a systolic pressure above 90 mmHg. Potential participants were excluded if they had significant coronary disease, active myocarditis, other life-threatening disease, or they deteriorated after a test dose of 5 mg of metoprolol twice daily for two to seven days. Digitalis, diuretics, and angiotensin converting enzyme (ACE) inhibitors were used as necessary.",
"   </p>",
"   <p>",
"    Of the patients who entered the study, the following significant benefits were noted in the",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?38/31/39417?source=see_link\">",
"     metoprolol",
"    </a>",
"    group when compared to therapy with placebo at 12 to 18 months:",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      A reduced likelihood of progressing to cardiac transplantation (1 versus 10 percent)",
"     </li>",
"     <li>",
"      A greater increase in LVEF (12 versus 6 percent) and exercise tolerance",
"     </li>",
"     <li>",
"      A subjective improvement in the quality of life",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    There was no significant difference in mortality &mdash; 12 versus 10 percent; however, the use of cardiac transplantation in patients who otherwise might have died may have prevented an improvement in mortality from being observed.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H12\">",
"    <span class=\"h3\">",
"     MERIT-HF trial",
"    </span>",
"    &nbsp;&mdash;&nbsp;In comparison to the nonsignificant benefit in the MDC trial, a mortality benefit with sustained release",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?38/31/39417?source=see_link\">",
"     metoprolol",
"    </a>",
"    succinate was demonstrated in the much larger MERIT-HF trial [",
"    <a class=\"abstract\" href=\"mobipreview.htm?35/27/36282/abstract/48,49\">",
"     48,49",
"    </a>",
"    ]. In the MERIT-HF trial, 3991 patients with class II to IV HF and an LVEF &le;40 percent who were receiving",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?28/27/29113?source=see_link\">",
"     digoxin",
"    </a>",
"    , an ACE inhibitor, and a diuretic, were randomly assigned to therapy with extended-release metoprolol, beginning with 12.5 or 25 mg daily and titrated up to 200",
"    <span class=\"nowrap\">",
"     mg/day,",
"    </span>",
"    or placebo [",
"    <a class=\"abstract\" href=\"mobipreview.htm?35/27/36282/abstract/48,49\">",
"     48,49",
"    </a>",
"    ]. The mean dose was 159",
"    <span class=\"nowrap\">",
"     mg/day,",
"    </span>",
"    with 64 percent of patients receiving the target dose; the discontinuation rate for patients taking active drug was 14 percent at one year. The study was prematurely terminated when the following significant benefits were noted in the metoprolol group:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      A 34 percent relative risk reduction in all-cause mortality at 12 months (7.2 versus 11 percent for placebo) (",
"      <a class=\"graphic graphic_figure graphicRef78949 \" href=\"mobipreview.htm?38/42/39597\">",
"       figure 3",
"      </a>",
"      ); there was also a reduction in the combined end point of death or need for transplant (7.5 versus 10.3 percent).",
"     </li>",
"     <li>",
"      A reduction in hospitalization for cardiovascular causes (20 versus 25 percent) or for HF (10 versus 15 percent) (",
"      <a class=\"graphic graphic_figure graphicRef60489 \" href=\"mobipreview.htm?40/61/41950\">",
"       figure 4",
"      </a>",
"      ).",
"     </li>",
"     <li>",
"      Improved NYHA functional class (",
"      <a class=\"graphic graphic_table graphicRef52683 \" href=\"mobipreview.htm?3/2/3117\">",
"       table 1",
"      </a>",
"      ) and quality of life measures",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    When analyzed by mode of death, there were significantly fewer SCDs (3.9 versus 6.6 percent) and fewer deaths from worsening of HF (1.5 versus 2.9 percent) in the",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?38/31/39417?source=see_link\">",
"     metoprolol",
"    </a>",
"    group. The proportion of SCDs decreased and those due to HF increased with increasing severity of HF.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H13\">",
"    <span class=\"h2\">",
"     Carvedilol trials",
"    </span>",
"    &nbsp;&mdash;&nbsp;The United States",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?9/22/9577?source=see_link\">",
"     Carvedilol",
"    </a>",
"    Heart Failure Program, which consisted of four component trials including MOCHA and PRECISE, was initially designed to evaluate nonfatal end points in patients with mild to moderate HF [",
"    <a class=\"abstract\" href=\"mobipreview.htm?35/27/36282/abstract/35,36,38,50\">",
"     35,36,38,50",
"    </a>",
"    ]. Mortality, which was not a prospectively designated primary end point, was also measured to assess safety and potential benefit. The results were combined to form a double-blind controlled study of almost 1100 patients with NYHA class II to III HF (",
"    <a class=\"graphic graphic_table graphicRef52683 \" href=\"mobipreview.htm?3/2/3117\">",
"     table 1",
"    </a>",
"    ) [",
"    <a class=\"abstract\" href=\"mobipreview.htm?35/27/36282/abstract/50\">",
"     50",
"    </a>",
"    ]. Patients were maintained on",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?28/27/29113?source=see_link\">",
"     digoxin",
"    </a>",
"    , diuretics, and ACE inhibitors and then randomly assigned to treatment with carvedilol or placebo.",
"   </p>",
"   <p>",
"    Marked improvement in mortality in patients treated with",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?9/22/9577?source=see_link\">",
"     carvedilol",
"    </a>",
"    (initial dose 6.25 mg twice daily and then gradually increased to a maximum of 25 mg twice daily) led to early termination of the study after 25 months of enrollment:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      There was a significant decrease in total mortality (3.2 versus 7.8 percent) (",
"      <a class=\"graphic graphic_figure graphicRef62633 \" href=\"mobipreview.htm?11/47/12029\">",
"       figure 5",
"      </a>",
"      ). This benefit was due to reductions in death due to progressive HF or SCD; it was independent of age, sex, HF etiology, LVEF, exercise tolerance, systolic blood pressure, or heart rate.",
"     </li>",
"     <li>",
"      There were also significant reductions in the need for hospitalization (14.1 versus 19.6 percent) and the number of intensive care unit days and length of hospital stay [",
"      <a class=\"abstract\" href=\"mobipreview.htm?35/27/36282/abstract/51\">",
"       51",
"      </a>",
"      ], and a 38 percent increase in event-free survival (15.8 versus 24.6 percent) (",
"      <a class=\"graphic graphic_figure graphicRef75356 \" href=\"mobipreview.htm?25/63/26621\">",
"       figure 6",
"      </a>",
"      ).",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    These benefits translated into an estimated reduction of in-patient costs for cardiovascular and HF admissions by 57 and 81 percent, respectively [",
"    <a class=\"abstract\" href=\"mobipreview.htm?35/27/36282/abstract/51\">",
"     51",
"    </a>",
"    ]. The most common adverse reaction was worsening HF, which was less frequent with",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?9/22/9577?source=see_link\">",
"     carvedilol",
"    </a>",
"    than with placebo (1.6 versus 2.3 percent).",
"   </p>",
"   <p>",
"    Despite these apparent benefits, this study was criticized for the following reasons [",
"    <a class=\"abstract\" href=\"mobipreview.htm?35/27/36282/abstract/52\">",
"     52",
"    </a>",
"    ]:",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      Very short average follow-up (6.5 months)",
"     </li>",
"     <li>",
"      Lack of mortality as a prospective primary end point",
"     </li>",
"     <li>",
"      A six-week run-in period to demonstrate patient tolerability to open-label",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?9/22/9577?source=see_link\">",
"       carvedilol",
"      </a>",
"      prior to randomization",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?9/22/9577?source=see_link\">",
"     Carvedilol",
"    </a>",
"    is also useful in patients with more severe HF (symptoms with minimal exertion at rest) as demonstrated in the COPERNICUS trial described below [",
"    <a class=\"abstract\" href=\"mobipreview.htm?35/27/36282/abstract/44,53\">",
"     44,53",
"    </a>",
"    ] and in patients with a dilated cardiomyopathy and HF who are on chronic hemodialysis [",
"    <a class=\"abstract\" href=\"mobipreview.htm?35/27/36282/abstract/54\">",
"     54",
"    </a>",
"    ]. (See",
"    <a class=\"local\" href=\"#H30\">",
"     'Class IV HF'",
"    </a>",
"    below and",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?25/61/26584?source=see_link\">",
"     \"Myocardial dysfunction in end-stage renal disease\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H14\">",
"    <span class=\"h2\">",
"     Bisoprolol (CIBIS and CIBIS II trials)",
"    </span>",
"    &nbsp;&mdash;&nbsp;After demonstration that",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?2/29/2520?source=see_link\">",
"     bisoprolol",
"    </a>",
"    had both hemodynamic benefits and a trend toward improved survival in 641 patients in CIBIS [",
"    <a class=\"abstract\" href=\"mobipreview.htm?35/27/36282/abstract/34,55\">",
"     34,55",
"    </a>",
"    ], the efficacy of bisoprolol was more fully evaluated in the much larger CIBIS II trial [",
"    <a class=\"abstract\" href=\"mobipreview.htm?35/27/36282/abstract/56,57\">",
"     56,57",
"    </a>",
"    ]. CIBIS II randomly assigned 2647 patients with class III or IV HF and an LVEF &lt;35 percent to bisoprolol or placebo; the patients also received standard therapy with diuretics and ACE inhibitors. After an average follow-up of 1.4 years, the trial was prematurely terminated when the following benefits were observed in the bisoprolol group:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      A significant reduction in total all-cause mortality (11.8 versus 17.3 percent) that was independent of the severity or cause of HF (",
"      <a class=\"graphic graphic_figure graphicRef63774 \" href=\"mobipreview.htm?17/1/17437\">",
"       figure 7",
"      </a>",
"      ). This benefit was primarily due to a reduction in SCD (3.6 versus 6.3 percent, p &lt;0.001), with a nonsignificant trend toward fewer deaths from HF.",
"     </li>",
"     <li>",
"      A significant 15 percent reduction in hospital admissions for any cause and a 30 percent reduction in admissions for HF (p &lt;0.0001). These benefits resulted in a 5 to 10 percent reduction in the cost of care for these patients [",
"      <a class=\"abstract\" href=\"mobipreview.htm?35/27/36282/abstract/58\">",
"       58",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      Although mortality and hospitalization for HF were significantly related to a higher baseline heart rate, the improvement in outcome with",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?2/29/2520?source=see_link\">",
"       bisoprolol",
"      </a>",
"      was similar at any level of resting heart rate or amount of change in heart rate at two months [",
"      <a class=\"abstract\" href=\"mobipreview.htm?35/27/36282/abstract/59\">",
"       59",
"      </a>",
"      ]. However, bisoprolol had no effect on outcome in patients in atrial fibrillation. (See",
"      <a class=\"medical medical_review\" href=\"mobipreview.htm?23/30/24042?source=see_link\">",
"       \"Atrial fibrillation in patients with heart failure\"",
"      </a>",
"      .)",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H15\">",
"    <span class=\"h2\">",
"     Bucindolol (BEST trial)",
"    </span>",
"    &nbsp;&mdash;&nbsp;The BEST trial evaluated the role of bucindolol (3 mg twice daily titrated up to 100 mg twice daily) in 2708 patients with class III (92 percent of the patients) or IV HF [",
"    <a class=\"abstract\" href=\"mobipreview.htm?35/27/36282/abstract/60\">",
"     60",
"    </a>",
"    ]. After a mean follow-up of two years, the study was prematurely terminated. At the time of termination, bucindolol did not reduce overall mortality compared to placebo (30 versus 33 percent). It did reduce cardiovascular mortality by 14 percent, but there was no difference in HF death, sudden death, death from myocardial infarction, or noncardiovascular mortality.",
"   </p>",
"   <p>",
"    On prespecified subgroup analysis, there was a significant survival benefit with bucindolol in nonblack patients. There was a trend toward improved survival in patients with class III HF, an LVEF above 20 percent, and nonischemic cardiomyopathy. There was no survival benefit with bucindolol in patients with an LVEF equal to or less than 20 percent or in blacks (see",
"    <a class=\"local\" href=\"#H34\">",
"     'Use in blacks'",
"    </a>",
"    below).",
"   </p>",
"   <p>",
"    Possible explanations for the lack of overall mortality benefit with bucindolol include differences in pharmacologic properties of bucindolol as compared to other studied beta blockers or differences in studied patients populations (such as racial composition). Although bucindolol is similar to",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?9/22/9577?source=see_link\">",
"     carvedilol",
"    </a>",
"    as a nonselective beta-blocking agent with weak alpha 1 blocking properties, unlike carvedilol it has inverse agonist and intrinsic sympathomimetic activity [",
"    <a class=\"abstract\" href=\"mobipreview.htm?35/27/36282/abstract/61,62\">",
"     61,62",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H16\">",
"    <span class=\"h2\">",
"     Comparison of beta blockers",
"    </span>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H17\">",
"    <span class=\"h3\">",
"     Comparison between metoprolol and carvedilol",
"    </span>",
"    &nbsp;&mdash;&nbsp;As described above, both sustained release",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?38/31/39417?source=see_link\">",
"     metoprolol",
"    </a>",
"    succinate and",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?9/22/9577?source=see_link\">",
"     carvedilol",
"    </a>",
"    reduce mortality in patients with HF. These two drugs have different pharmacologic properties: metoprolol has a high degree of specificity for the beta-1 adrenergic receptor, while carvedilol acutely blocks beta-1, beta-2, and alpha-1 adrenergic receptors. Whether the broader adrenergic blocking effects of carvedilol confer an additional advantage over beta-1 selective agents is not known [",
"    <a class=\"abstract\" href=\"mobipreview.htm?35/27/36282/abstract/63\">",
"     63",
"    </a>",
"    ]. The alpha-1 adrenergic blocking effect of carvedilol may not be significant in patients with HF on chronic beta blocker therapy [",
"    <a class=\"abstract\" href=\"mobipreview.htm?35/27/36282/abstract/64,65\">",
"     64,65",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    The effects of",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?9/22/9577?source=see_link\">",
"     carvedilol",
"    </a>",
"    and short-acting",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?38/31/39417?source=see_link\">",
"     metoprolol",
"    </a>",
"    (metoprolol tartrate) were directly compared in the COMET trial; carvedilol was more effective than metoprolol in reducing mortality [",
"    <a class=\"abstract\" href=\"mobipreview.htm?35/27/36282/abstract/66\">",
"     66",
"    </a>",
"    ] and vascular events [",
"    <a class=\"abstract\" href=\"mobipreview.htm?35/27/36282/abstract/67\">",
"     67",
"    </a>",
"    ]. This study enrolled 3029 patients with class II to IV HF, at least one admission for a cardiovascular diagnosis in the preceding two years, and an LVEF &le;35 percent. Subjects were randomly assigned to either carvedilol at a target dose of 25 mg twice daily or metoprolol tartrate at a target dose of 50 mg twice daily.",
"   </p>",
"   <p>",
"    At a mean follow-up of five years, the",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?9/22/9577?source=see_link\">",
"     carvedilol",
"    </a>",
"    arm had a significantly lower rate of all-cause mortality (34 versus 40 percent for",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?38/31/39417?source=see_link\">",
"     metoprolol",
"    </a>",
"    ) that was entirely due to a reduction in cardiovascular mortality (29 versus 35 percent). Extrapolation of the survival curves gave a significantly longer estimate of median survival for the carvedilol group (8.0 versus 6.6 years).",
"   </p>",
"   <p>",
"    A potentially important limitation to these findings is that the degree of beta blockade may not have been equivalent in the two arms of COMET [",
"    <a class=\"abstract\" href=\"mobipreview.htm?35/27/36282/abstract/68\">",
"     68",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      The",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?9/22/9577?source=see_link\">",
"       carvedilol",
"      </a>",
"      arm had significantly greater reductions in heart rate (13.3 versus 11.7 beats per minute with",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?38/31/39417?source=see_link\">",
"       metoprolol",
"      </a>",
"      ) and systolic blood pressure (3.8 versus 2.0 mmHg). These differences are consistent with carvedilol being given in a dose similar to that in the Carvedilol Trials, while the metoprolol goal dose was substantially lower than in the MDC and MERIT-HF trials (100 versus 150 and 200",
"      <span class=\"nowrap\">",
"       mg/day)",
"      </span>",
"      [",
"      <a class=\"abstract\" href=\"mobipreview.htm?35/27/36282/abstract/47-50\">",
"       47-50",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      Another potential concern is that short-acting",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?38/31/39417?source=see_link\">",
"       metoprolol",
"      </a>",
"      (metoprolol tartrate) was used in COMET, whereas the extended-release form (metoprolol succinate) was used in MERIT-HF.",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Data directly comparing outcomes on",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?9/22/9577?source=see_link\">",
"     carvedilol",
"    </a>",
"    versus extended release",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?38/31/39417?source=see_link\">",
"     metoprolol",
"    </a>",
"    (metoprolol succinate) are not available. A meta-analysis of 15 placebo controlled trials (nine using carvedilol and six using metoprolol of which four used the short-acting form and two used extended-release drug), suggested that carvedilol may produce a greater improvement in LVEF (placebo corrected increases of 6.5 versus 3.8 percent for the placebo-controlled trials) [",
"    <a class=\"abstract\" href=\"mobipreview.htm?35/27/36282/abstract/69\">",
"     69",
"    </a>",
"    ]. A similar difference in LVEF change was noted upon analysis of four trials directly comparing carvedilol and short-acting metoprolol. However, the relevance of differences in LVEF is uncertain. LVEF may be affected by afterload so its improvement does not prove an increase in contractility.",
"   </p>",
"   <p>",
"    A clinically important difference among beta blockers may be their effects on blood pressure. Patients with low blood pressure may be less likely to tolerate",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?9/22/9577?source=see_link\">",
"     carvedilol",
"    </a>",
"    because of its vasodilator activity. Conversely, those with higher blood pressure may have a greater lowering of blood pressure with carvedilol. In MERIT-HF,",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?38/31/39417?source=see_link\">",
"     metoprolol",
"    </a>",
"    resulted in a higher blood pressure than placebo, presumably because of improved cardiac function.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H18\">",
"    <span class=\"h3\">",
"     Comparison with other beta blockers",
"    </span>",
"    &nbsp;&mdash;&nbsp;Limited data are available comparing other beta blockers with",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?9/22/9577?source=see_link\">",
"     carvedilol",
"    </a>",
"    or",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?38/31/39417?source=see_link\">",
"     metoprolol",
"    </a>",
"    for treatment of HF.",
"   </p>",
"   <p>",
"    A meta-analysis compared the effects of vasodilating beta blockers, primarily",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?9/22/9577?source=see_link\">",
"     carvedilol",
"    </a>",
"    , with non-vasodilating beta blocker (largely",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?2/29/2520?source=see_link\">",
"     bisoprolol",
"    </a>",
"    ) using indirect evidence provided by trials comparing beta blocker to placebo [",
"    <a class=\"abstract\" href=\"mobipreview.htm?35/27/36282/abstract/70\">",
"     70",
"    </a>",
"    ]. Vasodilating beta blockers produced a greater survival benefit than nonvasodilating agents (45 versus 27 percent). This difference was primarily seen in patients with nonischemic cardiomyopathy.",
"   </p>",
"   <p>",
"    The beta blocker bucindolol reduced all-cause mortality in whites but not blacks, while other beta blockers appear to be equally effective in whites and blacks (see",
"    <a class=\"local\" href=\"#H34\">",
"     'Use in blacks'",
"    </a>",
"    below).",
"   </p>",
"   <p>",
"    Observational studies suggest that the beneficial effects of beta blockers on mortality in patients with HF may not be limited to those beta blockers with proven efficacy in randomized trials. However, such retrospective studies are difficult to interpret.",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Among 11,326 privately insured adults hospitalized for HF, 70 percent received beta blockers [",
"      <a class=\"abstract\" href=\"mobipreview.htm?35/27/36282/abstract/71\">",
"       71",
"      </a>",
"      ]. The mortality at one year varied with beta blocker use (",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?29/46/30440?source=see_link\">",
"       atenolol",
"      </a>",
"      , 20.1;",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?38/31/39417?source=see_link\">",
"       metoprolol",
"      </a>",
"      tartrate, 22.8;",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?9/22/9577?source=see_link\">",
"       carvedilol",
"      </a>",
"      , 17.7; and no beta blockers, 37 percent). After adjustment for confounders and the propensity to receive carvedilol, the risk of death at one year compared with atenolol was higher for metoprolol tartrate and no beta blockers but was not significantly different for carvedilol.",
"     </li>",
"     <li>",
"      Among 11,959",
"      <span class=\"nowrap\">",
"       Medicare/Medicaid",
"      </span>",
"      beneficiaries hospitalized with HF, 59 percent received no beta blockers, 23 percent received beta blockers with randomized controlled trial evidence of efficacy in treatment of HF (evidence based beta blocker [EBBB]:",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?9/22/9577?source=see_link\">",
"       carvedilol",
"      </a>",
"      ,",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?38/31/39417?source=see_link\">",
"       metoprolol",
"      </a>",
"      succinate or",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?2/29/2520?source=see_link\">",
"       bisoprolol",
"      </a>",
"      ), and 18 percent received other beta blockers (non-EBBB) [",
"      <a class=\"abstract\" href=\"mobipreview.htm?35/27/36282/abstract/72\">",
"       72",
"      </a>",
"      ]. Patients receiving no beta blockers had significant higher adjusted one year mortality than patients receiving either non-EBBB or EBBB (28.3 versus 22.8 and 24.2 percent). There was no difference in adjusted mortality between patients receiving non-EBBBs and EBBBs. Patients receiving EBBBs had a higher adjusted rehospitalization rate than patients not receiving beta blockers or patients taking non-EBBBs.",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Taken together, these retrospective data suggest a possible beneficial effect of non-EBBB, such as",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?29/46/30440?source=see_link\">",
"     atenolol",
"    </a>",
"    , but do NOT support a benefit for short-acting",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?38/31/39417?source=see_link\">",
"     metoprolol",
"    </a>",
"    , a conclusion that is also consistent with the effects of short-acting metoprolol in the COMET trial (see",
"    <a class=\"local\" href=\"#H17\">",
"     'Comparison between metoprolol and carvedilol'",
"    </a>",
"    above). However, important limitations of these studies include lack of information on HF severity, left ventricular ejection fraction, and indications for beta blocker use (treatment of hypertension or HF). Therefore, these studies do not provide a sufficient basis for recommendation of non-EBBB for HF treatment.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H19\">",
"    <span class=\"h2\">",
"     Use with other HF drugs",
"    </span>",
"    &nbsp;&mdash;&nbsp;Only three other drugs, ACE inhibitors, angiotensin II receptor blockers (ARBs), and aldosterone antagonists, also improve survival in patients with HF. The benefit from all of these drugs appears to be additive to that of beta blockers. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?37/63/38906?source=see_link\">",
"     \"Overview of the therapy of heart failure due to systolic dysfunction\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H20\">",
"    <span class=\"h3\">",
"     ACE inhibitors",
"    </span>",
"    &nbsp;&mdash;&nbsp;Most patients in the major trials evaluating",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?38/31/39417?source=see_link\">",
"     metoprolol",
"    </a>",
"    [",
"    <a class=\"abstract\" href=\"mobipreview.htm?35/27/36282/abstract/47-49\">",
"     47-49",
"    </a>",
"    ],",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?9/22/9577?source=see_link\">",
"     carvedilol",
"    </a>",
"    [",
"    <a class=\"abstract\" href=\"mobipreview.htm?35/27/36282/abstract/50\">",
"     50",
"    </a>",
"    ], and",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?2/29/2520?source=see_link\">",
"     bisoprolol",
"    </a>",
"    [",
"    <a class=\"abstract\" href=\"mobipreview.htm?35/27/36282/abstract/56\">",
"     56",
"    </a>",
"    ] were also treated with an ACE inhibitor (as well as diuretics and",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?28/27/29113?source=see_link\">",
"     digoxin",
"    </a>",
"    as necessary). Combination therapy with an ACE inhibitor and beta blocker is more effective than an ACE inhibitor or beta blocker alone (",
"    <a class=\"graphic graphic_figure graphicRef65184 \" href=\"mobipreview.htm?25/13/25821\">",
"     figure 1",
"    </a>",
"    and",
"    <a class=\"graphic graphic_figure graphicRef57443 \" href=\"mobipreview.htm?40/3/41021\">",
"     figure 2",
"    </a>",
"    ) [",
"    <a class=\"abstract\" href=\"mobipreview.htm?35/27/36282/abstract/73\">",
"     73",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    ACE gene polymorphisms may affect the response to combination therapy. The DD genotype of the ACE gene has been associated with increases in ACE activity and mortality and a reduction in transplant-free survival in patients with HF [",
"    <a class=\"abstract\" href=\"mobipreview.htm?35/27/36282/abstract/74\">",
"     74",
"    </a>",
"    ]. This difference may be abolished with beta blocker therapy as transplant-free survival is equivalent in patients with the DD, ID, and II genotypes. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?35/61/36825?source=see_link&amp;anchor=H4#H4\">",
"     \"Actions of angiotensin II on the heart\", section on 'ACE gene polymorphism'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H21\">",
"    <span class=\"h3\">",
"     ARBs",
"    </span>",
"    &nbsp;&mdash;&nbsp;Combination therapy with an ARB and a beta blocker also appears to be more effective than either agent alone. In the CHARM-Alternative trial of patients with HF who were treated with",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?37/48/38663?source=see_link\">",
"     candesartan",
"    </a>",
"    because they could not tolerate an ACE inhibitor (most often due to cough), a reduction in cardiovascular death or hospitalization for HF was seen whether or not the patient was taking a beta blocker [",
"    <a class=\"abstract\" href=\"mobipreview.htm?35/27/36282/abstract/75\">",
"     75",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?2/39/2680?source=see_link\">",
"     \"Angiotensin II receptor blockers in heart failure due to systolic dysfunction: Therapeutic use\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    There are conflicting data on the value of adding an ARB to patients already treated with an ACE inhibitor and beta blocker. In the CHARM-ADDED trial, outcomes were improved with the addition of",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?37/48/38663?source=see_link\">",
"     candesartan",
"    </a>",
"    , a benefit that was seen regardless of whether or not patients were also treated with a beta blocker [",
"    <a class=\"abstract\" href=\"mobipreview.htm?35/27/36282/abstract/76\">",
"     76",
"    </a>",
"    ]. In contrast, adding an ARB to an ACE inhibitor in patients treated with a beta blocker appeared to be associated with increased mortality in a post hoc subgroup analysis from the Val-HeFT trial [",
"    <a class=\"abstract\" href=\"mobipreview.htm?35/27/36282/abstract/77\">",
"     77",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    We regard the CHARM-Added findings as more definitive and suggest the addition of an ARB, if tolerated to a regimen including ACE inhibitors and beta blockers, in patients with persistent class II to III HF if the patient has normal renal function and low to normal serum potassium. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?2/39/2680?source=see_link\">",
"     \"Angiotensin II receptor blockers in heart failure due to systolic dysfunction: Therapeutic use\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H22\">",
"    <span class=\"h3\">",
"     Aldosterone antagonists",
"    </span>",
"    &nbsp;&mdash;&nbsp;Two major trials have demonstrated benefit from aldosterone antagonists in patients with HF; almost all patients in both trials were treated with an ACE inhibitor or ARB. The RALES trial evaluated",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?17/22/17767?source=see_link\">",
"     spironolactone",
"    </a>",
"    in patients with recent or current class IV HF [",
"    <a class=\"abstract\" href=\"mobipreview.htm?35/27/36282/abstract/78\">",
"     78",
"    </a>",
"    ]. Although the benefit from spironolactone was similar in all subgroups, only 10 percent were taking a beta blocker.",
"   </p>",
"   <p>",
"    More convincing evidence for benefit in association with beta blockers comes from EPHESUS in which 75 percent were taking a beta blocker [",
"    <a class=\"abstract\" href=\"mobipreview.htm?35/27/36282/abstract/79\">",
"     79",
"    </a>",
"    ]. The benefit from",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?4/58/5031?source=see_link\">",
"     eplerenone",
"    </a>",
"    was best seen in patients treated with both a beta blocker and an ACE inhibitor or ARB.",
"   </p>",
"   <p>",
"    Similarly, patients taking an aldosterone antagonist appear to benefit from a beta blocker. This was suggested in a post-hoc analysis from the COPERNICUS trial in which the benefits of",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?9/22/9577?source=see_link\">",
"     carvedilol",
"    </a>",
"    (reduced mortality and HF admissions) were similar in the subsets of patients who were (19 percent) and were not (81 percent) taking",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?17/22/17767?source=see_link\">",
"     spironolactone",
"    </a>",
"    [",
"    <a class=\"abstract\" href=\"mobipreview.htm?35/27/36282/abstract/80\">",
"     80",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H23\">",
"    <span class=\"h2\">",
"     Use with aspirin",
"    </span>",
"    &nbsp;&mdash;&nbsp;Concern has been raised that",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?24/7/24698?source=see_link\">",
"     aspirin",
"    </a>",
"    (ASA) may offset some of the benefit of ACE inhibitors in patients with HF, although most of the evidence does not support the presence of such an interaction. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?15/45/16090?source=see_link&amp;anchor=H12#H12\">",
"     \"ACE inhibitors in heart failure due to systolic dysfunction: Therapeutic use\", section on 'Use with aspirin'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Whether there is an interaction between ASA and beta blockers was addressed in a retrospective analysis of 293 patients enrolled in a randomized, placebo-controlled trial of",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?9/22/9577?source=see_link\">",
"     carvedilol",
"    </a>",
"    [",
"    <a class=\"abstract\" href=\"mobipreview.htm?35/27/36282/abstract/81\">",
"     81",
"    </a>",
"    ]. Among patients receiving carvedilol, those using ASA had less improvement in LVEF compared to ASA nonusers (6 versus 9.5 EF units). This effect was dose related; for each 81",
"    <span class=\"nowrap\">",
"     mg/day",
"    </span>",
"    increase in dose, there was a decrease of 0.5 EF units. The mechanism for this possible interaction is unknown.",
"   </p>",
"   <p>",
"    Given the demonstrated value of ASA and the confounding features of a retrospective analysis, it would be premature to modify recommendations for use of ASA until further data are available. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?41/3/42039?source=see_link&amp;anchor=H6#H6\">",
"     \"Drugs that should be avoided or used with caution in patients with heart failure\", section on 'Aspirin'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H24\">",
"    <span class=\"h1\">",
"     DEGREE AND DURATION OF BETA BLOCKADE",
"    </span>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H25\">",
"    <span class=\"h2\">",
"     Degree of beta blockade",
"    </span>",
"    &nbsp;&mdash;&nbsp;Individualized dose titration leading to effective beta blockade was supported by a post-hoc subgroup analysis from the MERIT-HF trial in which the patients were divided into a high-dose (mean",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?38/31/39417?source=see_link\">",
"     metoprolol",
"    </a>",
"    dose 192",
"    <span class=\"nowrap\">",
"     mg/day)",
"    </span>",
"    and low-dose group (mean 76",
"    <span class=\"nowrap\">",
"     mg/day);",
"    </span>",
"    a low heart rate was the most common cause for dose-limitation [",
"    <a class=\"abstract\" href=\"mobipreview.htm?35/27/36282/abstract/82\">",
"     82",
"    </a>",
"    ]. The two groups had similar heart rates at baseline (83 and 81",
"    <span class=\"nowrap\">",
"     beats/min)",
"    </span>",
"    and during therapy (67",
"    <span class=\"nowrap\">",
"     beats/min);",
"    </span>",
"    the similar fall in heart rate in the low-dose group suggested increased sensitivity to beta blocker therapy. The two groups, compared to placebo, had a similar reduction in mortality (38 percent) and other cardiovascular end points.",
"   </p>",
"   <p>",
"    Aiming for a particular resting heart rate or a particular reduction in heart rate is not of proven value [",
"    <a class=\"abstract\" href=\"mobipreview.htm?35/27/36282/abstract/59,83\">",
"     59,83",
"    </a>",
"    ]. This was illustrated in a post-hoc subgroup analysis from the MERIT-HF trial [",
"    <a class=\"abstract\" href=\"mobipreview.htm?35/27/36282/abstract/83\">",
"     83",
"    </a>",
"    ]. There was no relationship between the benefit from controlled",
"    <span class=\"nowrap\">",
"     release/extended",
"    </span>",
"    release",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?38/31/39417?source=see_link\">",
"     metoprolol",
"    </a>",
"    and the baseline heart rate, achieved heart rate, or change in heart rate.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H26\">",
"    <span class=\"h2\">",
"     Duration of therapy",
"    </span>",
"    &nbsp;&mdash;&nbsp;Although data about the duration of beta blocker therapy in HF are lacking, the available limited data favor continuation of beta blocker therapy in patients with left ventricular systolic dysfunction and history of HF [",
"    <a class=\"abstract\" href=\"mobipreview.htm?35/27/36282/abstract/84-86\">",
"     84-86",
"    </a>",
"    ]. This approach is supported by a report of 13 patients with a dilated cardiomyopathy who were successfully managed with",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?38/31/39417?source=see_link\">",
"     metoprolol",
"    </a>",
"    for &ge;30 months [",
"    <a class=\"abstract\" href=\"mobipreview.htm?35/27/36282/abstract/86\">",
"     86",
"    </a>",
"    ]. Within four months of tapering the dose and then discontinuing the drug, SCD or death from progressive HF occurred in four and clinical deterioration in three.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H27\">",
"    <span class=\"h1\">",
"     SPECIFIC PATIENT SUBSETS",
"    </span>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H28\">",
"    <span class=\"h2\">",
"     General approach",
"    </span>",
"    &nbsp;&mdash;&nbsp;Less evidence is available to support beta blocker use in specific patients subsets. As recommended in the 2005",
"    <span class=\"nowrap\">",
"     ACC/AHA",
"    </span>",
"    guidelines, in the absence of specific evidence to the contrary subgroups should receive therapy identical to that applied to the broader population [",
"    <a class=\"abstract\" href=\"mobipreview.htm?35/27/36282/abstract/87\">",
"     87",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H29\">",
"    <span class=\"h2\">",
"     Use in ischemic and nonischemic cardiomyopathy",
"    </span>",
"    &nbsp;&mdash;&nbsp;Clinical trials have demonstrated that improvements in exercise duration, stabilization of LV function, and mortality are similar in ischemic and nonischemic cardiomyopathies [",
"    <a class=\"abstract\" href=\"mobipreview.htm?35/27/36282/abstract/50,70,88\">",
"     50,70,88",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H30\">",
"    <span class=\"h2\">",
"     Class IV HF",
"    </span>",
"    &nbsp;&mdash;&nbsp;The benefit of beta blockade appears to extend to patients with severe class III and stable class IV HF (",
"    <a class=\"graphic graphic_table graphicRef52683 \" href=\"mobipreview.htm?3/2/3117\">",
"     table 1",
"    </a>",
"    ). In a subgroup analysis of 795 patients with severe HF (NYHA functional class",
"    <span class=\"nowrap\">",
"     III/IV)",
"    </span>",
"    in the MERIT-HF trial, the benefit of",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?38/31/39417?source=see_link\">",
"     metoprolol",
"    </a>",
"    was similar to that seen in the entire study population [",
"    <a class=\"abstract\" href=\"mobipreview.htm?35/27/36282/abstract/45\">",
"     45",
"    </a>",
"    ]. Metoprolol reduced total mortality (11.3 versus 18.2 percent for placebo), SCD (5.5 versus 9.8 percent), death from HF (3.3 versus 7 percent), and the number of hospitalizations for HF (15 versus 26 percent).",
"   </p>",
"   <p>",
"    Similar results were seen with",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?9/22/9577?source=see_link\">",
"     carvedilol",
"    </a>",
"    in the COPERNICUS trial, which specifically assessed the efficacy of beta blockade in 2289 patients with severe class III or stable class IV HF (symptoms with minimal exertion or at rest) and an LVEF less than 25 percent [",
"    <a class=\"abstract\" href=\"mobipreview.htm?35/27/36282/abstract/53\">",
"     53",
"    </a>",
"    ]. The trial was terminated one year prematurely (mean follow-up 10.4 months) because of a significant mortality benefit from carvedilol compared to placebo (annual mortality rate 11.4 versus 18.5 percent) (",
"    <a class=\"graphic graphic_figure graphicRef75953 \" href=\"mobipreview.htm?35/9/35997\">",
"     figure 8",
"    </a>",
"    ). Carvedilol was associated with an equivalent reduction in the total number of hospitalizations, hospitalizations for cardiovascular reasons, and those for HF. These benefits were seen in all subgroups, not being affected by age, LVEF, or the cause of the cardiomyopathy (",
"    <a class=\"graphic graphic_figure graphicRef51885 \" href=\"mobipreview.htm?30/53/31581\">",
"     figure 9",
"    </a>",
"    ). The patients treated with carvedilol also spent fewer days in the hospital per admission and were less likely to develop serious adverse events such as sudden death, ventricular tachycardia, or cardiogenic shock [",
"    <a class=\"abstract\" href=\"mobipreview.htm?35/27/36282/abstract/44\">",
"     44",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Based upon the results from COPERNICUS, the FDA has approved the use of",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?9/22/9577?source=see_link\">",
"     carvedilol",
"    </a>",
"    in patients with severe HF.",
"   </p>",
"   <p>",
"    These benefits were confirmed in a pooled analysis of 3836 patients with NYHA functional class",
"    <span class=\"nowrap\">",
"     III/IV",
"    </span>",
"    HF and an LVEF &le;25 percent enrolled in COPERNICUS, MERIT-HF, and CIBIS II [",
"    <a class=\"abstract\" href=\"mobipreview.htm?35/27/36282/abstract/45\">",
"     45",
"    </a>",
"    ]. Beta blockade was associated with a significant reduction in total mortality (13 versus 18 percent with placebo, relative risk 0.72) and a 45 percent reduction in the number of hospitalizations. However, initial worsening of symptoms may be more common in patients with severe disease [",
"    <a class=\"abstract\" href=\"mobipreview.htm?35/27/36282/abstract/89\">",
"     89",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?12/38/12905?source=see_link&amp;anchor=H20#H20\">",
"     \"Use of beta blockers in heart failure due to systolic dysfunction\", section on 'Worsening of HF symptoms'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H31\">",
"    <span class=\"h3\">",
"     Combination with PD inhibitor",
"    </span>",
"    &nbsp;&mdash;&nbsp;A potential approach to the therapy of severe HF, particularly in patients who cannot tolerate a beta blocker alone, is combination therapy with a phosphodiesterase (PD) inhibitor (a positive inotrope). It has been proposed that the beta blocker would prevent the deleterious effects on survival associated with long-term treatment with a PD inhibitor, while the PD inhibitor would permit the successful initiation and upward titration of beta blockade [",
"    <a class=\"abstract\" href=\"mobipreview.htm?35/27/36282/abstract/90\">",
"     90",
"    </a>",
"    ]. This hypothesis was not supported by the ESSENTIAL and EMPOWER studies which have been presented, but not published. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?7/37/7769?source=see_link\">",
"     \"Inotropic agents in heart failure due to systolic dysfunction\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H32\">",
"    <span class=\"h3\">",
"     Combination with dobutamine",
"    </span>",
"    &nbsp;&mdash;&nbsp;Patients with advanced HF who decompensate may be treated with",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?24/57/25494?source=see_link\">",
"     dobutamine",
"    </a>",
"    . In this setting, it may matter which beta blocker has been used. In a randomized, short-term study, pretreatment with",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?9/22/9577?source=see_link\">",
"     carvedilol",
"    </a>",
"    markedly reduced the inotropic response to dobutamine, whereas",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?38/31/39417?source=see_link\">",
"     metoprolol",
"    </a>",
"    had only a slight inhibitory effect [",
"    <a class=\"abstract\" href=\"mobipreview.htm?35/27/36282/abstract/91\">",
"     91",
"    </a>",
"    ]. Metoprolol is a relatively selective beta-1-receptor blocker that results in beta-1 receptor upregulation and does not inhibit the dobutamine effect on the beta-2 receptors. In contrast, carvedilol does not cause upregulation of the beta-1 receptors and blocks the beta-2 receptors, inhibiting both inotropic mechanisms of dobutamine. In contrast, the hemodynamic responses to enoximone were maintained or enhanced by both drugs. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?7/37/7769?source=see_link\">",
"     \"Inotropic agents in heart failure due to systolic dysfunction\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H33\">",
"    <span class=\"h2\">",
"     Use in women",
"    </span>",
"    &nbsp;&mdash;&nbsp;Women have been underrepresented in the beta blocker trials, but appear to benefit to the same degree as men. A post hoc analysis of 898 women enrolled in the MERIT-HF trial found that the beneficial effects of",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?38/31/39417?source=see_link\">",
"     metoprolol",
"    </a>",
"    extended to women [",
"    <a class=\"abstract\" href=\"mobipreview.htm?35/27/36282/abstract/92\">",
"     92",
"    </a>",
"    ]. Treatment with metoprolol reduced all-cause mortality or hospitalizations by 21 percent, cardiovascular hospitalizations by 29 percent, and hospitalizations for worsening of HF by 42 percent.",
"   </p>",
"   <p>",
"    A pooled analysis from MERIT-HF, COPERNICUS, CIBIS II, and the United States",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?9/22/9577?source=see_link\">",
"     Carvedilol",
"    </a>",
"    Heart Failure trials found that the mortality benefit from beta blocker therapy was the same in men and women (relative risk 0.66 and 0.63, respectively) [",
"    <a class=\"abstract\" href=\"mobipreview.htm?35/27/36282/abstract/93\">",
"     93",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H34\">",
"    <span class=\"h2\">",
"     Use in blacks",
"    </span>",
"    &nbsp;&mdash;&nbsp;There are conflicting data on the efficacy of beta blockers in black patients. In the",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?9/22/9577?source=see_link\">",
"     carvedilol",
"    </a>",
"    trials, the benefit of beta blockade was of similar magnitude in blacks and nonblack patients [",
"    <a class=\"abstract\" href=\"mobipreview.htm?35/27/36282/abstract/94\">",
"     94",
"    </a>",
"    ]. In comparison, it appeared that blacks derived no benefit with bucindolol in the BEST trial [",
"    <a class=\"abstract\" href=\"mobipreview.htm?35/27/36282/abstract/60\">",
"     60",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    A meta-analysis of beta blocker trials in HF confirmed this distinction, finding different results depending upon whether or not the BEST data were included [",
"    <a class=\"abstract\" href=\"mobipreview.htm?35/27/36282/abstract/93\">",
"     93",
"    </a>",
"    ]. In COPERNICUS, MERIT-HF, and United States",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?9/22/9577?source=see_link\">",
"     Carvedilol",
"    </a>",
"    Heart Failure trials, the reduction in all-cause mortality with beta blockers was the same for blacks and whites (relative risk 0.67 and 0.63 respectively). With inclusion of the data from BEST, the benefit of beta blockers remained significant for whites but was no longer significant in blacks (relative risk 0.69 and 0.97, respectively).",
"   </p>",
"   <p>",
"    These observations suggest that bucindolol, a beta blocker with inverse agonism and partial beta agonist activity [",
"    <a class=\"abstract\" href=\"mobipreview.htm?35/27/36282/abstract/62\">",
"     62",
"    </a>",
"    ], is not effective in reducing mortality in blacks. The reasons for this difference are not clear, but (as speculated by the authors of BEST) may include race-specific differences in the beta adrenergic pathway, although the difference could be due to chance or socioeconomic differences.",
"   </p>",
"   <p>",
"    A potential genetic explanation for variation in beta blocker therapy response was provided by a report of genetic variants of G protein-coupled receptor kinases (GRKs) [",
"    <a class=\"abstract\" href=\"mobipreview.htm?35/27/36282/abstract/95\">",
"     95",
"    </a>",
"    ]. GRKs desensitize beta adrenergic receptors and may therefore modify the effect of beta blocker therapy. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?21/49/22293?source=see_link&amp;anchor=H9#H9\">",
"     \"Peptide hormone signal transduction and regulation\", section on 'Desensitization'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    A GRK5-Leu41 polymorphism was identified as frequent (about 40 percent) among black subjects and rare (about 2 percent) among white subjects [",
"    <a class=\"abstract\" href=\"mobipreview.htm?35/27/36282/abstract/95\">",
"     95",
"    </a>",
"    ]. GRK5-Leu41 uncoupled isoproterenol-stimulated responses more effectively than GRK5-Gln41 (the most common variant) in transfected cells and transgenic mice and protected against experimental catecholamine-induced cardiomyopathy.",
"   </p>",
"   <p>",
"    Human association studies showed that the presence of GRK5-Leu41 polymorphism was associated with a lower rate of mortality or cardiac transplantation in 375 black patients with HF or cardiac ischemia. These findings suggest that GRK5-Leu41 may produce a beneficial \"genetic beta blockade\" and may explain the conflicting results of beta blocker trials in blacks [",
"    <a class=\"abstract\" href=\"mobipreview.htm?35/27/36282/abstract/95\">",
"     95",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H35\">",
"    <span class=\"h2\">",
"     Use in diabetes",
"    </span>",
"    &nbsp;&mdash;&nbsp;The above meta-analysis of beta blocker trials in HF included 1883 diabetics and 7042 nondiabetics [",
"    <a class=\"abstract\" href=\"mobipreview.htm?35/27/36282/abstract/93\">",
"     93",
"    </a>",
"    ]. The survival benefit with beta blocker therapy was significant for both those with diabetes and for those without (relative risk 0.77 and 0.65, respectively) [",
"    <a class=\"abstract\" href=\"mobipreview.htm?35/27/36282/abstract/93\">",
"     93",
"    </a>",
"    ]. The difference in risk reduction between diabetics and nondiabetics was not significant. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?27/57/28569?source=see_link&amp;anchor=H13#H13\">",
"     \"Heart failure in diabetes mellitus\", section on 'Therapy'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H36\">",
"    <span class=\"h2\">",
"     Use in patients with COPD",
"    </span>",
"    &nbsp;&mdash;&nbsp;Beta-1 selective beta blockers (eg,",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?29/46/30440?source=see_link\">",
"     atenolol",
"    </a>",
"    or",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?38/31/39417?source=see_link\">",
"     metoprolol",
"    </a>",
"    ) appear to be safe in patients with COPD, even when there is a bronchospastic component. In a meta-analysis of major trials, no changes in FEV1, respiratory symptoms, or the use of inhaled beta agonists were seen [",
"    <a class=\"abstract\" href=\"mobipreview.htm?35/27/36282/abstract/96,97\">",
"     96,97",
"    </a>",
"    ]. More limited data suggest that combined alpha and beta blockade (eg,",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?9/22/9577?source=see_link\">",
"     carvedilol",
"    </a>",
"    ) may be safe in the setting of COPD as well, but less well tolerated in patients with asthma [",
"    <a class=\"abstract\" href=\"mobipreview.htm?35/27/36282/abstract/98\">",
"     98",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H37\">",
"    <span class=\"h2\">",
"     Use in elderly adults",
"    </span>",
"    &nbsp;&mdash;&nbsp;All of the major randomized trials included many elderly patients who appeared to derive similar benefit as younger patients. In MERIT-HF, for example, the one-third of patients &ge;70 years of age had the same benefit from",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?38/31/39417?source=see_link\">",
"     metoprolol",
"    </a>",
"    as younger patients [",
"    <a class=\"abstract\" href=\"mobipreview.htm?35/27/36282/abstract/48\">",
"     48",
"    </a>",
"    ]. The risk reduction was also similar in patients above age 75 [",
"    <a class=\"abstract\" href=\"mobipreview.htm?35/27/36282/abstract/99\">",
"     99",
"    </a>",
"    ]. Similar findings were noted in the",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?9/22/9577?source=see_link\">",
"     carvedilol",
"    </a>",
"    trials; the mean age was 58 and the benefit of carvedilol was the same in patients &ge;59 years of age as in younger patients [",
"    <a class=\"abstract\" href=\"mobipreview.htm?35/27/36282/abstract/50\">",
"     50",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    The benefit of beta blockers in elderly adults was directly demonstrated in the SENIORS trial of 2128 patients &ge;70 years of age (mean 76 years) [",
"    <a class=\"abstract\" href=\"mobipreview.htm?35/27/36282/abstract/100\">",
"     100",
"    </a>",
"    ]. Inclusion in this trial was based on a history of HF (hospital admission for HF within the previous year or known LVEF &le;35 percent). About 35 percent of patients had an LVEF &gt;35 percent. The patients were randomly assigned to",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?31/34/32295?source=see_link\">",
"     nebivolol",
"    </a>",
"    , or placebo. Nebivolol is a beta 1 blocker, a beta 3 agonist (which attenuates contraction [",
"    <a class=\"abstract\" href=\"mobipreview.htm?35/27/36282/abstract/101\">",
"     101",
"    </a>",
"    ]) and a vasodilator. An ACE inhibitor was used in 82 percent, a diuretic in 86 percent,",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?28/27/29113?source=see_link\">",
"     digoxin",
"    </a>",
"    in 40 percent, and",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?24/7/24698?source=see_link\">",
"     aspirin",
"    </a>",
"    in 42 percent. At a mean follow-up of 21 months, nebivolol therapy was associated with a significant reduction in the primary end point of all-cause mortality or cardiovascular hospital admission (31.1 versus 35.3 percent, hazard ratio 0.86, 95% CI 0.74-0.99) and a trend toward lower all-cause mortality (15.8 versus 18.1 percent, hazard ratio 0.88, 95% CI 0.71-1.08). The effect of nebivolol was similar in those with preserved and impaired LVEF [",
"    <a class=\"abstract\" href=\"mobipreview.htm?35/27/36282/abstract/102\">",
"     102",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    These benefits are smaller than those noted in other trials. Possible explanations include the drug used, a higher rate of discontinuation during the study (35 percent compared to 14 percent overall and 20 percent in patients &ge;65 years of age in MERIT-HF [",
"    <a class=\"abstract\" href=\"mobipreview.htm?35/27/36282/abstract/48,99\">",
"     48,99",
"    </a>",
"    ]), the age of the patients, and the inclusion of patients with asymptomatic left ventricular dysfunction [",
"    <a class=\"abstract\" href=\"mobipreview.htm?35/27/36282/abstract/103\">",
"     103",
"    </a>",
"    ]. While the outcome benefits were similar in patients with an LVEF above or below 35 percent, reverse remodeling only occurred in the patients with an LVEF &le;35 percent. There was no evidence of improvement in diastolic function in those with an LVEF &gt;35 percent [",
"    <a class=\"abstract\" href=\"mobipreview.htm?35/27/36282/abstract/104\">",
"     104",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    It is possible that some elderly patients with comorbidities would have been excluded from these trials, potentially altering the clinical applicability of the findings. This issue was addressed in a cohort study of almost 12,000 elderly patients (mean age 79); during follow-up, 3539 were hospitalized for HF and 1162 received a beta blocker [",
"    <a class=\"abstract\" href=\"mobipreview.htm?35/27/36282/abstract/105\">",
"     105",
"    </a>",
"    ]. Beta blocker therapy was associated with substantial reductions in all-cause and HF mortality (adjusted hazard ratio 0.72 and 0.65); this benefit was seen in all subgroups, even those with a comorbidity score &ge;2. Although lower doses were associated with improved outcomes, the benefit was greater if the dose was titrated up to that used in the clinical trials.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H38\">",
"    <span class=\"h1\">",
"     USE OUTSIDE OF CLINICAL TRIALS",
"    </span>",
"    &nbsp;&mdash;&nbsp;The subjects enrolled in randomized trials represent a highly selected patient subset who tend to be healthier, younger, more compliant and more closely followed than those in clinical practice. The use of beta blockers in a nontrial setting was examined in a cohort of 1041 patients followed in a tertiary care HF clinic (median age 69 years; mean ejection fraction 33 percent; 51 percent with class III or IV HF) (",
"    <a class=\"graphic graphic_table graphicRef52683 \" href=\"mobipreview.htm?3/2/3117\">",
"     table 1",
"    </a>",
"    )&nbsp;[",
"    <a class=\"abstract\" href=\"mobipreview.htm?35/27/36282/abstract/106\">",
"     106",
"    </a>",
"    ]. The following observations were made:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      A total of 475 patients (46 percent of the study group) were prescribed beta blockers. The use of beta blockers was significantly associated with class I or II symptoms and with age younger than 69 years.",
"     </li>",
"     <li>",
"      The doses used in clinical trials were achieved in only 18 percent of the study group. The mean doses achieved were 27",
"      <span class=\"nowrap\">",
"       mg/day",
"      </span>",
"      for",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?9/22/9577?source=see_link\">",
"       carvedilol",
"      </a>",
"      and 81",
"      <span class=\"nowrap\">",
"       mg/day",
"      </span>",
"      for",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?38/31/39417?source=see_link\">",
"       metoprolol",
"      </a>",
"      tartrate.",
"     </li>",
"     <li>",
"      During 32 months of follow-up, beta blocker use was associated with significantly reduced mortality after adjusting for age, sex, ejection fraction, NYHA class, and concomitant medication use (hazard ratio 0.63).",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Observational data has also been analyzed to compare outcomes among various types of beta blockers. (See",
"    <a class=\"local\" href=\"#H18\">",
"     'Comparison with other beta blockers'",
"    </a>",
"    above.)",
"   </p>",
"   <p>",
"    Adherence to beta blocker use is discussed in detail separately. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?10/44/10953?source=see_link\">",
"     \"Guideline adherence and outcomes in coronary heart disease and heart failure\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"PATIENT_INFORMATION\">",
"    <span class=\"h1\">",
"     INFORMATION FOR PATIENTS",
"    </span>",
"    &nbsp;&mdash;&nbsp;UpToDate offers two types of patient education materials, &ldquo;The Basics&rdquo; and &ldquo;Beyond the Basics.&rdquo; The Basics patient education pieces are written in plain language, at the 5",
"    <sup>",
"     th",
"    </sup>",
"    to 6",
"    <sup>",
"     th",
"    </sup>",
"    grade reading level, and they answer the four or five key questions a patient might have about a given condition. These articles are best for patients who want a general overview and who prefer short, easy-to-read materials. Beyond the Basics patient education pieces are longer, more sophisticated, and more detailed. These articles are written at the 10",
"    <sup>",
"     th",
"    </sup>",
"    to 12",
"    <sup>",
"     th",
"    </sup>",
"    grade reading level and are best for patients who want in-depth information and are comfortable with some medical jargon.",
"   </p>",
"   <p>",
"    Here are the patient education articles that are relevant to this topic. We encourage you to print or e-mail these topics to your patients. (You can also locate patient education articles on a variety of subjects by searching on &ldquo;patient info&rdquo; and the keyword(s) of interest.)",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Beyond the Basics topic (see",
"      <a class=\"medical medical_patient\" href=\"mobipreview.htm?33/5/33877?source=see_link\">",
"       \"Patient information: Heart failure (Beyond the Basics)\"",
"      </a>",
"      )",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H40\">",
"    <span class=\"h1\">",
"     SUMMARY AND RECOMMENDATIONS",
"    </span>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Use of beta blockers in patients with HF due to systolic dysfunction, particularly",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?9/22/9577?source=see_link\">",
"       carvedilol",
"      </a>",
"      , extended release",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?38/31/39417?source=see_link\">",
"       metoprolol",
"      </a>",
"      succinate, and",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?2/29/2520?source=see_link\">",
"       bisoprolol",
"      </a>",
"      , improves indices of LV function, delays progression of myocardial dysfunction, and improves survival.",
"     </li>",
"     <li>",
"      Treatment with extended-release",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?38/31/39417?source=see_link\">",
"       metoprolol",
"      </a>",
"      succinate or",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?9/22/9577?source=see_link\">",
"       carvedilol",
"      </a>",
"      in patients with HF due to systolic dysfunction also improves HF symptoms.",
"     </li>",
"     <li>",
"      Beta blocker therapy improves exercise duration, stabilizes LV function, and improves mortality to a similar degree in patients with ischemic and nonischemic cardiomyopathies.",
"     </li>",
"     <li>",
"      Available evidence also supports beta blocker use for treatment of HF due to systolic dysfunction in subgroups including patients with ischemic and nonischemic cardiomyopathies, stable class IV HF, women, blacks, patients with diabetes, and elderly adults.",
"     </li>",
"     <li>",
"      Beta blockers should be initiated at the doses started in the controlled trials, and the doses should be titrated up to the target doses of these studies as tolerated.",
"     </li>",
"     <li>",
"      Although retrospective data suggest a possible beneficial effect in HF of some beta blockers without proven benefit in randomized controlled trials (eg,",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?29/46/30440?source=see_link\">",
"       atenolol",
"      </a>",
"      ), these studies do not provide a sufficient basis for recommendation of their use for HF treatment.",
"     </li>",
"     <li>",
"      Beta blocker therapy provides incremental benefit in patients with HF treated with an ACEI inhibitor or an ARB or an aldosterone antagonist. (See",
"      <a class=\"local\" href=\"#H19\">",
"       'Use with other HF drugs'",
"      </a>",
"      above.)",
"     </li>",
"    </ul>",
"   </p>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div class=\"headingAnchor\" id=\"references\">",
"   <h1>",
"    REFERENCES",
"   </h1>",
"   <ol id=\"reference\">",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/27/36282/abstract/1\">",
"      Packer M. The neurohormonal hypothesis: a theory to explain the mechanism of disease progression in heart failure. J Am Coll Cardiol 1992; 20:248.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/27/36282/abstract/2\">",
"      Cohn JN, Levine TB, Olivari MT, et al. Plasma norepinephrine as a guide to prognosis in patients with chronic congestive heart failure. N Engl J Med 1984; 311:819.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/27/36282/abstract/3\">",
"      Brophy JM, Joseph L, Rouleau JL. Beta-blockers in congestive heart failure. A Bayesian meta-analysis. Ann Intern Med 2001; 134:550.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/27/36282/abstract/4\">",
"      Foody JM, Farrell MH, Krumholz HM. beta-Blocker therapy in heart failure: scientific review. JAMA 2002; 287:883.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/27/36282/abstract/5\">",
"      Sackner-Bernstein JD, Mancini DM. Rationale for treatment of patients with chronic heart failure with adrenergic blockade. JAMA 1995; 274:1462.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/27/36282/abstract/6\">",
"      Bristow MR. beta-adrenergic receptor blockade in chronic heart failure. Circulation 2000; 101:558.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/27/36282/abstract/7\">",
"      Colucci WS. Molecular and cellular mechanisms of myocardial failure. Am J Cardiol 1997; 80:15L.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/27/36282/abstract/8\">",
"      Haunstetter A, Izumo S. Apoptosis: basic mechanisms and implications for cardiovascular disease. Circ Res 1998; 82:1111.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/27/36282/abstract/9\">",
"      Hunter JJ, Chien KR. Signaling pathways for cardiac hypertrophy and failure. N Engl J Med 1999; 341:1276.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/27/36282/abstract/10\">",
"      Small KM, Wagoner LE, Levin AM, et al. Synergistic polymorphisms of beta1- and alpha2C-adrenergic receptors and the risk of congestive heart failure. N Engl J Med 2002; 347:1135.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/27/36282/abstract/11\">",
"      Gilbert EM, Abraham WT, Olsen S, et al. Comparative hemodynamic, left ventricular functional, and antiadrenergic effects of chronic treatment with metoprolol versus carvedilol in the failing heart. Circulation 1996; 94:2817.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/27/36282/abstract/12\">",
"      Bristow MR, Minobe WA, Raynolds MV, et al. Reduced beta 1 receptor messenger RNA abundance in the failing human heart. J Clin Invest 1993; 92:2737.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/27/36282/abstract/13\">",
"      Bristow MR, Ginsburg R, Minobe W, et al. Decreased catecholamine sensitivity and beta-adrenergic-receptor density in failing human hearts. N Engl J Med 1982; 307:205.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/27/36282/abstract/14\">",
"      Gilbert EM, Anderson JL, Deitchman D, et al. Long-term beta-blocker vasodilator therapy improves cardiac function in idiopathic dilated cardiomyopathy: a double-blind, randomized study of bucindolol versus placebo. Am J Med 1990; 88:223.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/27/36282/abstract/15\">",
"      Yoshikawa T, Handa S, Anzai T, et al. Early reduction of neurohumoral factors plays a key role in mediating the efficacy of beta-blocker therapy for congestive heart failure. Am Heart J 1996; 131:329.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/27/36282/abstract/16\">",
"      Eichhorn EJ, McGhie AL, Bedotto JB, et al. Effects of bucindolol on neurohormonal activation in congestive heart failure. Am J Cardiol 1991; 67:67.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/27/36282/abstract/17\">",
"      Effects of metoprolol CR in patients with ischemic and dilated cardiomyopathy : the randomized evaluation of strategies for left ventricular dysfunction pilot study. Circulation 2000; 101:378.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/27/36282/abstract/18\">",
"      Krum H, Gu A, Wilshire-Clement M, et al. Changes in plasma endothelin-1 levels reflect clinical response to beta-blockade in chronic heart failure. Am Heart J 1996; 131:337.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/27/36282/abstract/19\">",
"      Murray DR, Prabhu SD, Chandrasekar B. Chronic beta-adrenergic stimulation induces myocardial proinflammatory cytokine expression. Circulation 2000; 101:2338.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/27/36282/abstract/20\">",
"      Ohtsuka T, Hamada M, Hiasa G, et al. Effect of beta-blockers on circulating levels of inflammatory and anti-inflammatory cytokines in patients with dilated cardiomyopathy. J Am Coll Cardiol 2001; 37:412.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/27/36282/abstract/21\">",
"      Prabhu SD, Chandrasekar B, Murray DR, Freeman GL. beta-adrenergic blockade in developing heart failure: effects on myocardial inflammatory cytokines, nitric oxide, and remodeling. Circulation 2000; 101:2103.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/27/36282/abstract/22\">",
"      Doughty RN, Whalley GA, Gamble G, et al. Left ventricular remodeling with carvedilol in patients with congestive heart failure due to ischemic heart disease. Australia-New Zealand Heart Failure Research Collaborative Group. J Am Coll Cardiol 1997; 29:1060.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/27/36282/abstract/23\">",
"      Groenning BA, Nilsson JC, Sondergaard L, et al. Antiremodeling effects on the left ventricle during beta-blockade with metoprolol in the treatment of chronic heart failure. J Am Coll Cardiol 2000; 36:2072.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/27/36282/abstract/24\">",
"      Bellenger NG, Rajappan K, Rahman SL, et al. Effects of carvedilol on left ventricular remodelling in chronic stable heart failure: a cardiovascular magnetic resonance study. Heart 2004; 90:760.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/27/36282/abstract/25\">",
"      Lowes BD, Gill EA, Abraham WT, et al. Effects of carvedilol on left ventricular mass, chamber geometry, and mitral regurgitation in chronic heart failure. Am J Cardiol 1999; 83:1201.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/27/36282/abstract/26\">",
"      Capomolla S, Febo O, Gnemmi M, et al. Beta-blockade therapy in chronic heart failure: diastolic function and mitral regurgitation improvement by carvedilol. Am Heart J 2000; 139:596.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/27/36282/abstract/27\">",
"      Cleland JG, Pennell DJ, Ray SG, et al. Myocardial viability as a determinant of the ejection fraction response to carvedilol in patients with heart failure (CHRISTMAS trial): randomised controlled trial. Lancet 2003; 362:14.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/27/36282/abstract/28\">",
"      Lowes BD, Gilbert EM, Abraham WT, et al. Myocardial gene expression in dilated cardiomyopathy treated with beta-blocking agents. N Engl J Med 2002; 346:1357.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/27/36282/abstract/29\">",
"      Epstein SE, Braunwald E. The effect of beta adrenergic blockade on patterns of urinary sodium excretion. Studies in normal subjects and in patients with heart disease. Ann Intern Med 1966; 65:20.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/27/36282/abstract/30\">",
"      Weil JV, Chidsey CA. Plasma volume expansion resulting from interference with adrenergic function in normal man. Circulation 1968; 37:54.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/27/36282/abstract/31\">",
"      GAFFNEY TE, BRAUNWALD E. Importance of the adrenergic nervous system in the support of circulatory function in patients with congestive heart failure. Am J Med 1963; 34:320.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/27/36282/abstract/32\">",
"      Waagstein F, Hjalmarson A, Varnauskas E, Wallentin I. Effect of chronic beta-adrenergic receptor blockade in congestive cardiomyopathy. Br Heart J 1975; 37:1022.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/27/36282/abstract/33\">",
"      Eichhorn EJ, Bedotto JB, Malloy CR, et al. Effect of beta-adrenergic blockade on myocardial function and energetics in congestive heart failure. Improvements in hemodynamic, contractile, and diastolic performance with bucindolol. Circulation 1990; 82:473.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/27/36282/abstract/34\">",
"      A randomized trial of beta-blockade in heart failure. The Cardiac Insufficiency Bisoprolol Study (CIBIS). CIBIS Investigators and Committees. Circulation 1994; 90:1765.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/27/36282/abstract/35\">",
"      Packer M, Colucci WS, Sackner-Bernstein JD, et al. Double-blind, placebo-controlled study of the effects of carvedilol in patients with moderate to severe heart failure. The PRECISE Trial. Prospective Randomized Evaluation of Carvedilol on Symptoms and Exercise. Circulation 1996; 94:2793.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/27/36282/abstract/36\">",
"      Colucci WS, Packer M, Bristow MR, et al. Carvedilol inhibits clinical progression in patients with mild symptoms of heart failure. US Carvedilol Heart Failure Study Group. Circulation 1996; 94:2800.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/27/36282/abstract/37\">",
"      Randomised, placebo-controlled trial of carvedilol in patients with congestive heart failure due to ischaemic heart disease. Australia/New Zealand Heart Failure Research Collaborative Group. Lancet 1997; 349:375.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/27/36282/abstract/38\">",
"      Bristow MR, Gilbert EM, Abraham WT, et al. Carvedilol produces dose-related improvements in left ventricular function and survival in subjects with chronic heart failure. MOCHA Investigators. Circulation 1996; 94:2807.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/27/36282/abstract/39\">",
"      Bello D, Shah DJ, Farah GM, et al. Gadolinium cardiovascular magnetic resonance predicts reversible myocardial dysfunction and remodeling in patients with heart failure undergoing beta-blocker therapy. Circulation 2003; 108:1945.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/27/36282/abstract/40\">",
"      Eichhorn EJ, Grayburn PA, Mayer SA, et al. Myocardial contractile reserve by dobutamine stress echocardiography predicts improvement in ejection fraction with beta-blockade in patients with heart failure: the Beta-Blocker Evaluation of Survival Trial (BEST). Circulation 2003; 108:2336.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/27/36282/abstract/41\">",
"      Andersson B, Hamm C, Persson S, et al. Improved exercise hemodynamic status in dilated cardiomyopathy after beta-adrenergic blockade treatment. J Am Coll Cardiol 1994; 23:1397.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/27/36282/abstract/42\">",
"      Bristow MR, O'Connell JB, Gilbert EM, et al. Dose-response of chronic beta-blocker treatment in heart failure from either idiopathic dilated or ischemic cardiomyopathy. Bucindolol Investigators. Circulation 1994; 89:1632.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/27/36282/abstract/43\">",
"      Demopoulos L, Yeh M, Gentilucci M, et al. Nonselective beta-adrenergic blockade with carvedilol does not hinder the benefits of exercise training in patients with congestive heart failure. Circulation 1997; 95:1764.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/27/36282/abstract/44\">",
"      Packer M, Fowler MB, Roecker EB, et al. Effect of carvedilol on the morbidity of patients with severe chronic heart failure: results of the carvedilol prospective randomized cumulative survival (COPERNICUS) study. Circulation 2002; 106:2194.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/27/36282/abstract/45\">",
"      Goldstein S, Fagerberg B, Kjekshus J, et al. Metoprolol controlled release/extended release in patients with severe heart failure: analysis of the experience in the MERIT-HF study. J Am Coll Cardiol 2001; 38:932.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/27/36282/abstract/46\">",
"      Krum H, Sackner-Bernstein JD, Goldsmith RL, et al. Double-blind, placebo-controlled study of the long-term efficacy of carvedilol in patients with severe chronic heart failure. Circulation 1995; 92:1499.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/27/36282/abstract/47\">",
"      Waagstein F, Bristow MR, Swedberg K, et al. Beneficial effects of metoprolol in idiopathic dilated cardiomyopathy. Metoprolol in Dilated Cardiomyopathy (MDC) Trial Study Group. Lancet 1993; 342:1441.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/27/36282/abstract/48\">",
"      Effect of metoprolol CR/XL in chronic heart failure: Metoprolol CR/XL Randomised Intervention Trial in Congestive Heart Failure (MERIT-HF). Lancet 1999; 353:2001.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/27/36282/abstract/49\">",
"      Hjalmarson A, Goldstein S, Fagerberg B, et al. Effects of controlled-release metoprolol on total mortality, hospitalizations, and well-being in patients with heart failure: the Metoprolol CR/XL Randomized Intervention Trial in congestive heart failure (MERIT-HF). MERIT-HF Study Group. JAMA 2000; 283:1295.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/27/36282/abstract/50\">",
"      Packer M, Bristow MR, Cohn JN, et al. The effect of carvedilol on morbidity and mortality in patients with chronic heart failure. U.S. Carvedilol Heart Failure Study Group. N Engl J Med 1996; 334:1349.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/27/36282/abstract/51\">",
"      Fowler MB, Vera-Llonch M, Oster G, et al. Influence of carvedilol on hospitalizations in heart failure: incidence, resource utilization and costs. U.S. Carvedilol Heart Failure Study Group. J Am Coll Cardiol 2001; 37:1692.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/27/36282/abstract/52\">",
"      Pfeffer MA, Stevenson LW. Beta-adrenergic blockers and survival in heart failure. N Engl J Med 1996; 334:1396.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/27/36282/abstract/53\">",
"      Packer M, Coats AJ, Fowler MB, et al. Effect of carvedilol on survival in severe chronic heart failure. N Engl J Med 2001; 344:1651.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/27/36282/abstract/54\">",
"      Cice G, Ferrara L, Di Benedetto A, et al. Dilated cardiomyopathy in dialysis patients--beneficial effects of carvedilol: a double-blind, placebo-controlled trial. J Am Coll Cardiol 2001; 37:407.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/27/36282/abstract/55\">",
"      Lechat P, Escolano S, Golmard JL, et al. Prognostic value of bisoprolol-induced hemodynamic effects in heart failure during the Cardiac Insufficiency BIsoprolol Study (CIBIS). Circulation 1997; 96:2197.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/27/36282/abstract/56\">",
"      The Cardiac Insufficiency Bisoprolol Study II (CIBIS-II): a randomised trial. Lancet 1999; 353:9.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/27/36282/abstract/57\">",
"      Leizorovicz A, Lechat P, Cucherat M, Bugnard F. Bisoprolol for the treatment of chronic heart failure: a meta-analysis on individual data of two placebo-controlled studies--CIBIS and CIBIS II. Cardiac Insufficiency Bisoprolol Study. Am Heart J 2002; 143:301.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/27/36282/abstract/58\">",
"      Reduced costs with bisoprolol treatment for heart failure: an economic analysis of the second Cardiac Insufficiency Bisoprolol Study (CIBIS-II). Eur Heart J 2001; 22:1021.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/27/36282/abstract/59\">",
"      Lechat P, Hulot JS, Escolano S, et al. Heart rate and cardiac rhythm relationships with bisoprolol benefit in chronic heart failure in CIBIS II Trial. Circulation 2001; 103:1428.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/27/36282/abstract/60\">",
"      Beta-Blocker Evaluation of Survival Trial Investigators. A trial of the beta-blocker bucindolol in patients with advanced chronic heart failure. N Engl J Med 2001; 344:1659.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/27/36282/abstract/61\">",
"      Maack C, Cremers B, Flesch M, et al. Different intrinsic activities of bucindolol, carvedilol and metoprolol in human failing myocardium. Br J Pharmacol 2000; 130:1131.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/27/36282/abstract/62\">",
"      Andreka P, Aiyar N, Olson LC, et al. Bucindolol displays intrinsic sympathomimetic activity in human myocardium. Circulation 2002; 105:2429.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/27/36282/abstract/63\">",
"      Bristow MR. What type of beta-blocker should be used to treat chronic heart failure? Circulation 2000; 102:484.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/27/36282/abstract/64\">",
"      Kubo T, Azevedo ER, Newton GE, et al. Lack of evidence for peripheral alpha(1)- adrenoceptor blockade during long-term treatment of heart failure with carvedilol. J Am Coll Cardiol 2001; 38:1463.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/27/36282/abstract/65\">",
"      Hryniewicz K, Androne AS, Hudaihed A, Katz SD. Comparative effects of carvedilol and metoprolol on regional vascular responses to adrenergic stimuli in normal subjects and patients with chronic heart failure. Circulation 2003; 108:971.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/27/36282/abstract/66\">",
"      Poole-Wilson PA, Swedberg K, Cleland JG, et al. Comparison of carvedilol and metoprolol on clinical outcomes in patients with chronic heart failure in the Carvedilol Or Metoprolol European Trial (COMET): randomised controlled trial. Lancet 2003; 362:7.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/27/36282/abstract/67\">",
"      Remme WJ, Torp-Pedersen C, Cleland JG, et al. Carvedilol protects better against vascular events than metoprolol in heart failure: results from COMET. J Am Coll Cardiol 2007; 49:963.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/27/36282/abstract/68\">",
"      Dargie HJ. Beta blockers in heart failure. Lancet 2003; 362:2.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/27/36282/abstract/69\">",
"      Packer M, Antonopoulos GV, Berlin JA, et al. Comparative effects of carvedilol and metoprolol on left ventricular ejection fraction in heart failure: results of a meta-analysis. Am Heart J 2001; 141:899.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/27/36282/abstract/70\">",
"      Bonet S, Agust&iacute; A, Arnau JM, et al. Beta-adrenergic blocking agents in heart failure: benefits of vasodilating and non-vasodilating agents according to patients' characteristics: a meta-analysis of clinical trials. Arch Intern Med 2000; 160:621.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/27/36282/abstract/71\">",
"      Go AS, Yang J, Gurwitz JH, et al. Comparative effectiveness of different beta-adrenergic antagonists on mortality among adults with heart failure in clinical practice. Arch Intern Med 2008; 168:2415.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/27/36282/abstract/72\">",
"      Kramer JM, Curtis LH, Dupree CS, et al. Comparative effectiveness of beta-blockers in elderly patients with heart failure. Arch Intern Med 2008; 168:2422.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/27/36282/abstract/73\">",
"      Exner DV, Dries DL, Waclawiw MA, et al. Beta-adrenergic blocking agent use and mortality in patients with asymptomatic and symptomatic left ventricular systolic dysfunction: a post hoc analysis of the Studies of Left Ventricular Dysfunction. J Am Coll Cardiol 1999; 33:916.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/27/36282/abstract/74\">",
"      McNamara DM, Holubkov R, Janosko K, et al. Pharmacogenetic interactions between beta-blocker therapy and the angiotensin-converting enzyme deletion polymorphism in patients with congestive heart failure. Circulation 2001; 103:1644.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/27/36282/abstract/75\">",
"      Granger CB, McMurray JJ, Yusuf S, et al. Effects of candesartan in patients with chronic heart failure and reduced left-ventricular systolic function intolerant to angiotensin-converting-enzyme inhibitors: the CHARM-Alternative trial. Lancet 2003; 362:772.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/27/36282/abstract/76\">",
"      McMurray JJ, Ostergren J, Swedberg K, et al. Effects of candesartan in patients with chronic heart failure and reduced left-ventricular systolic function taking angiotensin-converting-enzyme inhibitors: the CHARM-Added trial. Lancet 2003; 362:767.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/27/36282/abstract/77\">",
"      Cohn JN, Tognoni G, Valsartan Heart Failure Trial Investigators. A randomized trial of the angiotensin-receptor blocker valsartan in chronic heart failure. N Engl J Med 2001; 345:1667.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/27/36282/abstract/78\">",
"      Pitt B, Zannad F, Remme WJ, et al. The effect of spironolactone on morbidity and mortality in patients with severe heart failure. Randomized Aldactone Evaluation Study Investigators. N Engl J Med 1999; 341:709.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/27/36282/abstract/79\">",
"      Pitt B, Remme W, Zannad F, et al. Eplerenone, a selective aldosterone blocker, in patients with left ventricular dysfunction after myocardial infarction. N Engl J Med 2003; 348:1309.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/27/36282/abstract/80\">",
"      Krum H, Mohacsi P, Katus HA, et al. Are beta-blockers needed in patients receiving spironolactone for severe chronic heart failure? An analysis of the COPERNICUS study. Am Heart J 2006; 151:55.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/27/36282/abstract/81\">",
"      Lindenfeld J, Robertson AD, Lowes BD, et al. Aspirin impairs reverse myocardial remodeling in patients with heart failure treated with beta-blockers. J Am Coll Cardiol 2001; 38:1950.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/27/36282/abstract/82\">",
"      Wikstrand J, Hjalmarson A, Waagstein F, et al. Dose of metoprolol CR/XL and clinical outcomes in patients with heart failure: analysis of the experience in metoprolol CR/XL randomized intervention trial in chronic heart failure (MERIT-HF). J Am Coll Cardiol 2002; 40:491.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/27/36282/abstract/83\">",
"      Gullestad L, Wikstrand J, Deedwania P, et al. What resting heart rate should one aim for when treating patients with heart failure with a beta-blocker? Experiences from the Metoprolol Controlled Release/Extended Release Randomized Intervention Trial in Chronic Heart Failure (MERIT-HF). J Am Coll Cardiol 2005; 45:252.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/27/36282/abstract/84\">",
"      Eichhorn EJ. Beta-blocker withdrawal: the song of Orpheus. Am Heart J 1999; 138:387.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/27/36282/abstract/85\">",
"      Krum H, Roecker EB, Mohacsi P, et al. Effects of initiating carvedilol in patients with severe chronic heart failure: results from the COPERNICUS Study. JAMA 2003; 289:712.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/27/36282/abstract/86\">",
"      Morimoto S, Shimizu K, Yamada K, et al. Can beta-blocker therapy be withdrawn from patients with dilated cardiomyopathy? Am Heart J 1999; 138:456.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/27/36282/abstract/87\">",
"      Hunt SA, Abraham WT, Chin MH, et al. 2009 focused update incorporated into the ACC/AHA 2005 Guidelines for the Diagnosis and Management of Heart Failure in Adults: a report of the American College of Cardiology Foundation/American Heart Association Task Force on Practice Guidelines: developed in collaboration with the International Society for Heart and Lung Transplantation. Circulation 2009; 119:e391.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/27/36282/abstract/88\">",
"      Fisher ML, Gottlieb SS, Plotnick GD, et al. Beneficial effects of metoprolol in heart failure associated with coronary artery disease: a randomized trial. J Am Coll Cardiol 1994; 23:943.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/27/36282/abstract/89\">",
"      Macdonald PS, Keogh AM, Aboyoun CL, et al. Tolerability and efficacy of carvedilol in patients with New York Heart Association class IV heart failure. J Am Coll Cardiol 1999; 33:924.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/27/36282/abstract/90\">",
"      Kumar A, Choudhary G, Antonio C, et al. Carvedilol titration in patients with congestive heart failure receiving inotropic therapy. Am Heart J 2001; 142:512.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/27/36282/abstract/91\">",
"      Metra M, Nodari S, D'Aloia A, et al. Beta-blocker therapy influences the hemodynamic response to inotropic agents in patients with heart failure: a randomized comparison of dobutamine and enoximone before and after chronic treatment with metoprolol or carvedilol. J Am Coll Cardiol 2002; 40:1248.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/27/36282/abstract/92\">",
"      Ghali JK, Pi&ntilde;a IL, Gottlieb SS, et al. Metoprolol CR/XL in female patients with heart failure: analysis of the experience in Metoprolol Extended-Release Randomized Intervention Trial in Heart Failure (MERIT-HF). Circulation 2002; 105:1585.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/27/36282/abstract/93\">",
"      Shekelle PG, Rich MW, Morton SC, et al. Efficacy of angiotensin-converting enzyme inhibitors and beta-blockers in the management of left ventricular systolic dysfunction according to race, gender, and diabetic status: a meta-analysis of major clinical trials. J Am Coll Cardiol 2003; 41:1529.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/27/36282/abstract/94\">",
"      Yancy CW, Fowler MB, Colucci WS, et al. Race and the response to adrenergic blockade with carvedilol in patients with chronic heart failure. N Engl J Med 2001; 344:1358.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/27/36282/abstract/95\">",
"      Liggett SB, Cresci S, Kelly RJ, et al. A GRK5 polymorphism that inhibits beta-adrenergic receptor signaling is protective in heart failure. Nat Med 2008; 14:510.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/27/36282/abstract/96\">",
"      Salpeter S, Ormiston T, Salpeter E. Cardioselective beta-blockers for reversible airway disease. Cochrane Database Syst Rev 2002; :CD002992.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/27/36282/abstract/97\">",
"      Salpeter SR, Ormiston TM, Salpeter EE. Cardioselective beta-blockers in patients with reactive airway disease: a meta-analysis. Ann Intern Med 2002; 137:715.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/27/36282/abstract/98\">",
"      Kotlyar E, Keogh AM, Macdonald PS, et al. Tolerability of carvedilol in patients with heart failure and concomitant chronic obstructive pulmonary disease or asthma. J Heart Lung Transplant 2002; 21:1290.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/27/36282/abstract/99\">",
"      Deedwania PC, Gottlieb S, Ghali JK, et al. Efficacy, safety and tolerability of beta-adrenergic blockade with metoprolol CR/XL in elderly patients with heart failure. Eur Heart J 2004; 25:1300.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/27/36282/abstract/100\">",
"      Flather MD, Shibata MC, Coats AJ, et al. Randomized trial to determine the effect of nebivolol on mortality and cardiovascular hospital admission in elderly patients with heart failure (SENIORS). Eur Heart J 2005; 26:215.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/27/36282/abstract/101\">",
"      Rozec B, Erfanian M, Laurent K, et al. Nebivolol, a vasodilating selective beta(1)-blocker, is a beta(3)-adrenoceptor agonist in the nonfailing transplanted human heart. J Am Coll Cardiol 2009; 53:1532.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/27/36282/abstract/102\">",
"      van Veldhuisen DJ, Cohen-Solal A, B&ouml;hm M, et al. Beta-blockade with nebivolol in elderly heart failure patients with impaired and preserved left ventricular ejection fraction: Data From SENIORS (Study of Effects of Nebivolol Intervention on Outcomes and Rehospitalization in Seniors With Heart Failure). J Am Coll Cardiol 2009; 53:2150.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/27/36282/abstract/103\">",
"      McMurray J. Making sense of SENIORS. Eur Heart J 2005; 26:203.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/27/36282/abstract/104\">",
"      Ghio S, Magrini G, Serio A, et al. Effects of nebivolol in elderly heart failure patients with or without systolic left ventricular dysfunction: results of the SENIORS echocardiographic substudy. Eur Heart J 2006; 27:562.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/27/36282/abstract/105\">",
"      Sin DD, McAlister FA. The effects of beta-blockers on morbidity and mortality in a population-based cohort of 11,942 elderly patients with heart failure. Am J Med 2002; 113:650.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/27/36282/abstract/106\">",
"      Tandon P, McAlister FA, Tsuyuki RT, et al. The use of beta-blockers in a tertiary care heart failure clinic: dosing, tolerance, and outcomes. Arch Intern Med 2004; 164:769.",
"     </a>",
"    </li>",
"   </ol>",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 3496 Version 7.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.4 - C21.36",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     Southeast Alabama Med Ctr",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [0504-125.39.66.147-23B01FB2C7-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f35_27_36282=[""].join("\n");
var outline_f35_27_36282=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li>",
"     <a class=\"sr_button\" href=\"#H40\" id=\"summRecButton\">",
"      <span>",
"       SUMMARY &amp; RECOMMENDATIONS",
"      </span>",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H1\">",
"      INTRODUCTION",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H2\">",
"      RATIONALE FOR BETA BLOCKER THERAPY",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H3\">",
"      Possible mechanisms of benefit",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H4\">",
"      EFFECTS OF BETA BLOCKADE IN HF",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H5\">",
"      Ventricular performance",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H6\">",
"      Exercise capacity",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H7\">",
"      Cardiac remodeling",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H8\">",
"      Reduced risk of atrial fibrillation",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H9\">",
"      CLINICAL TRIALS",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H21350370\">",
"      Summary of benefits",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H10\">",
"      Metoprolol trials",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H11\">",
"      - MDC trial",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H12\">",
"      - MERIT-HF trial",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H13\">",
"      Carvedilol trials",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H14\">",
"      Bisoprolol (CIBIS and CIBIS II trials)",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H15\">",
"      Bucindolol (BEST trial)",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H16\">",
"      Comparison of beta blockers",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H17\">",
"      - Comparison between metoprolol and carvedilol",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H18\">",
"      - Comparison with other beta blockers",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H19\">",
"      Use with other HF drugs",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H20\">",
"      - ACE inhibitors",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H21\">",
"      - ARBs",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H22\">",
"      - Aldosterone antagonists",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H23\">",
"      Use with aspirin",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H24\">",
"      DEGREE AND DURATION OF BETA BLOCKADE",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H25\">",
"      Degree of beta blockade",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H26\">",
"      Duration of therapy",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H27\">",
"      SPECIFIC PATIENT SUBSETS",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H28\">",
"      General approach",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H29\">",
"      Use in ischemic and nonischemic cardiomyopathy",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H30\">",
"      Class IV HF",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H31\">",
"      - Combination with PD inhibitor",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H32\">",
"      - Combination with dobutamine",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H33\">",
"      Use in women",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H34\">",
"      Use in blacks",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H35\">",
"      Use in diabetes",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H36\">",
"      Use in patients with COPD",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H37\">",
"      Use in elderly adults",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H38\">",
"      USE OUTSIDE OF CLINICAL TRIALS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#PATIENT_INFORMATION\">",
"      INFORMATION FOR PATIENTS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H40\">",
"      SUMMARY AND RECOMMENDATIONS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a href=\"#references\">",
"      REFERENCES",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   <div class=\"openRelatedGraphics\" id=\"CARD/3496\" rel=\"outline_link\">",
"    GRAPHICS",
"    <a class=\"graphics_icon\" href=\"#\" title=\"View All Related Graphics\">",
"     View All",
"    </a>",
"   </div>",
"  </h1>",
"  <div id=\"relatedGraphics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"CARD/3496|FIG\">",
"      <a href=\"#\" title=\"FIGURES\">",
"       FIGURES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_figure\" href=\"mobipreview.htm?25/13/25821\" title=\"figure 1\">",
"      Carvedilol and LVEF",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_figure\" href=\"mobipreview.htm?40/3/41021\" title=\"figure 2\">",
"      Carvedilol LVEF dose response",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_figure\" href=\"mobipreview.htm?38/42/39597\" title=\"figure 3\">",
"      Mortality metoprolol HF",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_figure\" href=\"mobipreview.htm?40/61/41950\" title=\"figure 4\">",
"      Metoprolol hospitaliz HF",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_figure\" href=\"mobipreview.htm?11/47/12029\" title=\"figure 5\">",
"      Carvedilol in HF I",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_figure\" href=\"mobipreview.htm?25/63/26621\" title=\"figure 6\">",
"      Carvedilol in HF II",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_figure\" href=\"mobipreview.htm?17/1/17437\" title=\"figure 7\">",
"      Bisoprolol in HF CIBIS II",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_figure\" href=\"mobipreview.htm?35/9/35997\" title=\"figure 8\">",
"      Carvedilol death class IV HF",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_figure\" href=\"mobipreview.htm?30/53/31581\" title=\"figure 9\">",
"      Carvedilol HF subgroup analysis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"CARD/3496|TAB\">",
"      <a href=\"#\" title=\"TABLES\">",
"       TABLES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"mobipreview.htm?3/2/3117\" title=\"table 1\">",
"      Methods to assess cardiovascular disability",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?15/45/16090?source=related_link\">",
"      ACE inhibitors in heart failure due to systolic dysfunction: Therapeutic use",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?35/61/36825?source=related_link\">",
"      Actions of angiotensin II on the heart",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?2/39/2680?source=related_link\">",
"      Angiotensin II receptor blockers in heart failure due to systolic dysfunction: Therapeutic use",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?12/24/12682?source=related_link\">",
"      Antiarrhythmic drugs to maintain sinus rhythm in patients with atrial fibrillation: Clinical trials",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?23/30/24042?source=related_link\">",
"      Atrial fibrillation in patients with heart failure",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?10/53/11098?source=related_link\">",
"      Beta blockers in the management of acute coronary syndrome",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?19/25/19865?source=related_link\">",
"      Cardiac remodeling: Basic aspects",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?0/52/842?source=related_link\">",
"      Cardiac remodeling: Clinical assessment and therapy",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?8/35/8759?source=related_link\">",
"      Clinical syndromes of stunned or hibernating myocardium",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?34/3/34874?source=related_link\">",
"      Clinical utility of cardiovascular magnetic resonance imaging",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?41/3/42039?source=related_link\">",
"      Drugs that should be avoided or used with caution in patients with heart failure",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?27/59/28601?source=related_link\">",
"      Evaluation and management of asymptomatic left ventricular systolic dysfunction",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?9/36/9799?source=related_link\">",
"      Functional mitral regurgitation",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?10/44/10953?source=related_link\">",
"      Guideline adherence and outcomes in coronary heart disease and heart failure",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?27/57/28569?source=related_link\">",
"      Heart failure in diabetes mellitus",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?7/37/7769?source=related_link\">",
"      Inotropic agents in heart failure due to systolic dysfunction",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?25/61/26584?source=related_link\">",
"      Myocardial dysfunction in end-stage renal disease",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?12/36/12872?source=related_link\">",
"      Nitric oxide, other hormones, cytokines, and chemokines in heart failure",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?37/63/38906?source=related_link\">",
"      Overview of the therapy of heart failure due to systolic dysfunction",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?31/44/32455?source=related_link\">",
"      Pathophysiology of heart failure: Neurohumoral adaptations",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_patient\" href=\"mobipreview.htm?33/5/33877?source=related_link\">",
"      Patient information: Heart failure (Beyond the Basics)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?21/49/22293?source=related_link\">",
"      Peptide hormone signal transduction and regulation",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?32/48/33546?source=related_link\">",
"      Predictors of survival in heart failure due to systolic dysfunction",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?6/54/7018?source=related_link\">",
"      Treatment and prognosis of diastolic heart failure",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?12/38/12905?source=related_link\">",
"      Use of beta blockers in heart failure due to systolic dysfunction",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f35_27_36283="Allergen groups";
var content_f35_27_36283=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=ALLRG%2F80043&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=5\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=ALLRG%2F80043&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=5\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\">",
"   <div class=\"ttl\">",
"    Important sources of allergens and route of exposure",
"   </div>",
"   <div class=\"cntnt\">",
"    <table cellspacing=\"0\">",
"     <tbody>",
"      <tr>",
"       <td class=\"subtitle1\">",
"        Allergen group",
"       </td>",
"       <td class=\"subtitle1\">",
"        Mode of exposure*",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Grass pollens",
"       </td>",
"       <td>",
"        Inhalation (outdoor)",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Weed pollens",
"       </td>",
"       <td>",
"        Inhalation (outdoor)",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Tree pollens",
"       </td>",
"       <td>",
"        Inhalation (outdoor)",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Mold (hyphea-spores)",
"       </td>",
"       <td>",
"        Inhalation (outdoor and indoor)",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Dust mite fecal material",
"       </td>",
"       <td>",
"        Inhalation (indoor)",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Animal proteins (epidermal and serum)",
"       </td>",
"       <td>",
"        Inhalation (indoor)",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Foods",
"       </td>",
"       <td>",
"        Ingestion",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Insects",
"       </td>",
"       <td>",
"        Inhalation-injection (indoor and outdoor)",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Hymenoptera venoms",
"       </td>",
"       <td>",
"        Injection",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Parasites",
"       </td>",
"       <td>",
"        Ingestion-injection",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Drugs",
"       </td>",
"       <td>",
"        Injection-ingestion",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Occupational",
"       </td>",
"       <td>",
"        Contact-inhalation-ingestion",
"       </td>",
"      </tr>",
"     </tbody>",
"    </table>",
"   </div>",
"   <div class=\"lgnd\">",
"    <div class=\"footnotes\">",
"     * The principal location where the allergen source is encountered is specified in parentheses.",
"    </div>",
"    <div class=\"reference\">",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f35_27_36283=[""].join("\n");
var outline_f35_27_36283=null;
var title_f35_27_36284="Cutaneous SCC high-risk features";
var content_f35_27_36284=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=ONC%2F64366&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=2\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=ONC%2F64366&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=2\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\">",
"   <div class=\"ttl\">",
"    Features of squamous cell carcinoma that correlate with high risk for recurrence and metastasis",
"   </div>",
"   <div class=\"cntnt\">",
"    <table cellspacing=\"0\">",
"     <colgroup span=\"3\" width=\"33%\">",
"     </colgroup>",
"     <tbody>",
"      <tr>",
"       <td class=\"subtitle1\">",
"        &nbsp;",
"       </td>",
"       <td class=\"subtitle1\">",
"        Five-year recurrence rate (percent)",
"       </td>",
"       <td class=\"subtitle1\">",
"        Five-year metastatic rate (percent)",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"subtitle2_left\" colspan=\"3\">",
"        Clinical features",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        Size &ge;2 cm in diameter",
"       </td>",
"       <td class=\"centered\">",
"        15.2",
"       </td>",
"       <td class=\"centered\">",
"        30.3",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"sublist2_start\" colspan=\"3\">",
"        Location",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"sublist2\">",
"        Ear",
"       </td>",
"       <td class=\"sublist_other_centered\">",
"        18.7",
"       </td>",
"       <td class=\"sublist_other_centered\">",
"        11.0",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"sublist2\">",
"        Lip",
"       </td>",
"       <td class=\"sublist_other_centered\">",
"        10.5",
"       </td>",
"       <td class=\"sublist_other_centered\">",
"        13.7",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"sublist2\">",
"        Genitals",
"       </td>",
"       <td class=\"sublist_other_centered\">",
"        &ndash;",
"       </td>",
"       <td class=\"sublist_other_centered\">",
"        20-60",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        Arising within scar, sinus tract, chronic ulcer, or burn",
"       </td>",
"       <td class=\"centered\">",
"        NA",
"       </td>",
"       <td class=\"centered\">",
"        37.9",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        Locally recurrent",
"       </td>",
"       <td class=\"centered\">",
"        23.3",
"       </td>",
"       <td class=\"centered\">",
"        30.3",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        Immunosuppressed patient",
"       </td>",
"       <td class=\"centered\">",
"        NA",
"       </td>",
"       <td class=\"centered\">",
"        12.9",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        Rapid growth",
"       </td>",
"       <td class=\"centered\">",
"        &ndash;",
"       </td>",
"       <td class=\"centered\">",
"        &ndash;",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"subtitle2_left\" colspan=\"3\">",
"        Histologic features",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        Depth &ge;4 mm/Clark's level IV, V",
"       </td>",
"       <td class=\"centered\">",
"        17.2",
"       </td>",
"       <td class=\"centered\">",
"        45.7",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        Poorly differentiated",
"       </td>",
"       <td class=\"centered\">",
"        28.6",
"       </td>",
"       <td class=\"centered\">",
"        32.8",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        Perineural involvement",
"       </td>",
"       <td class=\"centered\">",
"        47.2",
"       </td>",
"       <td class=\"centered\">",
"        47.3",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        Intravascular invasion",
"       </td>",
"       <td class=\"centered\">",
"        &ndash;",
"       </td>",
"       <td class=\"centered\">",
"        87.5",
"       </td>",
"      </tr>",
"     </tbody>",
"    </table>",
"   </div>",
"   <div class=\"lgnd\">",
"    <div class=\"footnotes\">",
"     NA: not applicable.",
"    </div>",
"    <div class=\"reference\">",
"     Data from: Rowe DE, et al, J Am Acad Dermatol 1992; 26:1, Kwa RE, et al, J Am Acad Dermatol 1992; 26:976, Dinehart SM, et al, J Am Acad Dermatol 1989; 21:241, Johnson TM, et al, J Am Acad Dermatol 1992; 26:467, Alam M, et al, N Engl J Med 2001; 344:975, Staubitz WJ, et al, Cancer 1955; 8:371, Dean AL, J Urol 1948; 60:508, Srinivas V, et al, J Urol 1987; 137:880, Binder SW, et al, Gynecol Oncol 1990; 37:9, Ray B, et al, J Urol 1977; 117:741.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f35_27_36284=[""].join("\n");
var outline_f35_27_36284=null;
var title_f35_27_36285="Contents: Personality disorders";
var content_f35_27_36285=[" <script type=\"text/javascript\">",
"  $$.inlineInitCustomer(",
"	false);",
"	var quirksmode = document.compatMode == \"CSS1Compat\";",
"	if (quirksmode) {",
"		$(\"html\").addClass(\"ie-standards\");",
"	}",
" </script>",
" <div id=\"message-wrap\">",
"  <div id=\"message-bg\">",
"  </div>",
"  <iframe id=\"message-bk\">",
"  </iframe>",
"  <dl id=\"message-container\">",
"   <dt id=\"message-title\">",
"   </dt>",
"   <dd id=\"message-body\">",
"   </dd>",
"   <dd id=\"message-controls\">",
"   </dd>",
"  </dl>",
" </div>",
" <div id=\"topPanel\">",
"  <div id=\"header\">",
"   <div id=\"header_container\">",
"    <h2 id=\"logo\">",
"     <a href=\"./toc\">",
"      Wolters Kluwer Health UpToDate",
"     </a>",
"    </h2>",
"    <div id=\"header_right\">",
"     <div id=\"searchpanel\">",
"      <a href=\"/login\" id=\"loginbutton\">",
"       Log in",
"      </a>",
"      <div id=\"cmsSearchBox\">",
"       <div class=\"header-search\">",
"        <form action=\"./search\" id=\"cmssearch\" method=\"get\" name=\"SearchForm\">",
"         <div class=\"header-search-left\">",
"          <input autocomplete=\"off\" class=\"searchfield\" id=\"cmsTxtBox\" name=\"search\" placeholder=\"Search UpToDate\" type=\"text\"/>",
"         </div>",
"         <div class=\"header-search-right\">",
"          <input alt=\"Search\" id=\"cmsSearchSubmit\" src=\"/sites/all/themes/uptodate/images/search_button.png\" type=\"image\"/>",
"         </div>",
"         <div class=\"clear\">",
"         </div>",
"        </form>",
"       </div>",
"      </div>",
"      <div id=\"cms_lang_dropdown\">",
"       <form accept-charset=\"UTF-8\" action=\"/\" id=\"lang-dropdown-form\" method=\"post\">",
"        <div class=\"form-item form-type-select form-item-lang-dropdown-select\">",
"         <select class=\"lang-dropdown-select-element form-select\" id=\"edit-lang-dropdown-select\" name=\"lang_dropdown_select\" style=\"width:100px\">",
"          <option selected=\"selected\" value=\"en\">",
"           English",
"          </option>",
"          <option value=\"ja\">",
"           ���������������������������",
"          </option>",
"         </select>",
"        </div>",
"        <input name=\"lang_dropdown_type\" type=\"hidden\" value=\"language\">",
"         <input name=\"en\" type=\"hidden\" value=\"/\">",
"          <input name=\"ja\" type=\"hidden\" value=\"/ja\">",
"           <noscript>",
"            <div>",
"             <input class=\"form-submit\" id=\"edit-submit\" name=\"op\" type=\"submit\" value=\"Go\"/>",
"            </div>",
"           </noscript>",
"           <input name=\"form_build_id\" type=\"hidden\" value=\"form-on4lUWpxHun_wp6revUkjCG6rK2IBuCGME9Cw0HXeok\">",
"            <input name=\"form_id\" type=\"hidden\" value=\"lang_dropdown_form\">",
"            </input>",
"           </input>",
"          </input>",
"         </input>",
"        </input>",
"       </form>",
"      </div>",
"      <div class=\"clear\">",
"      </div>",
"     </div>",
"     <ul id=\"utility\">",
"      <li class=\"first\">",
"       <a href=\"/home/about-us\">",
"        About Us",
"       </a>",
"      </li>",
"      <li>",
"       <a href=\"/home/news-events\">",
"        News &amp; Events",
"       </a>",
"      </li>",
"      <li>",
"       <a href=\"/home/contact-us\">",
"        Contact Us",
"       </a>",
"      </li>",
"      <li class=\"last\">",
"       <a href=\"/help\">",
"        Help",
"       </a>",
"      </li>",
"     </ul>",
"    </div>",
"    <div class=\"clear\">",
"    </div>",
"   </div>",
"   <div id=\"nav\">",
"    <ul>",
"     <li id=\"productTab\">",
"      <a href=\"/home/product\">",
"       Product",
"       <span>",
"       </span>",
"      </a>",
"     </li>",
"     <li id=\"editoralTab\">",
"      <a href=\"/home/editorial\">",
"       Editorial",
"       <span>",
"       </span>",
"      </a>",
"     </li>",
"     <li id=\"whyUptodateTab\">",
"      <a href=\"/home/why-uptodate\">",
"       Why UpToDate",
"       <span>",
"       </span>",
"      </a>",
"     </li>",
"     <li id=\"supscriptionOptionsTab\">",
"      <a href=\"/home/subscription-options\">",
"       Subscription Options",
"       <span>",
"       </span>",
"      </a>",
"     </li>",
"     <li>",
"      <a href=\"/store\">",
"       Subscribe",
"       <span>",
"       </span>",
"      </a>",
"     </li>",
"     <li id=\"wkhcsTab\">",
"      <a href=\"/home/wolters-kluwer-health-clinical-solutions\">",
"       Wolters Kluwer Health Clinical Solutions",
"       <span>",
"       </span>",
"      </a>",
"     </li>",
"    </ul>",
"    <div class=\"clear\">",
"    </div>",
"   </div>",
"   <div id=\"greyBar\">",
"    <div id=\"greyBarTitle\">",
"     <span class=\"emphasis\">",
"      <a href=\"mobipreview.htm?3/3/3134\">",
"       Contents",
"      </a>",
"     </span>",
"     <img src=\"./../images/space_arrows.myextg\">",
"      <a href=\"mobipreview.htm?1/34/1568\">",
"       Family Medicine and General Practice",
"      </a>",
"      <img src=\"./../images/space_arrows.myextg\">",
"       Personality disorders",
"      </img>",
"     </img>",
"    </div>",
"    <div id=\"greyBarButtons\">",
"     <div id=\"printGB\">",
"      <a class=\"icontxt\" href=\"?view=print\">",
"       <img align=\"middle\" alt=\"Print this page\" border=\"0\" height=\"20\" src=\"./../images/icn_print.myextg\" width=\"24\"/>",
"      </a>",
"      <a class=\"icontxt\" href=\"?view=print\" title=\"Print this page\">",
"       Print",
"      </a>",
"     </div>",
"    </div>",
"   </div>",
"   <!-- menuMessage.jsp -->",
"   <!-- /menuMessage.jsp -->",
"  </div>",
"  <!-- header -->",
" </div>",
" <!-- topPanel -->",
" <div id=\"leftPanel\">",
"  <ul>",
"   <li>",
"    <a href=\"mobipreview.htm?3/45/3806\">",
"     Specialties",
"    </a>",
"   </li>",
"   <li>",
"    <a href=\"mobipreview.htm?18/22/18798\">",
"     Patient Information",
"    </a>",
"   </li>",
"   <li>",
"    <a href=\"mobipreview.htm?3/13/3294\">",
"     What's New",
"    </a>",
"   </li>",
"   <li>",
"    <a href=\"mobipreview.htm?0/37/606\">",
"     Calculators",
"    </a>",
"   </li>",
"   <li>",
"    <a href=\"mobipreview.htm?0/40/654\">",
"     Authors and Editors",
"    </a>",
"   </li>",
"  </ul>",
" </div>",
" <!-- leftPanel -->",
" <div id=\"rightPanel\">",
"  <noscript>",
"   <div id=\"javascriptDisabled\">",
"    It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"   </div>",
"  </noscript>",
"  <div id=\"printHeader\">",
"   <div id=\"printHeaderLogo\">",
"    <img alt=\"UpToDate\" src=\"./../images/wk_utd-rgb.myextg\" width=\"220px\">",
"    </img>",
"   </div>",
"   <div id=\"printHeaderText\">",
"    Official reprint from UpToDate",
"    <sup>",
"     &reg;",
"    </sup>",
"    <a href=\"file://www.uptodate.com\">",
"     www.uptodate.com",
"    </a>",
"    <br>",
"     &copy;2013 UpToDate",
"     <sup>",
"      &reg;",
"     </sup>",
"    </br>",
"   </div>",
"   <div id=\"printHeaderLinks\">",
"    <a href=\"#\" id=\"printHeaderPrint\" rel=\"\" title=\"Click here to print\">",
"     Print",
"    </a>",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"     Back",
"    </a>",
"   </div>",
"  </div>",
"  <div class=\"toctable\" border=\"0\" cellpadding=\"0\" cellspacing=\"0\" id=\"tocTable\" width=\"100%\">",
"   <trs>",
"    <tds>",
"     <h1>",
"      Contents:",
"			Personality disorders",
"     </h1>",
"    </tds>",
"   </trs>",
"   <trs>",
"    <tds>",
"    </tds>",
"   </trs>",
"   <trs>",
"    <tds valign=\"top\">",
"     <div class=\"toctable\" border=\"0\" cellpadding=\"0\" cellspacing=\"0\" width=\"100%\">",
"      <trs>",
"       <tds>",
"        <ul>",
"         <li>",
"          <a class=\"tocItem\" href=\"mobipreview.htm?41/26/42409\">",
"           Antisocial personality disorder: Epidemiology, clinical manifestations, course and diagnosis",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"mobipreview.htm?3/51/3896\">",
"           Approaches to the therapeutic relationship in patients with personality disorders",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"mobipreview.htm?10/19/10553\">",
"           Borderline personality disorder: Epidemiology, clinical features, diagnosis, and differential diagnosis",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"mobipreview.htm?41/1/42009\">",
"           Borderline personality disorder: Treatment and prognosis",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"mobipreview.htm?20/8/20615\">",
"           Establishing and maintaining a therapeutic relationship in psychiatric practice",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"mobipreview.htm?39/55/40824\">",
"           Personality disorders",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"mobipreview.htm?3/43/3769\">",
"           Treatment of antisocial personality disorder",
"          </a>",
"         </li>",
"        </ul>",
"       </tds>",
"      </trs>",
"     </div>",
"    </tds>",
"   </trs>",
"   <trs>",
"    <tds>",
"     <img height=\"10\" src=\"./../images/spacer.myextg\" width=\"1\"/>",
"    </tds>",
"   </trs>",
"  </div>",
"  <div id=\"footer\">",
"   <div id=\"footerNav\">",
"    <ul>",
"     <li>",
"      <a href=\"file://www.wolterskluwerhealth.com/\" rel=\"nofollow\" target=\"_blank\">",
"       Wolters Kluwer Health",
"      </a>",
"     </li>",
"     <li>",
"      <a href=\"file://www.factsandcomparisons.com/\" rel=\"nofollow\" target=\"_blank\">",
"       Facts &amp; Comparisons&reg;",
"      </a>",
"     </li>",
"     <li>",
"      <a href=\"file://www.medispan.com\" rel=\"nofollow\" target=\"_blank\">",
"       Medi-Span&reg;",
"      </a>",
"     </li>",
"     <li>",
"      <a href=\"file://www.provationordersets.com\" rel=\"nofollow\" target=\"_blank\">",
"       ProVation&reg; Order Sets",
"      </a>",
"     </li>",
"     <li>",
"      <a href=\"file://www.provationmedical.com\" rel=\"nofollow\" target=\"_blank\">",
"       ProVation&reg; Medical",
"      </a>",
"     </li>",
"     <li>",
"      <a href=\"file://pharmacyonesource.com/\" rel=\"nofollow\" target=\"_blank\">",
"       Pharmacy OneSource&reg;",
"      </a>",
"     </li>",
"     <li>",
"      <a href=\"file://www.medicom.com.cn/\" rel=\"nofollow\" target=\"_blank\">",
"       Medicom",
"      </a>",
"     </li>",
"     <li>",
"      <a href=\"file://www.lexi.com/\" rel=\"nofollow\" target=\"_blank\">",
"       Lexicomp",
"      </a>",
"     </li>",
"     <li class=\"last\">",
"      <a href=\"/home/privacy-policy\">",
"       Privacy Policy",
"      </a>",
"     </li>",
"    </ul>",
"   </div>",
"   <div id=\"footerLogo\">",
"    <a href=\"./toc\">",
"     Wolters Kluwer Health | UpToDate",
"    </a>",
"   </div>",
"   <div id=\"supportFooter\">",
"    <span class=\"sfInfo\">",
"     &copy; 2013 UpToDate, Inc. All rights reserved.",
"    </span>",
"    <span class=\"sfInfo\">",
"     <span class=\"pipeSpace\">",
"      |",
"     </span>",
"     Release: 21.3 - C21.34",
"    </span>",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    <span class=\"sfInfo\">",
"     <a href=\"/home/terms-use\">",
"      Terms of Use",
"     </a>",
"    </span>",
"    <br/>",
"    <span class=\"sfInfo\">",
"     Licensed to:",
"     <span class=\"emphasis\">",
"      UpToDate Marketing Professional",
"     </span>",
"    </span>",
"    <span class=\"sfInfo\">",
"     <span class=\"pipeSpace\">",
"      |",
"     </span>",
"     Support Tag: [0505-95.154.198.148-DCFBFEB65B-14]",
"     <br/>",
"    </span>",
"   </div>",
"  </div>",
" </div>",
" <!-- rightPanel -->",
"</body>"].join("\n");
var script_f35_27_36285=[""].join("\n");
var outline_f35_27_36285=null;
var title_f35_27_36286="Mechanical ptosis";
var content_f35_27_36286=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=NEURO%2F74219&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=NEURO%2F74219&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 470px\">",
"   <div class=\"ttl\">",
"    Patient with neurofibromatosis 1 and mechanical ptosis secondary to a plexiform neurofibroma on the right upper lid",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 432px; height: 133px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    Patient with a mechanical ptosis of the right upper lid secondary to a plasmacytoma.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Courtesy of Michael S Lee, MD.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f35_27_36286=[""].join("\n");
var outline_f35_27_36286=null;
var title_f35_27_36287="Russells sign";
var content_f35_27_36287=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=PSYCH%2F52728&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=2\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=PSYCH%2F52728&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=2\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 470px\">",
"   <div class=\"ttl\">",
"    Russell's sign",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 432px; height: 287px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Reproduced with permission from: Strumia R. Dermatologic signs in patients with eating disorders. Am J Clin Dermatol 2005; 6:165. Copyright &copy; 2005 Wolters Kluwer Health.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f35_27_36287=[""].join("\n");
var outline_f35_27_36287=null;
